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ABSTRACT OF DISSERTATION

EFFECTS OF INTRANASALLY ADMINISTERED DNSP-11
ON THE CENTRAL DOPAMINE SYSTEM
OF NORMAL AND PARKINSONIAN FISCHER 344 RATS
Due to the blood-brain barrier, delivery of many drugs to the brain has
required intracranial surgery which is prone to complication. Here we show that
Dopamine Neuron Stimulating Peptide 11 (DNSP-11), following non-invasive
intranasal administration, protects dopaminergic neurons from a lesion model of
Parkinson’s disease in the rat. A significant and dose-dependent increase in an
index of dopamine turnover (the ratio of DOPAC to dopamine) was observed in
the striatum of normal young adult Fischer 344 rats by whole-tissue
neurochemistry compared to vehicle administered controls.
Among animals challenged with a moderate, unilateral 6-hydroxydopamine (6-OHDA) lesion of the substantia nigra, those treated repeatedly with
intranasally administered DNSP-11 exhibited greater numbers of tyrosine
hydroxylase (TH) positive dopaminergic neuronal cell bodies in the substantia
nigra and greater TH+ fiber density in the striatum when compared to animals
treated intranasally with vehicle only or a scrambled version of the DNSP-11
sequence. Lesioned animals that received intranasal DNSP-11 treatment did not
exhibit abnormal, apomorphine-induced rotation behavior, contrasted with
animals that received only vehicle or scrambled peptide that did exhibit
significantly greater rotation behavior.
In addition, the endogenous expression of DNSP-11 from the pro-region of
GDNF was investigated by immunohistochemistry with a custom, polyclonal
antibody. Signal from the DNSP-11 antibody was found to be differentially
localized from the mature GDNF protein both spatially and temporally. While
DNSP-11-like immunoreactivity extensively colocalizes with GDNF
immunoreactivity at post-natal day 10, the day of maximal GDNF expression,
DNSP-11-like signal was found to be present in the 3 month old rat brain with
signal in the substantia nigra, ventral thalamic nucleus, dentate gyrus of the
hippocampus, with the strongest signal observed in the locus ceruleus where
GDNF is not expressed. Results from immunoprecipitation of brain homogenate
were not consistent with the synthetic, amidated 11 amino-acid rat DNSP-11
sequence. However, binding patterns in the literature of NPY, the only

homologous sequence present in the CNS, do not recapitulate the
immunoreactive patterns observed for the DNSP-11 signal.
This study provides evidence for a potential easy-to-administer intranasal
therapeutic using the DNSP-11 peptide for protection from a 6-OHDA lesion rat
model of Parkinson’s disease.
KEYWORDS: Parkinson’s disease, GDNF, 6-OHDA, aging, non-invasive
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Chapter One: Introduction
Parkinson’s Disease
A History of Parkinson’s Disease
Parkinson’s Disease (PD) was characterized in 1817 through the
observations of James Parkinson in the field of apothecary surgery. His work, An
Essay on the Shaking Palsy, characterized through six case studies a motor
disorder of the extremities which today affects an estimated 1% of the population
over the age of 65 (Tanner, 1992; de Lau and Breteler, 2006; NINDS, 2006), and
its prevalence is expected to double every 25 years due to the increased average
age of the population (Van Den Eeden et al., 2003; Dorsey et al., 2007; Wright
Willis et al., 2010; Collier et al., 2011). It was not until sixty years after Parkinson
produced his Essay that the disease began to carry his name when Jean Martin
Charcot distinguished the shaking palsy described by Parkinson as “Parkinson’s
disease”. Parkinson, in the final chapter of his Essay, describes the potential for
a cure, saying that, although there …
“exists no countervailing remedie […] there appears to be sufficient
reason for hoping that some remedial process may ere long be
discovered, by which, at least, the progress of the disease may be
stopped.”
Nearly 200 years later, a cure for the disease described by Parkinson is still
not available; but, as Parkinson concludes his work, there is reason for hoping
because:
“To such researches the healing art is already much indebted for the
enlargement of its powers of lessening the evils of suffering humanity.
Little is the public aware of the obligations it owes to those who, led by
professional ardour, and the dictates of duty, have devoted themselves
to these pursuits, under circumstances most unpleasant and forbidding.”
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Signs and Symptoms
Although much has changed between 1817 and today with regard to
research techniques, the signs and symptoms of Parkinson’s disease have
remained constant. Primary complaints focus on the cardinal motor symptoms:
resting tremor, bradykinesia or akinesia, “cogwheel” rigidity, shuffling gait and
postural instability. Secondary symptoms can include insomnia, urinary and fecal
incontinence, and orthostatic hypotension, disorders of olfaction, cognitive
decline, mood disorders and dementia. Indeed, as many as 47% of Parkinson’s
disease patients have symptoms of depression that arose prior to the cardinal
motor signs (Kummer and Teixeira, 2009; Lohle et al., 2009). In addition, a
plethora of secondary motor symptoms, although less common, can be present
especially in later stages, including muffled speech, loss of facial expression,
small hand-writing and difficulty swallowing (Jankovic, 2008).
Parkinson’s disease, as a progressive neurodegenerative disease, primarily
affects the aged population with a mean age of onset of 60 years with the
prevalence rising with age; but between 5-10% of Parkinson’s disease cases
occur in individuals between the ages of 20 and 50 years (NINDS, 2006). As the
average age of the population rises, it is expected that prevalence will also
increase.
Some estimates of the cost of the disease to the population of the United
States range from $5.6 billion (NINDS, 2006) to as high as $23 billion (Huse et
al., 2005; Findley, 2007). This includes not only the estimated cost of
pharmaceutical therapies of $10,000 per individual per year, but also surgical
treatment options, the cost of nursing home stays and the loss of economically
productive years and quality of life of both the patients and his or her family.
Pathogenesis of Parkinson’s Disease
There are two forms of Parkinson’s disease: familial and idiopathic (or
sporadic). Familial Parkinson’s disease accounts for approximately 5% of all
known cases of PD (NINDS, 2006) and always involves an inherited genetic
mutation. Several target genes in these population samples have been identified
and are the subject of study, especially the genes PINK1 (Valente et al., 2004),
2

PARKIN (Kitada et al., 1998), SNCA (Abou-Sleiman et al., 2006a), and LRRK2
(Mata et al., 2006). Many of these genes are translated to proteins that are
associated with either mitochondrial function (Abou-Sleiman et al., 2006b) or
proteasomal degradation (Dawson and Dawson, 2003; Bender et al., 2006;
Mizuno et al., 2006; Bueler, 2009). Familial Parkinson’s disease is also
associated with early onset of the disease, before the age of 40 years.
However, idiopathic Parkinson’s disease comprises the majority of
cases. Literally meaning that the cause of the disease is unknown, “idiopathic” or
sporadic Parkinson’s disease has in fact been linked to several factors, both
environmental and genetic. One especially potent non-genetic inducer that has
been identified is MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Langston
and Ballard, 1983; Langston et al., 1984). In 1976, illicit users of MPPP
(desmethylprodine), an opioid analgesic, were subjected to high levels of
impurities in the form of MPTP, a potent mitochondrial toxin, resulting in the
development of parkinsonian symptoms. One of these patients subsequently
died of unrelated causes, and an autopsy revealed extensive loss of
dopaminergic neurons of the substantia nigra (Fahn, 1996). This finding helped
lend credence to earlier studies showing a deficit of the neurochemical dopamine
in both the striatum and substantia nigra (Ehringer and Hornykiewicz, 1960;
Hornykiewicz, 1963). MPTP provided additional evidence for the role of
mitochondrial dysfunction of dopaminergic neurons in Parkinson’s disease.
Indeed, it has been determined that a loss in excess of approximately 60%
of dopaminergic neurons of the substantia nigra results in the onset of the
characteristically parkinsonian motor signs (Braak et al., 2006). This loss
correlates to an approximate 80% reduction in dopamine content (Gibb and
Lees, 1991). As determined from familial cases of Parkinson’s disease, it is
postulated that an accumulation of mitochondrial-associated mutations and
degradations throughout life ultimately are the causative agent of sporadic
parkinsonism (Bender et al., 2006). The cause of this accumulation can be
varied and multimodal.
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This life-long accumulation can be attributed to environmental elements,
typically pesticides and herbicides including rotenone and paraquat (Tanner et
al., 2011), and “Agent Orange” (IOM, 2009), and industrial agents such as
trichloroethylene (Gash et al., 2008), but can also include traumatic damage from
head injuries (Davie et al., 1995; Bower et al., 2003; Sauerbeck et al., 2011).
Many of these insults induce a concomitant inflammatory response within the
CNS, and in fact neuroinflammation has been implicated in many
neurodegenerative diseases including Parkinson’s disease (Hunter et al., 2007;
Whitton, 2007; Choi D. Y. et al., 2009). It is even thought that reactive oxygen
species created during normal dopamine metabolism can be a cause of
progressive dopaminergic neurodegeneration (Stokes et al., 1999).
A defining histological characteristic of the disease is the presence of
“Lewy Bodies”, or protein aggregates commonly observable within the cell bodies
of catecholaminergic neurons (Figure 1.1). Frederick Henry Lewey in 1912 was
the first to observe these eosinophilic sphereoidal inclusions encircled by fibrils in
the CNS of parkinsonian patients. A major component of Lewy Bodies is the αsynuclein protein implicated in familial cases of Parkinson’s disease; but αsynuclein containing Lewy Bodies are also present in several other diseases of
the CNS including Dementia with Lewy Bodies (or DLB), Multiple Systems
Atrophy (MSA), and corticobasal degeneration, all of which present with some,
but not all, of the symptoms of Parkinson’s disease. Some researchers believe
these protein aggregates are the causative element in Parkinson’s disease due
to their high correlation to areas of greatest neuronal loss (Gibb and Lees, 1989).
However, because of the wide array of neurological disorders characterized by
the presence of Lewy Bodies, and because Lewy Bodies are also present in
asymptomatic individuals, others hypothesize that these aggregates may be a
general protective mechanism against molecular damage to cellular enzymes,
serving as a kind of “waste dump” when proteasomal degradation processes are
insufficient (Burke et al., 2008), thus appearing as a marker for neuronal distress
and not acting as the direct cause of the dysfunction and death itself.
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Not all of the histological and neurochemical damage occurring in
Parkinson’s disease is isolated to the substantia nigra. Other catecholaminergic
centers of the brain are implicated in Parkinson’s disease as well. In particular,
degeneration of the locus ceruleus (Figure 1.2) is thought to be the causative
element in many of the non-motor symptoms observed in parkinsonian patients,
especially insomnia and dementia. The locus ceruleus, literally the “blue spot”
due to its high neuromelanin content, located in the dorsal tegmental pontine
brainstem, serves as the norepinephrinergic center of the brain and acts as a
“gain setting” nucleus for cognitive function. It sends projections throughout the
CNS, influencing cortical, subcortical, cerebellar, and brainstem circuitry and is
implicated in stress-response and attention focusing, memory, sleep-wake
cycles, and even postural stability. The locus ceruleus is self-modulatory and
may also play a role in compensatory mechanisms during pre-symptomatic
parkinsonism (Rommelfanger and Weinshenker, 2007), possibly explaining the
insidious loss of dopaminergic neurons without noticed behavioral deficits. In
addition to the locus ceruleus, the dorsal nucleus of the vagus nerve is implicated
in parkinsonian symptoms including incontinence. Due to the many systems
typically affected in Parkinson’s disease, a “dual-hit” hypothesis of the etiology of
sporadic Parkinson’s disease has been proposed, controversially suggesting
possible dual environmental vectors for entry to the CNS via the olfactory system
and spinal cord (Hawkes et al., 2007). The dopamine system, however, remains
the single most prevalent and consistent area of degeneration observed in
parkinsonism, and is responsible for the most frequent symptomatic complaints
in regards to the disease. As such, the majority of research focuses on
dopamine and the nigrostriatal system as the key to unlocking an intervention for
Parkinson’s disease.
The Discovery of Dopamine
Dopamine (DA) was first synthesized in 1910 by George Barger and
James Ewens, but this monoamine was considered merely to be a precursor in
the natural synthesis of norepinephrine (NE) (Blaschko, 1942). It was not
recognized to be a distinct catecholamine neurotransmitter in its own right until
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1958, after Arvid Carlsson and Nils-Åke Hillarp in Sweden elucidated the role of
the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) as a reserpine
antagonist (Carlsson et al., 1957; Abbott, 2007), followed closely by the
discovery of dopamine in the central nervous system (CNS) of the mammalian
brain (Montagu, 1957) and later in the human brain (Sano et al., 1959).
Dopamine Biosynthesis and Signaling
Dopamine is synthesized along the same enzymatic sequence as, and is
a precursor compound for, norepinephrine (NE) (Figure 1.3). The first, and ratelimiting, step of dopamine synthesis is the conversion of L-tyrosine to Ldihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH)
(Carlsson et al., 1972; Haavik and Toska, 1998). This step requires molecular
oxygen (O2), an iron atom co-factor (Fe2+) and tetrahydro-biopterin (BH4 or THB)
in order to add a hydroxyl group to the aromatic ring. From here, L-DOPA is
converted to dopamine by the enzyme aromatic L-amino acid decarboxylase,
which removes the carboxyl group from L-DOPA. Dopamine is then packaged
into synaptic vesicles by vesicular monoamine transporter 2 (VMAT2) for later
release. L-tyrosine, consumed in abundance in a normal diet, readily crosses the
blood-brain barrier, as does L-DOPA, but dopamine cannot and thus its utility is
spatially restricted. However, if L-tyrosine levels are low, L-phenylalanine may
be converted into L-tyrosine by phenylalanine hydroxylase.
After release into the synaptic terminal, dopamine interacts with a range of
receptors on the pre- and post-synaptic terminal, causing either neuronal
excitation or inhibition in the target neuron. Two entire families of dopamine
receptors have been indentified, composed of as many as five different isoforms,
each of which affect different intracellular signaling pathways. These two families
of dopamine receptors, D1 and D2, are both G-protein coupled receptors, but D1
receptors result in the depolarization of the neuron on which they are expressed,
whereas D2 receptors inhibit neuronal firing.
Once in the synaptic cleft, dopamine may either be transported back into
the pre-synaptic neuron via dopamine transporters (DAT) for repackaging or
remain in the extracellular space to be taken up by glial cells or metabolized on
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cellular membranes. Dopamine may be metabolized extraneuronally by
catechol-o-methyltransferase (COMT) to 3-methoxytyramine (3-MT) while
monoamine oxidase-B (MAO-B) will rapidly metabolize 3-MT to homovanillic acid
(HVA) (Tank et al., 1981; Kopin, 1985; Shih et al., 1999); or, inside the
cytoplasm, MAO and aldehyde dehydrogenase (ALDH) work together to convert
dopamine to DOPAC (Iversen, 2009).
As a result of this complex sequence, the modulation of dopamine can
occur not only at the level of the whole neuron, its projections, and neuronal
circuitry across the nervous system, but also during synthesis of dopamine
(transcriptional, translational, and post-translational regulation), synaptosomal
packaging (regulation of VMAT, transport of vesicle to synapse), dopamine
release (neuronal depolarization, calcium signaling, vesicle fusion), and via
reuptake and metabolism through regulation of the respective enzymes and their
spatial localization relative to their substrate. Although the cause of
parkinsonism is well known: a deficit of dopamine in the nigrostriatal pathway, the
underlying mechanisms for this dysfunction can be diverse.
Dopaminergic Pathways
The study of dopamine has led to the discovery of its central role in
reward-seeking behavior, wherein dopamine transmission becomes markedly
increased. This has resulted in research of the role of dopamine in a variety of
psychiatric conditions ranging from substance abuse, schizophrenia to attention
deficit disorder (Iversen, 2009). These conditions all involve disorders in the
mesolimbic and mesocortical pathways of dopamine innervation. The
mesolimbic pathway originates in the dopaminergic ventral tegmental area (VTA)
and substantia nigra (SN), which project to the nucleus accumbens and
amygdala, implicated in reward-stimulation and the fear-response. The
mesocortical pathway, while originating in these same anatomical nuclei,
innervate the prefrontral cortex, responsible for executive functioning, attention,
and complex planning. A third pathway, the tuberoinfundibular pathway, is
mainly responsible for the regulation of the neuroendocrine prolactin from the
anterior pituitary gland, which is well known for its role as a lactation inducer, but
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also has lesser roles in water/salt homeostasis and immuno-system and cellcycle regulation.
The nigrostriatal pathway is the pathway involved in the motor deficits
observed in Parkinson’s disease. This pathway is comprised of dopaminergic
neurons that originate in the substantia nigra and project to the striatum via the
medial forebrain bundle, forming synapses with several neuronal populations in
the putamen, caudate nucleus, GPi and STN. This forms the afferent
connections of the substantia nigra to the circuitry involved in motor movement,
the basal ganglia.
Basal Ganglia
The basal ganglia (or, more appropriately, the basal nuclei) are a
collection of nuclei located in the ventral forebrain which have been implicated in
voluntary motor control and habitual motor output while also playing a role in
cognition and emotional functions (Mink, 2007). The basal ganglia is comprised
of the striatum, globus pallidus and subthalamic nucleus, and has its
dopaminergic input from the substantia nigra (Figure 1.4). Dysfunctions in this
circuitry are core elements of a variety of motor disorders, including Huntington’s
disease, hemiballism, Tourette’s syndrome, and obsessive-compulsive disorder
(Fix, 2008). The basal ganglia also include the nucleus accumbens, ventral
pallidum, and VTA, which play a central role in reward learning, and dysfunction
in these nuclei have been implicated in schizophrenia and attention deficit
hyperactivity disorder (ADHD).
The striatum (Str), the largest of the basal ganglia nuclei, is the major
destination of the dopaminergic neurons of the substantia nigra. Named for its
striated appearance due to the prevalence of bands of white matter tracts, the
human striatum can be divided into two distinct sections, the caudate nucleus
more dorsomedially and the putamen ventrolaterally. The internal capsule and
its limbs, extensive bands of white matter axons traveling between the cortex and
the pyramids of the medulla, divide these units. The striatum of the rodent differs
from that of the human in that the caudate and putamen are not distinguishable
due to a poorly defined internal capsule. Instead, the striatum is separated
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histologically into “patch” and “matrix” (Desban et al., 1993). The patch is the
predominant target for dopaminergic projections, whereas the matrix possesses
acetylcholinesterase and is the site of arborization of the cortical
acetylcholinergic connections to the striatum (Gerfen, 1992). Classical
descriptions of the caudate and putamen suggested different functions, but
modern neuroscience attributes those differences to the somatotopic
organization of the striatum as a whole, so these observed neuroanatomical
differences may be a false distinction (Choi et al., 2012). The more dorsolateral
region of the striatum predominantly receives input from the substantia nigra and
is involved in motor control, the central region of the striatum is referred to as the
associative region, while the ventromedial region is involved in limbic function
receiving mainly VTA projections. In fact, this continuum may result in the
manifestation of some of the secondary complaints of Parkinson’s disease,
including dementia and depression. Medium spiny, inhibitory GABAergic afferent
neurons predominate throughout the striatum.
The pallidum, or globus pallidus (GP), is divided into two segments, the
internal and external segments. Both of these segments are predominantly
GABAergic, and thus inhibitory in effect, but they are constitutively active,
tonically inhibiting their targets.
The subthalamic nucleus (STN) is the only excitatory nucleus of the basal
ganglia complex and is one of the nuclei that receive tonic inhibition by the
globus pallidus (from the external segment).
The substantia nigra can be divided into two parts: pars compacta (SNc)
and pars reticulata (SNr). The pars reticulata receives glutamatergic innervation
from the STN and sends GABAergic projections to the ventral anterior and
ventrolateral nuclei of the thalamus. The pars reticulata also regulates the firing
of the pars compacta by sending GABAergic arborizations into this neighboring
region. The pars compacta is the dopaminergic center of the basal ganglia and
serves as midbrain input of the striatum. The pars reticulata is capable of
modulating the firing rate of the pars compacta throughout feedback from the
basal ganglia circuitry. The substantia nigra pars compacta, being the source of
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the primary dopamine projections to the motor region of the striatum, is the
region implicated in the motor symptoms of Parkinson’s disease.
Direct and Indirect Pathways
Motor output is modulated by the substantia nigra indirectly, through this
complex basal ganglia circuitry (Figure 1.5A) which serves as a “weigh-station”
for motor-output. The classical, simplified version of this pathway is described
below, but far more interconnections are present than defined here. A more in
depth review can be found in the literature (Alexander et al., 1986; Albin et al.,
1989; Mink, 2007). The dopaminergic fibers of the substantia nigra synapse in
the putamen of the striatum on two different populations of neurons: one
expressing the D1 family and the other expressing the D2 family of receptors.
The D1R family of neurons project to the GPi and are referred to as the “direct”
pathway. When dopamine is released on to and bound by these D1R neurons,
the intraneuronal pathways activated result in the excitation of this group of
striatal neurons. These “direct” pathway neurons release GABA, inhibiting the
GPi (Figure 1.5B).
The population of striatal neurons expressing the D2R family, when they
bind dopamine, undergo intracellular signaling that ultimately results in the
inhibition of this group of neurons. These D2R neurons, inhibited in firing when
dopamine is bound, send GABAergic projections to the GPe. The GPe in turn
sends constitutively active GABAergic projections to the STN, and the STN
projects excitatory glutamatergic fibers to the GPi. This is referred to as the
“indirect” pathway.
Both pathways ultimately synapse on the GPi, which balances the input
from the two pathways, resulting in a net output to the ventral anterior nucleus of
the thalamus (VA). The GPi, like the GPe, is constitutively active, tonically
releasing GABA into synapses within the VA. In a sense, motor output is
normally inhibited by the GPi. As a result, when the input to the GPi from the
“direct” pathway is outweighing the input from the “indirect” pathway, the net
result is inhibition of the inhibitory GPi. This effectively “disinhibits” motor output.
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However, when dopamine is not present or its release has been reduced,
as is the case in Parkinson’s disease, the “indirect” pathway begins to outweigh
the “direct” pathway (Figure 1.5C). The normal inhibition of the VA by the GPi,
and thus the corresponding motor output, becomes even stronger, resulting in
poor motor initiation and decreased motor speed in accordance with the
observed signs of Parkinson’s disease.
Rat Models of Parkinson’s Disease
In order to study neurodegenerative diseases, animal models of the
disease state must be developed. Many models have been developed, some
using the genetic mutations or non-genetic toxins discussed above, especially
rotenone, paraquat, and MPTP (Blesa et al., 2012). However, not every model
can perfectly replicate the human disease in the animal. For instance, due to the
rat’s tolerance for the MPTP toxin, in contrast with mice and primates, MPTP
does not make an effective rat model of parkinsonism.
A widely used and perhaps the oldest model of Parkinson’s disease in the
rat, and the model used for the present work, is the unilateral 6-hydroxydopamine
(6-OHDA) lesion model. As a catecholaminergic-neurotoxin, 6-OHDA selectively
destroys dopaminergic and norepinephrinergic neurons. In order to induce
parkinsonism in rats via dopaminergic cell death, 6-OHDA is injected into points
along the nigrostriatal pathway in various amounts. Injection into the striatum
can produce a partial lesion, while injection into the medial forebrain bundle
(MFB) typically produces extensive lesions in the nigrostriatal pathway. Injection
directly into the substantia nigra typically produces moderate lesions, leaving the
animal with some intact functionality. This theoretically produces a disease state
similar to moderate Parkinson’s disease in humans, a time at which point a
therapeutic intervention may begin. Also, it is noted that the pattern of cell loss in
Parkinson’s disease is mimicked most closely by lesions of the substantia nigra
directly (German et al., 1989; Goto et al., 1989; Deumens et al., 2002).
The unilateral nature of this lesion not only is easier for the animal to
tolerate, but also provides some interesting behavioral consequences. Because
the motor system has a deficit in only one hemisphere, the aggregate
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movements of the animal will result in a net rotation. This can be quantified to
provide an accurate estimate of the number of neurons lost due to the toxic insult
(Perese et al., 1989; Hudson et al., 1993; Deumens et al., 2002), especially with
the use of dopamine-system modulating compounds to induce elevated activity.
One such compound, apomorphine, increases activity in the animal by acting as
a dopamine receptor agonist. As dopaminergic innervation of the striatum is lost,
the striatal neurons compensate by increasing the expression of dopamine
receptors, inducing a state of super-sensitivity. Apomorphine then binds to this
upregulated receptor activity in the denervated hemisphere, producing increased
motor output from that hemisphere. This results in the animal rotating
contralaterally, “away from” the lesioned hemisphere; or, in other words, the
lesioned hemisphere is toward the outside of the imaginary circle formed by the
animal’s rotation. Because apomorphine-induced rotation behavior relies on
striatal super-sensitization due to a denervation of greater than 90%, it produces
a more binary effect: animals tend to either rotate or not to rotate.
Some 6-OHDA lesion models may be considered a progressive model of
the disease (Zigmond et al., 1990). Lesions of the substantia nigra by 6-OHDA
result in cell death within a week of injection (Wright et al., 2009), but behavioral
consequences tend not to stabilize until several weeks after injection (Perese et
al., 1989). Although rapid in pace, this progression allows some potential for the
study of preventive interventions. 6-Hydroxydopamine achieves its neurotoxicity
by way of its ability to act as a dopamine analogue with catecholamine
transporters, taking advantage of selective transportation into the cytoplasm.
From there, 6-OHDA reacts to form reactive oxygen species including hydrogen
peroxide and the quinone form of the compound. In order to selectively target
dopaminergic catecholamine neurons, desipramine may be used to inhibit the
uptake by norepinephrinergic neurons. Monoamine oxidase can also be
administered to prolong the life, and thus enhance the effect of 6-OHDA
(Zigmond et al., 1990).
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Treatment Options
A variety of treatment options are currently available for Parkinson’s
disease, but all are palliative and do not slow the progression of the disease or
affect the loss of dopaminergic neurons of the substantia nigra. These
treatments can be divided into three categories: dopamine supplementation,
dopamine replacement, and surgical intervention.
Dopamine supplementation therapies attempt to increase the natural
levels of dopamine in the CNS by a number of ways. The first of these and the
“gold” standard of such treatment is the administration of L-DOPA, the immediate
precursor in the synthesis of dopamine, commonly combined with carbidopa to
reduce peripheral effects by inhibiting DOPA decarboxylase. L-DOPA has the
benefit of being able to cross the blood-brain barrier (BBB) and so can be
administered systemically in oral pill form. By providing a surfeit of precursor to
the remaining dopaminergic neurons, this allows for the ready production of
dopamine.
Dopamine levels can also be increased on the opposite end, by inhibiting
the break-down of dopamine that has already been synthesized. By inhibiting
monoamine oxidase, dopamine that has been released into the synapse can be
more readily recycled by the pre-synaptic neuron for later reuse instead of being
metabolized to DOPAC.
Elevated levels of dopamine, either in the brain or the periphery, can result
in a wide array of side effects. Common neurological effects include
disorientation, hallucinations, anxiety, increased libido, and somnolence or
narcolepsy. Peripheral side effects can be even more severe, including cardiac
arrhythmias, hypotension, respiratory disturbances, gastrointestinal bleeding,
nausea and even hair loss. Chronic L-DOPA administration leads to dyskinesia,
freezing during motor movement, drug resistance, serotonin depletion, loss of
impulse control, deterioration of function and dopamine dysregulation syndrome
(Merims and Giladi, 2008). In addition, dopamine supplementation therapies
become ineffective in late stages of Parkinson’s disease, when no dopaminergic
connections remain that can be supplemented.
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Other compounds – such as pramipexole, ropinirole, and apomorphine –
function as a dopamine receptor agonist and have the potential to be true
dopamine replacement therapy in late stage patients. Due to apomorphine’s
highly emetic activity, it is commonly given as a subcutaneous injection. It can
enter the CNS and begin affecting the striatum within 20 minutes of injection, and
its effects can last for as long as 90 minutes, providing motor function for that
period. Due to apomorphine’s injection-based delivery and its relatively short
time of effect, it can only provide brief periods of functional recovery and cannot
fully ameliorate parkinsonian symptoms. The constant infusion of apomorphine
via implantable pump is an available treatment in Europe, but apomorphine is a
non-selective DA receptor agonist and produces many of the same side effects
as dopamine supplementation therapy. In addition to nausea and vomiting, other
effects are also present including increased sweating, agitation, behavioral and
mood changes, persistent headache, cardiovascular effects and changes in
vision. For these reasons, apomorphine is rarely used as a treatment in the
United States, but more selective agonists, such as pramipexole or ropinirole,
may be prescribed with different side effect profiles.
Surgical interventions for Parkinson’s disease are varied and some are
currently in the developmental phase. Deep-brain stimulation (DBS) relies on the
intracranial implantation of electrodes and is used for several disorders, including
Parkinson’s disease. A procedure called subcortical lesioning can produce
similar effects. These surgeries attempt to upset the balance between the
“direct” and “indirect” pathways of the basal ganglia to compensate for the loss of
dopaminergic innervation in the direct pathway.
Deep-brain stimulating surgery requires the implantation of the lead,
placed in the target brain region, an extension that is located under the skin, and
a battery-powered, implanted pulse generator. This system is similar to a
pacemaker, providing electrical pulses to the lead or electrode. This electrical
pulse is thought to inhibit the brain region in association with the electrode, and
thus this system usually targets either the subthalamic nucleus or the internal
segment of the globus pallidus for Parkinson’s disease, and the
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ventrointermediate nucleus of the thalamus to treat Essential Tremor.
Subcortical lesioning is similar in its approach, but its outcome is irreversible.
None of these approaches affect the disease mechanism, nor slow the
progression of the disease, and most may have severe side effects or
complications. An ideal treatment would be easy to administer without
complication, would target the specific brain regions affected producing few side
effects, and halt or reverse the progression of the disease. This goal led to the
search for neurotrophic factors that could actually affect the disease progression.
Neurotrophic Factors
History
The groundwork for the discovery of neurotrophic factors was laid in 1948
by Elmer Bueker. In grafting a tumor tissue line from the mouse (known as
sarcoma 180) into embryonic chicks, it was discovered that sensory nerve fibers
from the nearby dorsal root ganglia, but not motor neurons, invaded the tumor
(Bueker, 1948). These results were expanded upon by Rita Levi-Montalcini, who
not only compared the results to non-tumorous embryonic tissue implants (LeviMontalcini and Hamburger, 1951), but later showed that the cause of these
neurogenic growths was due to a diffusible nerve growth factor (Levi-Montalcini,
1952; Levi-Montalcini et al., 1954). Stanley Cohen, a member of Levi-Montalcini’s
group, identified a purification fraction that elicited this nerve growth promotion
(Cohen et al., 1954), but in the process of purification, which required the use of
moccasin snake venom to break down the nuclear DNA, discovered that the
snake venom itself enhanced this neurogenic activity, leading to the discovery of
a 20 kDa protein that would become known as Nerve Growth Factor (NGF)
(Cohen and Levi-Montalcini, 1956). This discovery began a conceptual shift
resulting in the search for other soluble signaling proteins with neurotrophic
effects, and in 1993 a potent neurotrophic factor responsible for the protection
and maintenance of dopaminergic neurons was identified (Lin et al., 1993).
Purified from the B49 rat glioma cell line, it became known as Glial cell lineDerived Neurotrophic Factor (GDNF).

15

The Effects of GDNF
Natural cell death is an important element of an organism’s development,
which ensures only properly formed and connected neurons remain. Indeed,
natural or developmental cell death is responsible for the elimination of 50% or
more of the neurons in the CNS (Cowan et al., 1984; Oppenheim, 1991). In
order to be spared of this neuronal paring process, a neuron’s projections must
interact with its target (Barde, 1989). By releasing neurochemical compounds
into a synapse with a receptive neuron, the post-synaptic, target neuron releases
a signal to the pre-synaptic neuron that it has received the message. This signal
is the neurotrophic factor. This is true of the nigrostriatal pathway, in which the
dopamine-sensitive neurons of the striatum release GDNF as confirmation of the
dopamine signal from the projections of the substantia nigra. The developmental
process of sparing in the nigrostriatal pathway in the rat coincides with maximal
GDNF expression levels found in the first post-natal week. The potential of
exogenous GDNF administration in an aged or diseased-state is in the capability
of GDNF to spare and restore dopaminergic neurons.
To that end, it was demonstrated that the protective effects of GDNF
extends to protection from cell toxins, including 1-methyl-4-phenylpyridinium ion
(MPP+) in cell culture (Hou et al., 1996), reducing markers of cell death and
dysfunction including caspase-3 activation and reactive oxygen species
production (Zeng et al., 2006). Exogenous GDNF, administered directly to the
substantia nigra in the rodent, also protects dopaminergic neurons from a 6OHDA lesion (Kearns and Gash, 1995; Kearns et al., 1997), and this treatment
corresponds to a preservation of evoked-release of dopamine (Cass and
Manning, 1999). Glial cell-line derived neurotrophic factor, when administered to
the striatum, also reduced apomorphine-induced rotation behavior four weeks
after a unilateral 6-OHDA lesion of the medial forebrain bundle (Hoffer et al.,
1994). These and other studies in rodents spurred pre-clinical trials in nonhuman primate models of Parkinson’s disease. Intracranial injections of GDNF in
a MPTP-induced model of Parkinson’s disease in non-human primates resulted
in significant improvements in parkinsonian symptoms with improved dopamine
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levels in the substantia nigra and enhancing dopaminergic fiber and cell size in
these animals (Gash et al., 1996; Zhang Z. et al., 1997; Grondin et al., 2002).
Clinical Trials of GDNF
Glial cell-line Derived Neurotrophic Factor, delivered intracranially via
pump and catheter system, proceeded to clinical trials. Two initial open-label
phase I trials of GDNF resulted in a 24% average increase in “off L-DOPA”
Unified Parkinson’s Disease Rating Scale (UPDRS) score, and a 39% average
increase in “on” UPDRS scores (Gill et al., 2003); and in a different study a 30%
bilateral increase in UPDRS “on” and “off” scores (Slevin et al., 2005). However,
a double-blind placebo-controlled phase IIa clinical trial did not meet the trial
requirements of 25% improvement in UPDRS “off” scores (Sherer et al., 2006).
For a variety of reasons, these results from the phase II trial were
controversial. The variability in UPDRS score effect observed between trials was
of concern. However, each of the three trials used different catheter designs and
infusion parameters which may have contributed to differences in diffusion of
GDNF, and resulted in differences in the rate and dose of delivery of GDNF
between studies. All of these changes are capable of altering the volume of
efficacious delivery (Salvatore et al., 2006; Sherer et al., 2006), contributing to
the inter-trial variability. Supporting this explanation are studies revealing
variability in the area of GDNF delivery around the catheter tip, and that this
diffusion area, although adequate in rhesus macaques, only covers 2 to 9% of
the human putamen (Salvatore et al., 2006). Safety concerns also arose when
antibodies to GDNF were found in 10% of the patients undergoing the trial; while
no adverse effects were observed in the patients (Slevin et al., 2006) the
possibility of the neutralization of endogenous GDNF by these antibodies and
observed toxicity in the cerebellum of non-human primates prompted the
discontinuation of the trial (Gill et al., 2003; Slevin et al., 2005; Lang et al., 2006).
Cerebellar Purkinje cell loss was observed in rhesus macaques, at a dose three
times as high as in the clinical trials, and after being subjected to three months of
withdrawal prior to histological examination (Hovland et al., 2007b). In contrast
to that study in non-human primates is MRI data from patients who participated in
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the GDNF clinical trials which indicated no cerebellar changes were present, in
agreement with clinical motor-function examination (Chebrolu et al., 2006).
Due to these obstacles, including the volume of diffusion of GDNF, its
potential side effects, the need for the implantation of the pump and catheter for
delivery of GDNF and the patent issues surrounding GDNF, the search for
mimetics of GDNF began.
The Search for Mimetics, Signal and Pro-Proteins
Mimetics for GDNF, compounds with similar function but with a different
structure, are attractive areas of research for a variety of reasons. Mimetics may
have the advantage of being smaller compounds with the capability of being
chemically or biologically engineered for greater efficacy or more specific
targeting for their effect. For this reason, such compounds could be more
versatile in their delivery approach, utilizing oral or nasal administration.
Mimetics can also avoid economic barriers to the pharmaceutical market by
being more easily synthesized and by avoiding patent infringement. To that end,
several compounds are being researched that may activate the same signaling
pathway as – or stimulate the endogenous release of – GDNF for the treatment
of Parkinson’s disease.
Glial cell-line derived neurotrophic factor itself is synthesized as a larger
pro-protein of 211 amino acids before being cleaved to produce the mature,
soluble GDNF protein targeted for clinical trials of Parkinson’s disease.
However, the pro-region of many neurotrophic factors produce biological effects
on their own (Lu, 2003). For this reason, attention was given to the pro-region of
many neurotrophic factors, including GDNF.
Development of DNSP-11
John Glass, Ph.D. (Stony Brook, NY USA) predicted the proteolytic
cleavage of 3 peptide sequences in the preproGDNF protein by in silico studies
of known post-translational cleavage pathways, and these sequences were
independently reported on by a team at the University of Helsinki (Immonen et
al., 2008) that also predicted a fourth peptide cleavage product. Of these
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theoretical cleavage products (Figure 1.6), one of them, named Dopamine
Neuron Stimulation Peptide -11 (DNSP-11) for its 11 amino acid sequence length
(PPEAPAEDRSL-NH2), has been the most studied (Immonen et al., 2008;
Bradley et al., 2010; Kelps et al., 2011).
Previously published data (Bradley et al., 2010) show that an antibody
raised against the DNSP-11 sequence produces strong signal in the midbrain
substantia nigra and ventral tegmental area that is highly colocalized with
tyrosine hydroxylase positive neurons. Exogenously administered DNSP-11 is
rapidly and specifically taken up by TH+ neurons after intracranial injection. In
cell culture, DNSP-11 potently increases the percentage of TH+ neurons in E14
rat primary cell culture at a greater range of doses than GDNF. In these primary
cell cultures, both DNSP-11 and GDNF significantly increased cell survival,
combined neurite length, and average number of branches per neuron, while not
affecting soma size. In normal rats, the baseline concentrations of dopamine and
its metabolites DOPAC and HVA are significantly elevated in animals
administered DNSP-11 up to 28 days prior to striatal microdialysis. In rats
subjected to a 6-OHDA lesion of the medial forebrain bundle and their lesion
allowed to stabilize for four-weeks, a single DNSP-11 treatment reduced
apomorphine-induced rotation behavior and increased striatal dopamine levels
as determined by HPLC-EC analysis of substantia nigra and dorsolateral striatal
tissue punches.
In that same body of work (Bradley et al., 2010), it was reported that
DNSP-11 is protective of MN9D cultured cells from a variety of toxins. DNSP-11
reduces TUNEL positive cells similarly to GDNF when co-administered with 6OHDA, and it also reduces caspase-3 activity to control levels in these cultures.
When co-administered with staurosporin, DNSP-11 reduces cytotoxicity beyond
control levels, whereas GDNF does not protect against this toxin, in B65 cells.
Similary, DNSP-11 but not GDNF protects against gramicidin cytotoxicity in cell
culture. Staurosporin triggers the release of cytochrome c and the loss of
mitochondrial potential, while gramicidin is a mitochondria depolarizing
substance, suggesting a mitochondrial protective role of DNSP-11, which is quite
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dissimilar to the cell preservation signaling pathway of GDNF, involving GFRα1
and RET. A direct ELISA binding assay confirmed that DNSP-11 does not bind
to GFRα1. A cytosolic homogenate pull-down assay identified an array of
proteins (by MALDI-TOF mass spectrometry), many of which possess metabolic
functions in the cell. Most notable of these is GAPDH (glyceraldehyde-3phosphate dehydrogenase), which has been linked to Parkinson’s disease
(Tatton N. A., 2000) and apoptosis (Tatton W. G. et al., 2000; Hara et al., 2005),
and is thus a target for drug development (Kragten et al., 1998; Carlile et al.,
2000; Tatton W. et al., 2003; Hara et al., 2006). Later work (Kelps et al., 2011)
shows that DNSP-11 protects against a 3-NP toxin that targets succinate
dehydrogenase of the mitochondrial complex II, in non-neuronal HEK-293 cells,
again suggesting powerful mitochondrial protection. It was also shown that
DNSP-11 remains stable in citrate buffered saline at 37 °C for 31 days, a critical
element of any pharmacological compound. It has also been shown that DNSP11 increases both mitochondrial potential and the uncoupled rate of
mitochondrial oxygen consumption indicating an increased respiratory reserve
capacity (Turchan-Cholewo et al., 2010).
Not only do these studies characterize DNSP-11 as being potently
protective of mitochondria both in vitro and in vivo for protection from models of
Parkinson’s disease, but they comprise a body of bioassays that can be used for
analysis of dosing optimization and bioavailability enhancements, as well as for
engineered alterations to the sequence or structure. Through such biochemical
engineering, the potency, stability, and versatility of the peptide may be further
enhanced in future studies.
Delivery of Drugs to the Central Nervous System
Blood-Brain Barrier
One problem in the use of pharmacological compounds for
neurodegenerative diseases is the safe delivery of the drug to the central
nervous system (Pardridge, 2005). Due to extensive tight-junctions between
endothelial vasculature, only very small non-polar compounds, typically less than
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500 Daltons, may pass this so-called blood-brain barrier (Pardridge, 2003) and
reach the CNS by systemic-vascular delivery. An alternative method of infusing
drugs in the CNS requires the intracranial implantation of a catheter. This
catheter is placed at the disease’s focal point and is anchored to the skull; a
connecting tube runs subcutaneously to a subcutaneously implanted infusion
pump . These pumps can be refilled by injection with a common needle, and
recharged and reprogrammed by induction field. Such an approach provides
precise targeting and control of delivered quantity of a therapeutic compound to a
brain region of interest. However, this surgical implantation itself can introduce
complications in addition to any side-effects a delivered compound may produce.
One peer-reviewed survey of a similar surgery, deep-brain stimulation surgery,
observed a 12.8% overall complication rate from the surgery itself.
Complications ranged from misplacement of the lead, to intracranial infections,
hemorrhaging, and even death (Umemura et al., 2003). While complication rates
have improved over the past decade, not all patients are good candidates for the
surgical implantation and recovery is still lengthy. For these reasons other
approaches to deliver therapeutics to the CNS need to be considered.
Penetration
Although surgical penetration of the blood-brain barrier is prone to
complication, there are alternative approaches that may temporarily disrupt the
barrier. One such possibility is disruption by ultrasound (McDannold et al.,
2008b; McDannold et al., 2008a). It is believed that certain frequency ranges of
ultrasound produce microbubbles that temporarily affect the microvasculature
(Reed and Leighton, 1994). With focused ultrasound, a highly targeted region of
the brain can be transiently permeabilized to systemic blood-flow, allowing the
transport of a systemically delivered drug to enter the CNS in bulk. This
approach is still experimental and is not yet approved by the US FDA for use in
human patients. As such, the safety of the technique is unknown. This also
requires systemic delivery of the drug, either intravenously or intraorally, which is
not suitable for the delivery of peptide or protein therapeutics which are quickly
inactivated and broken down in the gastrointestinal tract and blood circulation.
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Also, penetration by ultrasound requires expensive equipment and must be
performed by a trained individual, so is not ideal for use at home by the patient.
Compounds have been identified that can transiently enhance transport
across the blood-brain barrier (Cannon et al., 2012). A major active component
of the blood-brain barrier is P-glycoprotein, a membrane-bound transport protein
with broad substrate specificity ranging from lipids to peptides and
glucocoriticoids as well as a variety of therapeutic chemical compounds. This
pump is ATP-dependent and can be inhibited by sphingolipid signaling. This
approach enhances intracellular trafficking of a therapeutic compound, because it
does not affect the intercellular tight junctions that comprise the blood-brain
barrier. Because of this the delivered compound must have blood-brain barrier
crossing characteristics, such as being lipophilic and nonpolar. In effect,
inhibition of P-glycoprotein prevents the efflux of compounds that have already
entered the CNS.
Circumvention
Research is also being performed on the circumvention of the blood-brain
barrier. As opposed to physically affecting the continuity of the endothelial
junctions, these approaches attempt to utilize natural transports into the CNS.
For instance, immune cells such as activated monocytes readily cross into the
CNS (Miller, 1999; Engelhardt and Ransohoff, 2012). By masking a compound
intracellularly, it can bypass the barrier and potentially be released within the
CNS. In a similar vein, encapsulation of compounds within liposomes allows
compounds which are otherwise too large, hydrophilic, or polar to be protected
within systemic circulation and to cross the blood brain barrier (de Lima et al.,
2005; Frank et al., 2011). These approaches may allow a compound to enter the
CNS, but once there, it remains in this encapsulated state, masked not only from
the blood-brain barrier but also from key receptors to affect their ultimate
function.
Natural openings in the blood-brain barrier exist in the form of
circumventricular zones. These zones lack the extensive network of tight
junctions in the vasculature. However, these zones are typically in areas of
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outward flow, for instance where hormones from the pituitary are released into
systemic circulation. Without specific retrograde transport, these
circumventricular zones provide little therapeutic use in terms of delivering drugs
to the CNS.
More interesting approaches to bypassing the barrier involve conjugating
a therapeutic compound to natural sequences that target compounds for entry to
the CNS. One such conjugation element is the Tat-protein. Tat is a regulatory
protein encoded by the Tat gene of HIV. The Tat protein consists of a proteintransduction domain which allows it to penetrate cellular membranes. By
conjugating the Tat protein transduction domain to other compounds, it is
possible to induce cellular penetration, and even the circumvention of the bloodbrain barrier after systemic delivery (Kilic et al., 2005; Rapoport and LorberboumGalski, 2009). However, due to its broad functionality, Tat will deliver the
conjugated compound across any and all cellular membranes, thus producing a
possible increase in side effects, and even reactions to the Tat protein itself. A
combined approach, liposomal-encapsulation with membrane-bound rabies viral
transduction elements (rabies virus glycoprotein peptide), attempts to enhance
delivery across the blood-brain barrier (Tao et al., 2012), but downsides of both
techniques still exist.
An ideal technique for targeting the CNS with a therapeutic compound
would not subject the patient to increased risk of infection by opening the bloodbrain barrier, it would specifically target the brain and anatomical subregions of
interest, and it would be easy-to-administer requiring no specialized equipment or
requiring new FDA approval. Intranasal administration for delivery to the CNS
may provide many of these benefits.
Intranasal Administration Bypasses the Blood-Brain Barrier
The concept behind a passage-way between the nasal cavity and the
brain dates back to 1929 when Le Gros Clark proposed such a route for the
transit of infections from the nasal epithelium to the central nervous system.
Indeed, Braak’s “dual-hit” hypothesis of Parkinson’s disease suggests a nasal
route as one vector for the entry of Parkinson’s-inducing factors to the brain
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(Prediger et al., 2012). This pathway relies on the patency of the perineural
space around the olfactory receptor neurons and their olfactory ensheathing cells
(Brierley and Field, 1948) due to a purported lack of tight-junctions (Steinke et al.,
2008), the proteins that normally seal cells together especially in the formation of
the blood-brain barrier. But it wasn’t until 1986 that this open pathway was
visualized with electron microscopy using an intranasally administered tracer
molecule (Balin et al., 1986). This process was found to be primarily extracellular
in nature; however, a variety of routes may be responsible for transport to the
brain. These routes are thought to include extracellular routes such as perineural
routes described above, perivascular routes fascilitated by pulsatile arterial flow,
and intracellular routes such as specific receptor-mediated endocytosis or nonspecific pinocytosis followed by retro-grade transport (see Figure 1.7) (Illum,
2003). Since that time much work has been done not only to visualize
(Lochhead and Thorne, 2012) but to also quantify the delivery of compounds
from the nasal cavity to the brain (Thorne et al., 2004; Dhuria et al., 2010).
Evidence in the literature also implicates not only the olfactory receptor route to
the olfactory bulb, but also the trigeminal nerve as providing transport to the
brainstem (Thorne et al., 2004). Furthermore, administration along a number of
cranial nerves has been identified, including the optic nerve via intraocular
administration (Rapoport and Lorberboum-Galski, 2009) and by way of the
trigeminal and facial nerves through transdermal buccal patch (Yang, 2010; Yuan
et al., 2011). Traumatic forces, such as those in a motor-vehicle collision, can
often tear the olfactory nerves at the cribriform plate; however, intranasal and
other administrations, due to the variety of routes for transit, may still be suitable
even in cases of such olfactory denervation.
Much work has been done since the pathway was first identified using
molecular tracer molecules, and in 1989 William Frey II, Ph.D. patented the
concept of intranasal delivery of therapeutics to the brain by intranasal delivery
(Frey II, 1997; Frey II, 2002). With mounting scientific data to validate intranasal
delivery (Illum, 2000; Lochhead and Thorne, 2012), phase II United States Food
and Drug Administration clinical trials began with the goal of delivering insulin to
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the brain to prevent Alzheimer’s Disease in humans (Craft, 2006; Craft et al.,
2012). Data from this trial suggest that intranasal insulin slows the progression in
patients from mild cognitive impairment to entering full-on dementia (Craft et al.,
2012), improves verbal memory (Reger et al., 2008a) and modulates β-amyloid
in early stage Alzheimer’s disease, without affecting systemic blood-glucose and
insulin levels (Reger et al., 2008b). Due in part to the successes of this trial,
other trials that utilize the nose-to-brain route for delivery of therapeutics to the
CNS have entered pilot stages (Liu, 2011). These include the use of NAP (or
AL-108) for schizophrenia and dementia (Javitt, 2007) to oxytocin for treatment of
autism (Anagnostou, 2010).
This pathway between the olfactory epithelium and the deeper regions of
the brain parenchyma may serve a developmental role in the organism. Neurons
that secrete gonadotropin-releasing hormone (GnRH) develop in the olfactory
placode, or epithelium, and migrate along the olfactory receptor neurons to enter
deeper regions of the brain, especially the pre-optic area of the hypothalamus
(Hilal et al., 1996; Wray, 2010). In addition, olfactory receptor neurons
themselves constantly turn-over. As an olfactory receptor neuron dies, another
takes its place through the constant replenishment from both the rostral migratory
stream, which replaces and restructures granule and glomeruli layers in the bulb,
and differentiation of olfactory precursor neurons in the olfactory epithelium to
replace peripheral, olfactory receptor neurons. This constant turn-over may
result in the open extracellular pathways that allow the passage of compounds to
the brain.
The mucociliary clearance mechanisms in the nasal epithelium are
extensive and rapid (Illum, 2003). The mechanical action of ciliated cells in the
epithelium ensure the rapid movement of substances to the posterior nasal cavity
in as little as 20 minutes (Soane et al., 1999) where it is swallowed and degraded
in the gastro-intestinal tract. In addition, the nasal epithelium contains high
concentrations of oxidizing enzymes and aminopeptidases that will quickly
metabolize compounds and peptide drugs. In fact, the concentrations of
degradation enzymes in the nasal epithelium are comparable to that found in the
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liver (Sarkar, 1992) and serve as a potentially major roadblock to administration
via this route. A range of methods to maximize the transport of nasally applied
compounds to the CNS is an area of burgeoning research (Patel et al., 2009),
and many of the techniques used in the circumvention of the blood-brain barrier
during systemic delivery are being applied with intranasal delivery. For instance,
the conjugation of the Tat-protein to FGF significantly increased concentrations
of the factor in the brain compared to non-conjugated FGF, and increased the
efficacy of the compound at the same dose-concentration (Lou et al., 2012).
Liposomal encapsulation of intranasally delivered compounds seems to increase
transport to the CNS (Migliore et al., 2010) by increasing paracellular transport
and protecting the loaded compound from degradation. The co-administration of
short peptide sequences has been shown to enhance transport by saturating
aminopeptidases in the epithelium (Sarkar, 1992). Chitosan, a
mucopolysaccharide, has also shown promise in increasing bioadhesion and
enhancing absorption perhaps through the modulation of tight-junctions
(Artursson et al., 1994; Dodane et al., 1999), leading to an increased
bioavailability of nerve growth factor (NGF) by as much as 14-fold over the same
concentration without chitosan (Vaka S. R. et al., 2009) and BDNF by 12-fold
(Vaka S. et al., 2010). However, bioavailability of cefotaxime, a cephalosporin
antibiotic of 455 Daltons, was not found to be increased intranasally with chitosan
compared to intravenous injection with chitosan (Manda et al., 2011). Questions
remain as to whether such enhancers result in greater biological efficacy than a
simple aqueous solution formulated at an optimized concentration, pH and
osmolarity (Illum, 2007). The advantages of a simpler, saline solution include a
more expedited FDA-approval process for clinical trials potentially with the need
for fewer safety studies, and a more stable drug solution for longer life and
versatility in storage conditions for improved patient compliance and outcomes.
The low-cost and ease of administration of this route has the potential to
open up a new range of brain-targeting treatments for neuropsychiatric disorders
that would otherwise go untreated or be treated with poorly targeted compounds.
With the advent of a greater understanding of neurotrophic factors, their
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receptors and signaling cascades, and their role in development and cellular
maintenance, a wide range of intracellular signaling processes and receptors are
available for targeting through biopharmacological engineering. One of the main
issues that remain is the ability to effectively deliver these compounds to the
regions of the brain sensitive to such therapies. Intranasal administration may,
with the right compound, be capable of transporting these new classes of drugs
to the CNS.

Goal
To determine if the DNSP-11 peptide can be administered to the nasal
cavity and be transported to the brain in sufficient quantity to produce protective
effects from neurodegenerative diseases such as Parkinson’s disease.

Study Outline
In order to test the hypothesis that intranasally administered DNSP-11
enters the CNS and protects the nigrostriatal dopamine system from a
unilaterally injected 6-hydroxydopamine lesion of the substantia nigra in Fischer
344 rats, three endpoints for analysis were performed: histological,
neurochemical, and behavioral. In addition, some measures of the safety of the
drug were recorded, and questions regarding the presence of the DNSP-11
sequence as an endogenous peptide were addressed. All studies and analyses
were performed in a blinded, randomized controlled manner.
The aim of the histological endpoint was to quantify the number of tyrosine
hydroxylase (TH) positive cells in the lesioned substantia nigra as a percentage
of the unlesioned, contralateral substantia nigra. Tyrosine hydroxylase positive
striatal fiber density was also quantified by computerized threshold analysis as a
percentage of the unlesioned hemisphere. Tissue sections of 30 µm in thickness
were immunoreacted with a monoclonal antibody against TH and visualized by
nickel-enhanced DAB chromogen. The presence of DNSP-11 in the CNS was
also examined by quantification of an iodine-125 radiolabelled version of the
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modified peptide sequence. These studies provided information about the
quantity of this neuronal population and their projections to the striatum, and this
work comprises the whole of Chapter Three.
Neurochemical quantification was performed by two methods: whole
striatal tissue neurochemical content, and functional release by striatal
microdialysis. Baseline, tonic release of dopamine in the striatum was collected
by microdialysis probe and analyzed by HPLC-EC. Potassium-evoked release of
dopamine and outflow of dopamine by d-amphetamine were also studied during
striatal microdialysis. The whole striatum was excised post-mortem and its
neurochemical content analyzed by HPLC-EC. Acute effects of DNSP-11 on
striatal dopamine release were also performed by reverse microdialysis. These
studies can be found in Chapter Four.
The unilateral 6-OHDA rodent lesion model of Parkinson’s disease
produces a rotation behavior due to asymmetric motor output that can be
accentuated by the injection of apomorphine or other compounds. This provides
an interesting quantification of possible protection from the motor symptoms of
parkinsonism. Animals were administered apomorphine and placed in a
standardized rotation apparatus in which their rotations were unbiasedly
quantified by computer. In addition, to continuously measure changes in activity
levels and body temperature as a quantification of treatment safety, animals were
implanted with a wireless, battery free device that transmitted activity levels and
body temperature data to a computer by induction field located under their
homecage. The animals’ body weight was also measured daily as a measure of
rate of recovery from lesion induction. These data are provided in Chapter Five.
Finally, it is hypothesized that the DNSP-11 sequence is endogenously
processed from the pro-region of its parent protein, GDNF. A custom, polyclonal
antibody to DNSP-11 was acquired and differential immunoreactivity patterns in
naïve Fischer 344 brain tissue was characterized both at post-natal day 10 and
at 3 months of age. Finally, tissue sections were homogenized and reacted for
the DNSP-11 antigen in immunoprecipitation, and the eluent sequenced. This
study is contained within Chapter Six.
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Figure 1.1 – Images of α-synuclein containing Lewy Bodies.
Lewy Bodies, visualized here as dark brown intracellular inclusions, are protein
aggregates located within neurons of the central nervous system, especially the
substantia nigra and are characteristic of Parkinson’s disease and other
disorders of the CNS. Lewy Bodies typically are spherical in shape with a dense
central core surrounded by small fibrils comprising a shell or corona. Image from
(Spillantini et al., 1997).
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Figure 1.2 – Sectional anatomy of the human brain comparing parkinsonian and
normal patients.
Shown are the substantia nigra (A) dorsal to the cerebral peduncles in the
midbrain, and locus ceruleus (B) located in the dorsal tegmental pontine
brainstem. Both the substantia nigra and locus ceruleus are catecholaminergic
neurons and contain high concentrations of neuromelanin. In each inset image,
the left section shows an example of a normal human brain, and the right section
is an example of a parkinsonian brain. Notice the loss of the darkly colored
nuclei in both sections, indicated by the red arrows. (Images modified from:
MedScape <http://emedicine.medscape.com/>; Rosenblum, W. I., VCU
<http://www.pathology.vcu.edu>)
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Figure 1.3 – The biosynthetic pathway of dopamine and norepinephrine from Ltyrosine.
This pathway is utilized by catecholaminergic neurons, such as those of the
substantia nigra pars compacta and locus ceruleus. (Image from Wikimedia:
<http://en.wikipedia.org/wiki/File:Catecholamines_biosynthesis.svg>)
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Figure 1.4 – Drawings from sagittal sections of the human brain showing the
nuclei of the basal ganglia.
The striatum is comprised of both the caudate nucleus dorsomedially and the
putamen ventrolaterally, which are separated by the white matter tract known as
the internal capsule. The globus pallidus contains both internal (GPi) and
external (GPe) segments. The subthalamic nucleus (STN) is proximal to the
substantia nigra (SN) of which the pars reticulata segment is innervated by the
STN. The substantia nigra pars compacta is the dopaminergic input to the
striatum. (Images modified from Shuenke et al, Atlas of Anatomy, 2007, pp. 312313. Illustrated by Markus Voll).
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Figure 1.5 – Simplified version of the basal ganglia circuitry.
Arrow color indicates the type of projection. Blue is dopaminergic projections,
which can either be stimulatory of the D1R “direct” pathway or inhibitory of the
D2R “indirect” pathway. Red is inhibitory, GABAergic projections, for example
from the striatum, the GPe, and GPi. Green is excitatory, glutamatergic
projections, for instance from the STN, VA, and motor cortex. Note that this
circuit diagram does not represent all of the known connections,
interconnections, or nuclei of this pathway, but it does serve to illustrate the
functional roles of the direct and indirect pathways. A) The first illustration shows
the complete connections of this simplified circuit diagram. B) The second
illustrates an example of a normally functioning individual during motor output,
while C) shows the balance in the pathways when the putamen is not receiving
dopaminergic input from the substantia nigra. (GPi, globus pallidus internal
segment; GPe, external segment; STN, subthalamic nucleus; VA, ventral
anterior nucleus of the thalamus; SNc, substantia nigra pars compacta.)
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Figure 1.6 – The immature or prepro-form of GDNF.
Represented here in single letter amino acid sequence and block diagram form is
the location of the DNSP-11 sequence within the pro-region of GDNF as
determined by in silico examination of purported dibasic peptidase cleavage sites
(Bradley et al., 2010), including two other potentially cleaved “DNSP” sequences
with identified biological activity (Kelps et al., 2011; Littrell et al., 2012), DNSP-5
between the signal peptide and DNSP-11, and DNSP-17 within the mature
GDNF sequence. It is theorized that DNSP-11 is cleaved from proGDNF by a
combination of enzymes including prohormone convertase, endopeptidases and
caroxypeptidase H, followed by amidation by peptidylglycine amidating
monooxygenase (PAM). (Modified from Bradley 2010).
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Figure 1.7 – Diagram of the olfactory epithelium.
Olfactory epithelium at the top of the image contains the olfactory receptor
neuron cell bodies which project as a nerve bundle into the lamina propria then
through the foramenae of the cribriform plate to synapse in the glomeruli layer of
the olfactory bulb. Three possible means of transit from the nasal cavity to the
brain exist: a) intracellular, b) paracellular, and c) transcellular transport as
illustrated starting at the top of the diagram. Intracellular transport through the
projections of the olfactory epithelium could occur slowly by non-specific
mechanisms. A purported lack of tight junctions between the olfactory receptor
neuron and the olfactory ensheathing cell surrounding the neuron facilitates
extracellular pathways referred to here as paracellular and transcellular, resulting
in access to the perivascular and perineural spaces. Modified from (Lochhead
and Thorne, 2012).
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Chapter Two: Materials and Methods
Reagents
All reagents used for surgical procedures were U.S. Pharmacopeia (USP)
purity certified when available, or of the highest purity available if not regulated
by the USP. Reagents used for histology were procured from Fisher Scientific
(Fisher Chemical, Fairlawn, NJ) and reagents for neurochemistry were obtained
from Sigma Aldrich (St. Louis, MO), unless otherwise noted. The 6hydroxydopamine was obtained from Sigma Aldrich at 99.9% purity.
Animals
Ethics Statement
All procedures were conducted at the University of Kentucky, accredited
by the Association for Assessment and Accreditation of Laboratory Animal Care
International, and approved by Institutional Animal Care and Use Committee.
Animal Care and Housing
Three to four month old male Fischer 344 rats were used in this study,
housed in an environmentally controlled vivarium and kept under a standard 12hr light/dark cycle and provided with food and water ad libitum.
Surgical Procedures
Prior to surgery, animals were visually assessed for normal activity,
inquisitiveness, condition of hair coat, eating, drinking, evidence of defecation
and urination in the animal’s homecage, appearance of eyes, breathing rate, gait,
and bodyweight. If any abnormal conditions were observed, the animal was not
used and the Department of Laboratory Animal Research veterinary services
were consulted.
All surgical procedures were performed under aseptic conditions and
sterile field, using ethylene-oxide or autoclave sterilized tools and devices. The
surgical incision site was scrubbed three times alternating between both
isopropyl alcohol and betadine (iodine) disinfectant. The anesthetic primarily
used was isoflurane at 5% in an anesthetic chamber to ensure anesthetic depth,
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then moving to a nose-cone, typically at 2-3% isoflurane, to maintain anesthetic
plane. However, when noted, urethane and pentobarbital anesthesia were also
used. Anesthetic depth was determined by toe-pinch or corneal reflex response.
Incisions were closed with 4-0 vicryl sutures (Ethicon, Johnson & Johnson)
placed in a simple, interrupted pattern approximately 2 to 4 mm apart. Animals
were monitored post-operatively until awake and ambulatory in a fresh cage and
then returned to the vivarium. Animals were monitored daily post-operatively for
3 to 5 days for signs of discomfort or infection and observations noted in a postoperative chart. If signs of distress were observed, Department of Laboratory
Animal Research veterinary services was consulted.
Unilateral 6-OHDA lesion of the substantia nigra
Animals were anesthetized with isoflurane and placed in a stereotactic
frame. A hole over the area of injection was created and a Hamilton syringe (26
gauge, 10 µL, tip style #3) was inserted at the following coordinates (with respect
to bregma): AP: -5.4 mm, ML: -2.2 mm, DV: -7.5 mm (from dural surface), TB: 3.3 mm (Figure 2.1) (Paxinos and Watson, 2005). A fresh solution of 6-hydroxydopamine HCl (6-OHDA·HCl, 99.9% purity, 4.0 mg/mL in 0.9% saline with 0.02%
ascorbic acid) was injected at a total volume of 2.0 µL delivered over a 2 minute
period. The syringe was removed 2 minutes following injection. Lesion site was
verified histologically post-mortem on a subset of animals. (AP: anterioposterior;
ML: mediolateral; DV: dorsoventral; TB: tooth bar.)
Blinded intranasal administration
Solutions of vehicle only, scrambled peptide, or DNSP-11 were prepared
by Luke H. Bradley, Ph.D. and provided as coded vials randomly assigned to
subjects. Animals were anesthetized via isoflurane nose-cone and placed
supine. Coded solutions were administered in 12.5 µL boluses by micropipetter
at the opening of each nostril and allowed to be naturally drawn into the nasal
cavity by inhalation. The administration was repeated after a 2 to 5 minute
period to allow nasal clearance. Administration of the solutions, endpoint
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processes, quantification and analyses were performed by a researcher blind to
the solution contents.
Solution containing either DNSP-11, scrambled peptide, or vehicle only
was administered intranasally five consecutive days a week for three weeks (two
consecutive days of rest from administration for every 5 days of administration)
by a researcher blind to the solutions. Animals were administered as above,
alternately administering 12.5 µL to each nostril with 2 to 5 minute intervals
between administrations for a total of 50 µL of solution per animal per day
distributed between both nostrils (Figure 2.2). On the 21st day after lesion
induction, after two days off-treatment, the animals were subjected to endpoint
analysis. (Figure 2.3)
Peptide Synthesis and Dilution
As reported previously (Bradley et al., 2010), peptide synthesis and
purification were performed by GenScript (Piscataway, NJ USA). The following
peptide validations, preparations, and dilutions, as described in this section, were
all performed by the laboratory of Luke H. Bradley, Ph.D. Peptides were verified
as >98% purity upon receipt via reverse-phase HPLC, LC-MS, and amino acid
sequencing; and to be stable at physiologically relevant conditions by in vitro
assay. DNSP-11 peptide (PPEAPAEDRSL-NH2) was diluted to 2 µg/µL, 6 µg/µL,
or 20 µg/µL in normal saline (0.9% NaCl vehicle) and the researchers were blind
to the solution contents. Controls included saline vehicle only and a scrambled
DNSP-11 peptide sequence (LPSPREDAEPA-NH2) used at the same
concentrations. For studies involving iodinated, radiolabelled DNSP-11 peptide,
the sequence was modified to include a lysine residue (R9K), synthesized by
AAPPTEC (Advanced Automated Peptide Protein Technologies, Louisville, KY)
and contract iodinated by the Bolton-Hunter method to a specific activity of 50
µCi/g of DNSP-11 (Perkin Elmer NEN, Waltham, MA) and verified to be 95%
pure by HPLC. The bioactivity of these peptides was confirmed by in vitro assay,
and purity by TLC. For a list of these peptide sequences, see Table 2.1
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MiniMitter Automated Monitoring System
MiniMitter E-Mitter (Philips Respironics, Bend, OR, USA) devices are
wireless, implantable, battery-free devices that continuously records an animal’s
activity levels and body temperature. The animal’s home cage is then placed on
top of a specialized induction-field pad (Figure 2.4) connected to a computer with
specialized MiniMitter software that translates the data into “Activity Units” or
“Counts” and temperature. Activity units are an arbitrary unit calculated by a
change in the signal strength of the E-Mitter transmitter in the induction field.
Any change in signal is counted as an activity unit and the total number of these
changes during the designated time interval is given for that data point. These
devices were used to determine the activity levels and body temperature of the
animals in the study.
Surgical implantation of the MiniMitter device was performed at the same
time as lesion induction. Up to 24 hours prior to surgical implantation, and daily
for three days post-operatively, the animal received carprofen (5 mg/kg, s.c. or
p.o.) analgesic. The animals, anesthetized via isoflurane, were weighed and
placed in the surgical prep area. The hair covering the surgical site, between the
scapulae on the back, was clipped and the site prepared with anesthetic scrubs.
Ocular lubricant (“artificial tears”) was applied to the eyes. A small medio-lateral
incision was made and a subcutaneous pocket was created in the fascial plane
for insertion of the ethylene-oxide sterilized MiniMitter device.
Statistical analysis
Unless otherwise stated, column analysis was performed using unpaired
Student’s t test or one-way ANOVA and grouped analysis was performed using
two-way ANOVA. Multiple comparisons were corrected for by Bonferroni’s posthoc test. Due to the observed protective effects from previous studies of DNSP11 (Bradley et al., 2010), Student’s t tests were one-tailed unless otherwise
stated, with 95% confidence levels, α=0.05, β=0.80 with significance defined as
P<0.05. Error bars are mean ± SEM. Statistical analyses were performed on
GraphPad Prism 6.01. (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.)
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Table 2.1 – Amino acid sequences of peptides administered in this study.
Peptide

Sequence

Human DNSP-11

PPEAPAEDRSL-NH2

Modified DNSP-11 for 125I

PPEAPAEDKSL-NH2

Scrambled peptide

LPSPREDAEPA-NH2

Three different synthetic peptides were administered in the present studies,
including the human DNSP-11 sequence, a version of the DNSP-11 sequence
modified to accept iodination (R9K), and a scrambled version of the DNSP-11
sequence as a negative control. All peptides were C-terminal amidated.
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cerebral
cortex

SNc
III
VTA

SNr
cp

Figure 2.1 – Representation of the 6-OHDA lesion injection of the SN.
The vertical black line represents the needle at its final position at the following
coordinates (with respect to bregma): AP: -5.4 mm, ML: -2.2 mm, DV: -7.5 mm
(from dural surface), TB: -3.3 mm. Modified from (Paxinos and Watson, 2005).
(SNc, substantia nigra pars compact; SNr, substantia nigra pars reticulate; VTA,
ventral tegmental area; cp, cerebral peduncle; III, root of optic nerve or cranial
nerve III)
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12.5 µL

12.5 µL

2-5 min

12.5 µL =50 µL

12.5 µL

2-5 min

2-5 min

2-5 min

Figure 2.2 – Illustration of intranasal administration in the rat.
Intranasal administration was performed as follows. Animals were anesthetized
via isoflurane nose cone and laid supine. Using a micropipetter, a bolus was
ejected into the opening of the nostril, here shown is a 12.5 µL ejection first
performed on the right nostril. The animal was given 2 to 5 minutes for the
solution to be cleared from the nasal cavity, and then a bolus was ejected into
the opposite nostril, followed by a 2 to 5 minute clearance period. This was
repeated again for a total of 50 µL over approximately 10 minutes as shown here.
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Day 0

Day 2

Day 3
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Day 5

Intranasal Intranasal Intranasal Intranasal Intranasal

Rotation

6-OHDA

Day 6

Day 7

Off

Day 1

Day 8

Day 9

Day 10

Day 11

Off

Day 12

Intranasal Intranasal Intranasal Intranasal Intranasal

Off

Rotation
Day 13
Off

Day 14

Day 15

Day 16

Day 17

Day 18

Day 19

Intranasal Intranasal Intranasal Intranasal Intranasal

Off

Rotation
Day 20

Day 21

Off

Off

Rotation

Endpoint

Figure 2.3 – Study timeline, schedule of treatment, lesion induction, and
analysis.
Outlined above is the overall study timeline with the time of lesion induction
defined as “Day 0”. The day prior to lesion induction, animals underwent
baseline rotation behavior testing. The next morning, the animals received their
first intranasal administration followed approximately 30 minutes later by 6-OHDA
lesion induction of the substantia nigra (shown with red background). The
animals received intranasal treatment (shown with blue background) for five of
seven days a week for three weeks (two days “off” treatment every seven), with
weekly rotation behavior. On Day 21, the animals were taken for endpoint
analysis, either for histology or neurochemical studies (data collection points
shown with orange background). Animal body weight was recorded daily.
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B

A

Figure 2.4 – Example images of MiniMitter device and setup.
The small E-Mitter probe, shown in (A), is the approximate size of an osmotic
mini-pump and can be implanted in the back or abdomen. The animal, with EMitter implanted, is then placed in their homecage which is set atop an induction
field pad, the black box shown in (B), which continuously monitors changes in the
signal from the E-Mitter, and changes in temperature recorded by the E-Mitter
thermistor.

Copyright © James William Hendry Sonne
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Chapter Three: A study of the effects of intranasally administered DNSP-11
on tyrosine hydroxylase positive dopaminergic neurons and their
projections in a 6-hydroxydopamine lesion rat model of Parkinson’s
disease
Hypothesis: Efficacious doses of DNSP-11 can be delivered intranasally to
enter the CNS in quantities sufficient to protect tyrosine hydroxylase positive
neurons from a moderate 6-hydroxydopamine lesion of the substantia nigra.

Introduction
In order to test the hypothesis, young adult male Fischer 344 rats were
subjected to a unilateral 6-OHDA lesion directly to the substantia nigra following
an initial intranasal treatment thirty minutes prior to lesion induction (see Chapter
Two). The animals were intranasally administered solutions, by a researcher
blind to treatment, five of seven consecutive days a week for three weeks (see
Figure 2.3). On the 21st day the animals were euthanized by transcardiac
perfusion for immunohistochemical analysis of tyrosine hydroxylase positive
neurons of the substantia nigra and fibers of the striatum. In a separate cohort of
animals, a 125I-radiolabeled version of the DNSP-11 peptide was administered
intranasally and thirty minutes after administration the animal was euthanized by
transcardiac perfusion its brain was sectioned and quantified for signal by
gamma counter.
Tyrosine Hydroxylase Enzyme
Tyrosine hydroxylase (TH) is the enzyme involved in the rate-limiting step
in the dopamine synthetic pathway and is responsible for converting L-tyrosine to
L-DOPA (see Figure 1.3). The activity of the TH enzyme is dependent on
phosphorylation of a number of serine sites, primarily serine-40 by the cAMPdependent protein kinase A (PKA) (Fitzpatrick, 1999). The activity of TH is
subject to feedback inhibition by the products of the enzyme, namely
catecholamines including dopamine (Daubner et al., 1992). Once the enzyme is
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active, it uses diatomic oxygen (O2) and tetrahydrobiopterin (BH4) in conjunction
with an active site iron atom to hydroxylate the tyrosine substrate.
In the human, nine transcripts for TH have been identified, but only four of
these isoforms are translated to functioning enzymes. Of those four, only two are
prevalent in the human brain and they differ by the number of phosphorylation
sites present on the enzyme. Transcriptional regulation is responsible for longterm regulation of the TH enzyme. Because TH is necessary for catecholamine
synthesis, its presence in a neuron can be used as a marker for
catecholaminergic cells such as the dopaminergic neurons of the substantia
nigra.
Aside from phosphorylation, evidence in the literature suggests that TH is
regulated by enzymatic complexing. It has been reported that the protein 14-3-3,
after phosphorylation by CaMKII, complexes with TH to enhance its activity
(Ichimura et al., 1987; Wang J. et al., 2009); while α-synuclein has been shown
to bind to TH and decrease its activity through the dephosphorylation of serine40 and the increase in activity of protein posphatase 2A (Peng et al., 2005).
While the quantification of tyrosine hydroxylase positive (TH+) cells in the
substantia nigra has long been a key component of pre-clinical studies of
potential therapies for Parkinson’s disease or dopaminergic neurodegeneration
(Kearns and Gash, 1995; Kearns et al., 1997; Ai et al., 2003), it cannot be the
only metric for efficacy due to its vast array of post-translational regulatory
possibilities. It does serve as a powerful molecular marker of neuronal
phenotype and morphology. For this reason, TH+ cell counts of the substantia
nigra and the quantification of their fiber projections to the striatum have long
been powerful endpoints as one element of the analysis of potential therapies.
Materials and Methods
Animals were dosed intranasally while supine under isoflurane anesthesia,
for five of seven consecutive days a week (see Chapter Two) by a researcher
blind to treatment. The first intranasal dose was given approximately 30 minutes
prior to unilateral 6-OHDA lesion induction (see Chapter Two). On the 21st day
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after lesion induction (see Figure 2.3) animals were euthanized for
immunohistochemical analysis.
Tissue preparation and immunohistochemical processing
Animals were perfused transcardially with cold saline and 4%
paraformaldehyde fixative, the brain or whole skull was immersed in fixative for
24 to 48 hours, followed by submersion in 30% sucrose. Tissue was then
sectioned coronally (30 µm) and stored in cryoprotectant solution (30.0%
sucrose, 30.0% ethylene glycol in 100 mM NaPB pH 7.2) at -20 °C until
immunostaining procedure.
Every 12th section underwent 10 mM sodium citrate buffered antigen
retrieval (with 0.05% Tween 20) at 80 °C for 10 minutes, then blocked with 4%
normal goat serum for 1 hour at room temperature. The sections were then
immunolabeled with a monoclonal anti-tyrosine hydroxylase antibody (1:1000,
Chemicon Millipore, Temecula, CA USA) and incubated overnight at 4°C. The
sections were repeatedly washed and then incubated with peroxidaseconjugated secondary antibody (1:1000, Vector Labs, Burlingame, CA USA).
Immunoreactivity was visualized with NiDAB chromogen. This procedure is
modified from one previously described (Ai et al., 2003).
Substantia nigra TH+ cell counting
Tyrosine hydroxylase positive cells of the substantia nigra were quantified
in three 30 µm thick sections per animal according to the following criteria: only
TH+ cells with clear nuclei and lying lateral to the oculomotor nerve root were
included in the quantification. Three sections per animal were chosen in relation
to the 6-OHDA injection site: the section containing the injection point (-5.4 mm
with respect to bregma), the section 360 µm rostral to the injection site
(approximately -5.0 mm) and the section 360 µm caudal to the injection site
(approximately -5.8 mm). Images were captured at 5x magnification and
quantified by a researcher blind to treatment. The contralateral unlesioned
hemisphere was also quantified and the proportion of TH+ cells in the lesioned
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versus the unlesioned hemispheres is shown. A total of 18 animals were used
for this analysis (Table 3.1).
Striatal fiber density quantification
Striatal fiber density measures were quantified using contrast threshold
analysis software (BioQuant, Nashville, TN USA). Again, three striatal sections
were analyzed per animal. The unlesioned hemispheres were standardized to
approximately 90% TH+ striatal area and the lesioned hemispheres compared as
a percentage of unlesioned hemispheres. Quantification was performed by a
researcher blind to treatment.
Tracking of radiolabeled peptide to the CNS
The DNSP-11 sequence was conservatively modified to contain a lysine
residue (R9K, see Table 2.1), and this sequence was confirmed by previously
defined in vitro bioassay in the laboratory of Luke H. Bradley, Ph.D. (Bradley et
al., 2010) to produce similar biological effect as DNSP-11. Modified DNSP-11
was radiolabeled by contract (Perkin Elmer NEN, Boston, MA) with iodine-125 by
the Bolton Hunter method.
A total of 50 µCi (300 µg) was administered intranasally in a total of 50 µL
as previously described. Thirty minutes after the first intranasal dose was
administered, a sample of CSF was removed by cisternal puncture, the animal
was euthanized by thoracotomy and a blood sample was taken from the left
ventricle. Transcardiac perfusion with cold saline was performed followed by
decapitation. The brain was removed and 2 mm thick sections were serially
collected using a brain mold. Sample weight was determined and gamma
counting was performed to quantify the amount of radioactivity present in the
CNS. A total of seven animals was used in this study (Table 3.2), four given
radiolabelled I125-DNSP-11, three given saline only. One of the four I125-DNSP11 treated animal was excluded from this group due to poor perfusion quality.
This study was performed by Mallory J. Stenslik.
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Results
Scrambled DNSP-11 as a negative control
Concerns existed that the constituent amino acids in the DNSP-11
sequence may be cleaved by the numerous aminopeptidases and oxidative
enzymes in the olfactory epithelium (Sarkar, 1992) to cross the blood-brain
barrier via amino acid transporters, entering the CNS and producing a stimulatory
effect on the dopamine system. To control for this possible effect in protection
bioassays, a scrambled version of the DNSP-11 sequence (6 µg/µL, see Table
2.1) was administered intranasally along with DNSP-11 or saline vehicle only, all
of which were assigned randomly and administered in a blinded manner.
Scrambled peptide was then evaluated against the saline vehicle control treated
animals for tyrosine-hydroxylase protection determined by TH+ positive
substantia nigra neuronal cell counts. It was observed that scrambled peptide
and vehicle treated animals resulted in the same TH+ neuronal cell loss in the
substantia nigra (P=0.88. Vehicle treated cell loss: 91.4% ±4.1%, n=6. Scramble
treated cell loss: 92.2% ±3.5%, n=6.). Comparisons between Vehicle only and
Scrambled peptide treated animals were performed for all measurements with no
significant differences observed (P > 0.05). As such, vehicle-only and scramble
treated animals were combined as one negative control group.
Cell counts of the substantia nigra
In order to determine if intranasally administered DNSP-11 peptide could
result in protection of tyrosine hydroxylase positive neurons and fibers, Fischer
344 rats received the first intranasal treatment approximately 30 minutes prior to
a unilateral 6-OHDA (4.0 mg/kg) lesion of the substantia nigra (see Chapter
Two). The animals were given intranasal treatment 5 days a week for 3 weeks,
and euthanized by perfusion fixation on day 21 post-lesion. The animals brains
were removed and processed for immunohistochemical analysis of tyrosine
hydroxylase (TH) reactivity compared with the unlesioned hemisphere. When
those animals treated intranasally with scrambled peptide or vehicle only were
combined in one negative control group, animals treated intranasally with DNSP-
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11 exhibit significantly greater TH-positive neuronal cell bodies in the substantia
nigra (Figure 3.1, P=0.0192, n=18). Negative control treated animals exhibited a
92.1% (±2.6%, n=12) TH+ nigral cell loss 21 days after 6-OHDA lesion, while
DNSP-11 treated animals exhibited a 75.2% (±9.5%, n=6) cell loss. Animals
treated with DNSP-11, unlike negative control animals, closely resembled
unlesioned substantia nigra tissue (Figure 3.2). There were no statistically
significant differences observed in the number of TH+ cell counts of the intact,
unlesioned substantia nigra (data not shown, P=0.9223, n=18). No statistical
outliers by Grubb’s test were present, and the lesion site was histologically
verified prior to analysis. All procedures and analyses were performed by a
researcher blind to the treatment group identities.
Fiber density of the striatum
In this same cohort, TH+ fiber density in the striatum was quantified by
computerized threshold analysis. Animals that received intranasal DNSP-11
treatment exhibited significantly greater striatal densities compared to control
treated animals (Figure 3.3, P=0.047, n=18). DNSP-11 treated animals exhibited
76.2% (±9.8%, n=6) striatal TH+ density loss, compared with 90.7% (±3.1%,
n=12) loss in control treated animals. Animals treated with DNSP-11, unlike
negative control animals, more closely resembled unlesioned striatal tissue
(Figure 3.4). A linear regression of TH reactivity of nigral cell bodies to striatal
fiber density resulted in a significantly non-zero slope (
Figure 3.5, m=0.716 ±0.158, P=0.0003, R2=0.561), indicating intra-animal TH+
immunoreactivity levels are reflected in both critical regions of the dopaminergic
motor system. No statistical outliers by Grubb’s test were present. All
procedures and analyses were performed by a researcher blind to the treatment
group identities.
Quantification of peptide by radiolabel
Presence of the radiolabel was confirmed in the CNS 30 minutes after
intranasal administration. Mean radiolabel signal corresponded to approximately
0.29% of the 300 µg administered to the nose. (Table 3.3)(Figure 3.6)
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Discussion
Overview and Interpretation
These results support the hypothesis that intranasally administered
DNSP-11 enters the CNS and protects TH+ neurons from the 6-OHDA toxin in
the Fischer 344 male young adult rat. This provides important data to support
the overall hypothesis that DNSP-11 can be administered intranasally, enter the
CNS and protect TH+ neurons from degeneration.
Lesion accuracy and quality as a potential variable
The design of this study relied on a concomitant delivery of the lesioninducing toxin (6-OHDA) immediately after delivery of a protective agent (DNSP11) against the toxin. This design can elicit questions as to the causative
variable in the quantity of cell loss observed as the endpoint. However, because
the treatments were performed in a manner blind to the treatment contents, this
protects the results of the study from bias. Lesion variability among the negative
control groups was low (92.1% cell loss ±2.6%, n=12), indicating high precision
of the standard operating procedure used for lesion induction among this cohort.
Finally, a higher resolution technique for more precise quantification of TH+ cells
of the substantia nigra, to include cell body size, may identify additional
differences between groups.
Permeabilization of the blood-brain barrier from 6-OHDA lesion
It has been shown that a 6-OHDA lesion can transiently permeabilize the
blood-brain barrier (Cooper et al., 1982), which may allow systemic delivery
during the timeframe of this study. It was not felt that this was a major concern,
as an increased permeability of the blood-brain barrier has been described in
Parkinson’s disease (Hunot and Hirsch, 2003; Kortekaas et al., 2005; Rite et al.,
2007), thus a degree of blood-brain barrier permeability may model the disease
state. Due to this observation in the literature, it was not a specific concern to
determine whether or not protection resulting from intranasally administered
DNSP-11 occurs through a direct transit along cranial nerve routes or through
systemic vascular delivery. However, studies of the radiolabeled DNSP-11
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peptide (Figure 3.6) support the hypothesis that intranasal administration of this
peptide may result in direct transit to the CNS through the olfactory system but
does not rule out vascular delivery (see Figure 1.7 for a description of transport
across the olfactory epithelium). And although it is assumed that the peptide is
excluded from the CNS by the blood-brain barrier, the possibility of the peptide’s
active transport across the blood-brain barrier is not addressed in this study.
Quantification of radiolabeled peptide
The observed distribution of radioactivity after intranasal administration of
the radiolabelled peptide supports the hypothesis of transit of the peptide from
the nasal cavity to the brain. Radioactivity was found throughout the brain rostrocaudally at the thirty minute time point.
Variability in the perfusion quality may affect the overall quantity of
radiolabel found in the brain. For this reason, it is hypothesized that quantities of
the radiolabel within the vascular system contributed to the total quantity
observed in the brain, increasing the level of noise. In order to confirm the direct
nose to brain route, future studies may be designed to compare the
pharmacokinetics of intranasal and intravascular delivery using the radiolabelled
peptide in a time-response study. If intranasal administration results in a peak
concentration in the brain prior to a peak observed after intravascular
administration then this suggests a direct route from the nasal cavity. In addition,
such a time-response study would provide more precise data on the total quantity
that enters the brain after a single administration. Finally, to confirm that the
intact DNSP-11 transits to the CNS, an immunoprecipitation for DNSP-11 after
intranasal administration of the 125I-labeled peptide followed by quantification by
gamma counting would be strong evidence to support the observed biological
effects. A highly sensitive, monoclonal antibody would benefit such a study.
The present study, while not addressing these issues, does support the
transport of intranasal DNSP-11 to the brain; however, the possibility remains
that the peptide is being degraded within the nasal cavity or vasculature and that
the constituent amino acids (of which the lysine residue is radiolabeled in this
study) would be able to enter the CNS by the cationic amino acid transporter,
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producing a false positive. Taken in conjunction with the biological activity of the
DNSP-11 peptide, the similarity of that effect to the intracranially injected DNSP11 peptide, and the lack of effect observed in the scrambled peptide treated
animals, this suggests that the intact peptide is directly entering the CNS in
biologically efficacious quantities. Indeed, the preponderance of evidence in the
literature indicates that this direct route into the CNS is sufficient for compounds
as small as dopamine and as large as entire mesenchymal stem cells to enter
the CNS.
Finally, it is important to keep in mind the translational nature of this work.
While intranasal delivery of DNSP-11 in rats is an important step, the ultimate
goals are intranasal administration in non-human primates and eventually
humans. The percentage of transit to the CNS from the nasal cavity may be
quite different between species. Changes in formulation aimed at increasing
intranasal delivery to the CNS in rats may not translate to improvements in
primates. While the quantification of radiolabeled DNSP-11 may be a
satisfactory proof of concept experiment, it may be an ineffective assay for a
translationally aimed study.
Implications of post-transcriptional regulation of the tyrosine
hydroxylase enzyme
Although the hypothesis is supported and TH+ neurons and their fiber
projections are higher in the animals treated with intranasal DNSP-11, because
TH can be post-translationally regulated these results are insufficient to show
efficacy for the treatment of Parkinson’s disease and the resultant behavioral or
motor deficits of the disease. These neurons may maintain their TH+ phenotype
but may not produce or release dopamine in the striatum. For this reason, an
evaluation of dopamine content and its functional release in the striatum,
including an evaluation of the animal’s behavior, must follow.
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Table 3.1 – Animal groups for TH+ histological study

Numbers:

DNSP-11
Treated

Vehicle-only
Treated

Scrambled
Treated

6

6

6

A total of 18 young adult male Fischer 344 rats were used for the histological
quantification of TH+ cells of the substantia nigra and fiber density of the
striatum. Due to similarities in response between the Vehicle and Scrambled
peptide treated groups, these two groups were combined to one “Negative
Control” group. The DNSP-11 treated group received 300 µg in 50 µL per
treatment. No animals were excluded from this study.
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Figure 3.1 – Percentage of intact TH+ cells of the substantia nigra of animals 21
days after 6-OHDA lesion induction.
Of animals with a 6-OHDA lesion of the substantia nigra, those that received
intranasally administered DNSP-11 at 300 µg/day (75.2% cell loss ±9.5%, n=6)
exhibited significantly more TH+ cells in the substantia nigra (*P=0.0192,
t(16)=2.257) 21 days after lesion induction when contrasted with the cell counts of
those that received negative control treatment (92.1% cell loss ±2.6%, n=12;
either saline vehicle only (n=6), or a scrambled version of the peptide sequence
(n=6)). As predicted, animals treated with scrambled peptide or vehicle only
were not significantly different from each other (P=0.806) and were grouped as
one “Negative Control” group. Numbers are represented as the percent of
unlesioned hemisphere. Analysis by t-test.
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DNSP-11
Treated

Negative Control
Treated

Figure 3.2 – Representative sections showing TH+ immunoreactivity of the
substantia nigra in treated and negative control animals 21 days after 6-OHDA
lesion induction.
Images contrast enhanced for clarity. Measurement bar represents 200 µm.
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Figure 3.3 – Percentage of intact TH+ fiber density in the striatum of animals 21
days after 6-OHDA lesion induction.
Of animals with a 6-OHDA lesion of the substantia nigra, those that received
intranasally administered DNSP-11 at 300 µg/day (76.2% density loss ±9.8%,
n=6) exhibited significantly greater TH+ striatal fiber density (*P=0.0468,
t(16)=1.782) 21 days after lesion induction when contrasted with the fiber density
of those that received negative control treatment (90.7% density loss ±3.1%,
n=12; either saline vehicle only (n=6), or a scrambled version of the peptide
sequence (n=6)). As predicted, animals treated with scrambled peptide or vehicle
only were not significantly different from each other (P=0.654) and were grouped
as one “Negative Control” group. Numbers are represented as the percent of
unlesioned hemisphere. Analysis by t-test.
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DNSP-11
Treated

Negative Control
Treated

Figure 3.4 – Representative sections showing TH+ immunoreactivity of the
striatum in treated and negative control animals 21 days after 6-OHDA lesion
induction.
Images contrast enhanced for clarity. Measurement bar represents 500 µm.
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Figure 3.5 – Correlation of TH+ nigral cell counts and striatal fiber density in 6OHDA lesioned animals.
Animals that exhibited the greatest number of remaining TH+ cells in the
substantia nigra also tended to have the greatest TH+ striatal fiber density, as
illustrated by the significantly non-zero (P=0.0003, F(1,16)=20.45) linear regression
slope (m=0.716). Dotted curves indicated 95% confidence interval.
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Table 3.2 – Animal groups for radiolabel tracking study.

Perfused with:

Intranasal
I125-DNSP-11
Normal saline

Intranasal
Saline
Normal saline

CSF collected?

Cisternal puncture

Cisternal puncture

Numbers:

4

3

To determine the quantity of radioactivity in the CNS, blood, and CSF after
intranasal administration, three groups of animals were used: four animals
received intranasal I125-DNSP-11 and three animals received intranasal saline
only. One I125-DNSP-11 treated animal was excluded from this group due to
poor perfusion quality. This study was performed by Mallory J. Stenslik.
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Table 3.3 – Quantification of radioactivity in the CNS after administration of I125
labeled, modified DNSP-11 peptide.
Intranasal
I125-DNSP-11
(ng/mg ± SEM)
1.46+0.18
0.22+0.047
0.086+0.005
0.051+0.011
0.054+0.007
0.027+0.023
0.057+0.011
0.061+0.008
0.059+0.011
0.059+0.006
0.057+0.003
0.058+0.010
0.064+0.013
0.080+0.002

Blood
CSF
Olfactory Bulb
Section 1
Section 2
Section 3
Section 4
Section 5
Section 6
Section 7
Section 8
Section 9
Section 10
Section 11

Tabular quantification of radioactivity (calculated nanograms of 125I-DNSP-11 per
milligram of tissue). Brain tissue was sectioned in 2 mm thick serial coronal
sections using a rat brain mold. Animals treated with radiolabeled DNSP-11
(n=3) produced significant signal, while control animals treated with normal saline
(n=3) were observed to have CPM values at or below background levels (<100
CPM). This study was performed by Mallory J. Stenslik.
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Figure 3.6 – Normalized DNSP-11 Concentrations (ng/mg) at 30 Minutes in
Blood, CSF and Brain.
Calculated concentrations of DNSP-11 after administration of a radiolabeled
version of the peptide support the hypothesis that DNSP-11 enters the CNS after
intranasal administration. Male Fischer 344 rats (n=3 per group) were either
given a total bilateral dose (50 µCi/300 µg) of 125I-labeled DNSP-11 in vehicle (50
µL of normal saline) or vehicle only. At 30 minutes post administration, aortic
blood (Blood) and cerebrospinal fluid (CSF) were taken. The animals were
euthanized, perfused with 200 mL of normal saline and serial sections of the
animals’ brains were removed rostro-caudally in 2 mm thick sections (OB:
olfactory bulb, 1-11: brain sections). The percentage of 125I-labeled-DNSP-11
found in blood, CSF and total brain were 0.27%, 0.0084% and 0.29%
respectively. Animals treated with normal saline were found to have CPM values
below background levels (100 CPM). This study was performed by Mallory J.
Stenslik.
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Chapter Four: A study of the effects of DNSP-11 on monoamine
neurotransmitter tissue content and functional dopamine release in normal
and 6-hydroxydopamine lesioned rats
Hypothesis: Efficacious doses of DNSP-11 can be delivered intranasally to
modulate dopamine tissue content and metabolites in normal rats and to protect
dopamine tissue content and functional release from a moderate 6hydroxydopamine lesion of the substantia nigra.

Introduction
In order to test the hypothesis, normal unlesioned young adult male
Fischer 344 rats were intranasally administered a range of doses of DNSP-11 for
five of seven consecutive days a week for three weeks (Chapter Two). On the
18th day, approximately 30 minutes following the final intranasal administration,
animals were euthanized and the olfactory bulb, striatum, and substantia nigra
were removed for analysis of whole tissue neurochemical content.
Then, a separate cohort of young adult male Fischer 344 rats was
subjected to a unilateral 6-OHDA lesion of the substantia nigra directly (see
Chapter Two) following an initial intranasal protective treatment 30 minutes prior
to lesion induction. The animals were intranasally administered DNSP-11, a
scrambled version of the peptide, or vehicle only five consecutive days a week
for three weeks (see Figure 2.3). On the 21st day the animals were subjected to
striatal microdialysis under urethane anesthesia to measure baseline, K+ and damphetamine evoked release of dopamine, then euthanized and a 2 mm thick
section of the striatum was collected at the level of the optic chiasm for whole
tissue neurochemical content analysis.
Finally, unlesioned rats with no prior treatment were subjected to
microdialysis during which potassium-evoked release of dopamine was initiated,
followed by perfusion with a solution of DNSP-11 through the microdialysis
probe. Then a second potassium-evoked release of dopamine was initiated to
determine intra-animal changes after DNSP-11 perfusion.
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Increases in dopamine tissue content ameliorate parkinsonian
symptoms
The loss of dopamine in the striatum of both humans and in animal
models of Parkinson’s disease is the hallmark sign correlated to motor function
deficit. It has been observed that a loss of 80% of striatal dopamine content
corresponds to the onset of motor symptoms (Gibb and Lees, 1991) as a result
of an approximate 60% loss of dopaminergic neurons (Braak et al., 2006). The
biosynthesis of dopamine occurs in the cytoplasm of tyrosine hydroxylase
positive neurons from the precursor L-DOPA, so an elevated presence of TH+
nigral neurons and their striatal fibers may allow for the production of elevated
dopamine content in the target striatum. For this reason, the determination of
dopamine content in the putamen of the striatum has been an important endpoint
in studies of Parkinson’s disease treatment models.
Contrasting neurochemical content and functional release
Dopamine content on its own is only a snap-shot of the absolute quantity
of dopamine present, and does not reveal functional characteristics regarding the
release and metabolism of dopamine. The use of an intra-striatal microdialysis
probe (CMA 11, 6000 MW cut-off), allows for the collection of dopamine and its
metabolites from the interstitial space. By simultaneously perfusing through the
probe solutions designed to stimulate the release of dopamine, the functional
characteristics of the circuitry may be elucidated. For instance, perfusion with a
100 mM K+ solution in artificial cerebrospinal fluid will induce a change in the
ionic membrane potential and the synaptic release of dopamine by a mechanism
dependent on intracellular Ca2+ stores similar to physiological release. Also, damphetamine (d-amp) increases extracellular dopamine by increasing the net
efflux of dopamine through the dopamine transporter, which can provide
information about total intracellular dopamine and the function of the dopamine
transporter. d-Amphetamine acts through a variety of mechanisms. One such
mechanism is by acting as a substrate for the dopamine transporter (DAT)
effectively inhibiting the reuptake of extracellular dopamine by binding to the
normal “outward-facing” or “inward-flowing” conformity of DAT thus competitively
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blocking the influx of extracellular dopamine in a calcium-independent manner
(Rothman et al., 2012). Furthermore, d-amphetamine forces dopamine out of
synaptic vesicles by altering ionic gradients across lipid membranes (Tsai et al.,
2000). These intracellular ionic changes have also been shown to alter the
conformity of the dopamine transporter to its inward-facing, outward-flowing
conformity (Zhen et al., 2005) effectively reversing its flow to cause the efflux, or
carrier-mediate release, of cytoplasmic dopamine (Liang et al., 2009; Steinkellner
et al., 2012). Data from studies of the functional release of dopamine, in
conjunction with tissue dopamine content, can provide information on the
functioning of the circuitry in ways that dopamine content alone cannot provide.
Materials and Methods
Dose response study in normal animals
In order to determine the appropriate intranasal dose required to elicit a
biological response, 100 µg, 300 µg, 1000 µg of DNSP-11, or vehicle only was
administered intranasally using the administration protocol described in Chapter
Two. In short, animals were administered intranasal DNSP-11 or vehicle (Table
4.1) by a researcher blind to treatment for five of seven consecutive days a week
while under isoflurane anesthesia and laid supine. With the day of the first
administration defined as day 0, animals were euthanized by isoflurane overdose
on the 18th day immediately following intranasal administration, their brains
removed and the neurochemical tissue content of the olfactory bulb, striatum,
and substantia nigra were investigated, as described below.
Neurochemical protection studies in lesioned animals
A target dose of 300 µg DNSP-11 was administered intranasally (using the
same regimen as in Chapter Three and as described by Figure 2.3) in order to
determine the protective effects of this dose on dopamine neurochemical tissue
content and functional release of dopamine by striatal microdialysis.
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Tissue preparation for neurochemical quantification
In order to acquire samples of brain tissue, animals were overdosed with
isoflurane and euthanized by decapitation. The brain was removed, submerged
in ice-cold saline, and then a 2 mm section of the whole striatum was removed at
the level of the optic chiasm. The sections were weighed, flash-frozen in dry ice
and stored at approximately -74 °C. Immediately prior to analysis by HPLC-EC,
tissue samples were sonicated in 300 μl of cold 0.1 M perchloric acid containing
dihydroxybenzylamine as an internal standard. The samples were centrifuged
for 5 min at 12,000 g and the supernatant transferred to 0.22 μm pore size
Millipore Ultrafree centrifugal filters and spun at 12,000 g for 1 min. The filtrate
was diluted with HPLC mobile phase and 50 μL injected onto the HPLC column.
For dialysis samples, 20 μL of the dialysate was injected directly onto the
column.
Neurochemical quantification by HPLC-EC
All neurochemical assays were performed by the laboratory of Wayne A.
Cass, Ph.D. as previously described (Cass et al., 2003). The HPLC system
consisted of a Beckman Model 118 pump, a Beckman Model 507 autoinjector
and an ESA Model 5200A Coulochem II electrochemical detector with a Model
5011 dual-detector analytical cell (detector 1 set at +350 mV and detector 2 set
at −300 mV). An ESA Hypersil ODS 3 μm particle C18 column (80Χ4.6 mm) was
used for separations. Flow rate was 1.4 mL/min and the mobile phase was a pH
4.1, 0.17 M citrate–acetate buffer (containing 5 mg/L EDTA, 70–80 mg/L
octanesulfonic acid, and 7–8% methanol). Chromatograms were recorded from
both detectors using two dual-channel strip chart recorders. Retention times of
standards were used to identify peaks, and peak heights were used to calculate
recovery of internal standard and amount of DA and metabolites.
Striatal microdialysis
The microdialysis technique allows for collection of extracellular
compounds, especially monoamine neurotransmitters of interest in this study, by
passive diffusion across the semipermeable probe membrane. Microdialysis is
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performed as a non-recovery surgery in this study. Prior to in vivo microdialysis,
probes were prepared by perfusion with 70% ethanol at 3 µL/min for
approximately 20 minutes followed by reverse-osmosis water at 0.2 µL/min until
in vitro probe recovery collection was performed. Probes were then submerged
in a solution containing known quantities of the analytes of interest (see p. 68)
and perfused with artificial cerebrospinal fluid (see p. 68).

The animals were

anesthetized with urethane (1.25 g/kg in 0.9% NaCl, i.p.) and placed in a
stereotactic frame. A rostro-caudal incision was made in the skin above the
calvarium and a craniotomy was performed allowing the microdialysis probe
(CMA 11 probe with 4 mm Cuprophane membrane length and 6000 Da MW cutoff. CMA Harvard Apparatus Co., Kista, SE) to be placed in the whole striatum
using stereotactic coordinates with respect to bregma: AP: +1.5 mm, ML: -2.3
mm, DV: -8.0 mm (from dural surface), TB: -3.3 mm (Figure 4.1). The probe tract
was visualized post-mortem. Artificial cerebrospinal fluid (aCSF) was then
perfused at a rate of 1 µL/min and the probe was submerged in a standard
solution containing known concentrations of the analytes of interest and a 20 min
(20 µL) sample was collected for determination of probe recovery. Then the
probe was placed in the striatum using the above coordinates and samples
collected after each 20 min period (totaling 20 µL per sample). Six samples (0120 minutes) were collected and then the perfusate solution was switched to a
100 mM potassium (K+) aCSF solution using a CMA 110 liquid switch for the
seventh sample. The seventh sample was collected over a 20 minute period and
then perfusate solution was switched back to aCSF for the collection of the next
four samples (140-220 minutes). After the eleventh sample was collected, the
perfusate was switched to a d-amphetamine containing aCSF solution. Sample
12 was collected over a 20 minute period and the perfusate switched back to
aCSF for the following five samples (240-340 minutes). The animals were then
euthanized via anesthetic overdose and their brains removed for determination of
neurochemical tissue content. Sections of the substantia nigra were retained
and submersion fixed, and a subset was processed histologically for TH
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immunoreactivity to confirm lesion induction. Solutions for microdialysis
perfusion were prepared as described below.
Solutions for microdialysis
Microdialysis perfusates include three separate solutions: artificial
cerebrospinal fluid (or aCSF, 124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 1 mM NaH2PO4, 25 mM NaHCO3, 5.9 mM d-glucose), 100 mM K+ aCSF
(26 mM NaCl, 100 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4, 25 mM
NaHCO3, 5.9 mM d-glucose), and 250 µM d-amphetamine aCSF (250 µM damphetamine sulfate, 124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM
NaH2PO4, 25 mM NaHCO3, 5.9 mM d-glucose), and all were pH adjusted with
sulfuric acid and/or sodium hydroxide to within the 7.2-7.4 range.
A standard solution of analytes for probe recovery contained the following
concentrations (M) of neurochemicals: 2 x 10-7 norepinephrine (NE), 1 x 10-7 3,4dihydroxyphenylacetic acid (DOPAC), 2 x 10-7 dopamine (DA), 1 x 10-7
homovanillic acid (HVA), 2 x 10-7 serotonin (5-hydroxytryptamine, 5-HT), 4 x 10-7
5-hydroxyindoleacetic acid (5-HIAA).
Perfusion of DNSP-11 through microdialysis probe
In order to determine the percentage of DNSP-11 that perfuses through
the CMA 11, 6000 Da MW cut-off, microdialysis probe, probes were submerged
in solutions containing a range of concentrations of DNSP-11 between 0.1 µM
and 1000 µM in aCSF that was kept at approximately 37°C via water bath.
Probes were perfused as described above, with aCSF at 1 µL/min, and samples
were collected every 20 minutes. The concentration of DNSP-11 was quantified
by enzyme-linked immunosorbent assay (ELISA).
Enzyme-linked immunosorbent assay
A 1:1 serial dilution of the DNSP-11 peptide provided a detection range of
5 ng/mL to 2000 ng/mL. Sample was placed in wells with sodium
carbonate/bicarbonate coating buffer (pH 9.6) overnight at 4°C, followed by
blocking (0.1% purified BSA in PBS) at room temperature for 1 hour. The
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custom, polyclonal antibody to DNSP-11 (1:2000, α-Diagnostic, San Antonio,
Texas USA) was added and allowed to incubate for 2 hours at room temperature,
followed by a 1 hour incubation at room temperature with secondary, peroxidaselabeled antibody (1:10,000). The chromogen (R&D Systems, Reagent Kit
DY999) was allowed to develop for 20 minutes at room temperature at which
time the reaction was quenched (R&D Systems, Stop Solution DY994). The
optical density of the wells was recorded at 450 nm immediately after quenching.
Acute perfusion of DNSP-11 during microdialysis
In order to determine possible acute effects of DNSP-11 on the release of
dopamine, a 50 µM DNSP-11 solution in aCSF was perfused through the CMA
11 microdialysis probe. Microdialysis was performed as above with
modifications. The probe was perfused with aCSF for the 1st through 5th 20
minute samples, then the perfusate was switched to the 100 mM K+ aCSF
solution for the 6th sample collection. For the 7th through 9th sample collections,
the perfusate was switched back to aCSF; then the perfusate was switched to an
aCSF solution or a solution of 50 µM DNSP-11 in aCSF which was perfused for
the 10th to 14th samples. For the 15th sample the perfusate was switched back to
the 100 mM K+ aCSF, followed by perfusion with aCSF for the 16th through 18th
samples. A total of 8 animals were used in this study, four controls and four
DNSP-11. Two animals in the DNSP-11 group were excluded due to nondetectable baselines.
Results
Dose response in normal animals
Normal, unlesioned animals given DNSP-11 intranasally for five of seven
days a week for three weeks showed significant changes in monoamine
neurochemicals at different doses (Table 4.2). While dopamine levels
significantly decreased at 100 and 1000 µg doses, DOPAC significantly
increased at 300 µg (Figure 4.2). This resulted in a significantly higher dopamine
turnover (here defined as the ratio of all dopamine metabolites (HVA+DOPAC) to
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dopamine) in animals that received 300 µg per treatment of DNSP-11 (Figure
4.3, **P=0.0014, 24.3% increase).
Significant changes the monoamine in the substantia nigra were also
observed (Table 4.3). Both DOPAC and HVA were significantly elevated in the
animals that received 300 mg of DNSP-11 per treatment (Figure 4.4). Dopamine
turnover in the substantia nigra of these animals was also significantly elevated
at this dose (Figure 4.5, ****P<0.0001, 33.7%, n=12), and at the 1000 µg per
treatment dose (31.6% increase, n=12). Also of note, the level of serotonin in the
substantia nigra of animals given 1000 µg per treatment was significantly
decreased (Figure 4.6, ***P=0.0003, 31.3% decrease, n=12) with a significant
increase in serotonin turnover (Figure 4.7, ***P=0.0006, 21. 3% increase, n=12).
Finally, in the olfactory bulb (Table 4.4), dopamine levels were significantly
affected by DNSP-11 treatment, but there was no observed effect on dopamine
metabolites (Figure 4.8) and turnover was not significantly affected (Figure 4.9).
Whole striatum neurochemical content in lesioned animals
Of the lesioned animals (Table 4.5) treated with DNSP-11, scrambled
peptide, or vehicle-only, no changes to striatal monoamine neurochemical tissue
content was observed (Table 4.6). when comparing the negative control treated
animals and the DNSP-11 treated animals (Figure 4.10, P=0.3727). The
unlesioned hemispheres also were not significantly different between groups
(P=0.8437). However, the animals in this study were present in two distinct
populations within each group: those with a partial lesion of striatal dopamine
content, and those with a severe lesion (<1000 ng/g DA, see Figure 4.10).
These populations were separated for further analysis of the effects of intranasal
DNSP-11 treatment.
When analyzing only the partially lesioned animals, a significant difference was
observed with respect to treatment. Firstly, animals treated with vehicle only or
scrambled peptide were not significantly different from each other (P=0.7905, see
Table 4.7), as predicted, and were combined as one “Negative Controls” group.
When comparing DNSP-11 and negative control treated animals, the effect of
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treatment was significant, and the DNSP-11 treated animals contained 56.4%
more striatal dopamine content than the negative control animals (Figure 4.11.
###

P=0.0006, DNSP-11: 10037 ± 1672 ng/g DA; Negative Controls: 6417 ± 835.6

ng/g DA). This effect in the DNSP-11 treated animals resulted in dopamine
content in the lesioned hemisphere that was not significantly different from the
unlesioned hemispheres (P=0.6017). Also of note, the unlesioned hemispheres
of DNSP-11 treated animals contains significantly greater dopamine by 18.2%
than that of the unlesioned hemispheres of negative control treated animals
(Figure 4.11, P=0.0301. DNSP-11 unlesioned hemispheres: 12101 ± 783.9;
Negative Controls, unlesioned hemispheres: 10235 ± 522.9). However, in the
severely lesioned animals, there was no significant difference in monoamine
neurotransmitter levels (Table 4.8) between treatment groups (Figure 4.12).
Functional neurochemical release by microdialysis in lesioned
animals
Of the animals subjected to striatal microdialysis (Table 4.9), significance
changes with respect to potassium-evoked dopamine overflow and DOPAC
levels were observed (Table 4.10). It was observed that treatment with DNSP11 resulted in a significant decrease in the potassium-evoked overflow of
dopamine (****K+ P<0.0001, 45.8% less than the combined negative controls.
Figure 4.13). The vehicle and scrambled peptide treated groups were not
significantly different (P=0.9573). However, baseline dopamine and metabolite
overflows were not significantly different between the negative control treated
and DNSP-11 treated groups (Figure 4.13), nor were baseline dopamine
metabolite concentrations (Figure 4.14). The effect of decreased evoked
dopamine overflow was driven primarily by animals determined to be in the
severely lesioned subgroup (<1000 ng/g striatal dopamine: DNSP-11 n=3,
Vehicle n=4, Scrambled n=1). When those severely lesioned animals were
removed from the analysis, no significant differences between groups of partially
lesioned animals was observed (P=0.9929, Figure 4.15).
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Perfusion of DNSP-11 through microdialysis probe in vitro
By comparing the quantity of DNSP-11 collected during microdialysis to a
sample of the quantity in the vial in which the probe was submerged, it was
determined that an average of 1.6% ± 0.66 DNSP-11 is recovered by the
microdialysis probe in vitro at 37°C. It was determined that 50 µM concentration
of DNSP-11 in aCSF solution would result in approximately 0.8 µM perfused in
the brain every 20 minute sampling period. This concentration is within an order
of magnitude of the concentration in the brain after intranasal administration of
300 µg of DNSP-11 and after intracranial injection of 30 µg of DNSP-11, which is
known to produce biological effects at the two-week time point (Littrell, 2011).
Acute effects of DNSP-11 on potassium evoked release of dopamine
After perfusion of 50 µM DNSP-11 in aCSF through the microdialysis
probe for 100 minutes, dopamine overflow during potassium-evoked release was
significantly lower than the normal potassium-evoked release recorded in the
same animals prior to infusion with DNSP-11 (Figure 4.16; Decrease of 40.8%,
****P<0.0001). No significant differences in baseline dopamine, DOPAC (Figure
4.17) or HVA (Figure 4.18) levels were observed.
Discussion
Overview and interpretation
These studies provide data on the possible long-term and immediate
effects of DNSP-11, in both normal and lesioned animals, while providing
important dosing information for future studies. The dose response study in
normal animals resulted in observed changes in monoamine neurochemical
levels of the striatum and substantia nigra, with especially strong changes to
dopamine metabolism in the substantia nigra. Due to these results, the 300 µg
dose became the focus for protection studies of intranasal DNSP-11 in 6-OHDA
lesioned animals.
When considering all of the 6-OHDA lesioned animals in the protection
study, treatment with DNSP-11 did not have an effect on striatal dopamine
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content; however, due to variability of the lesion within this cohort the animals
were present in two subgroups: those with severe lesions (<1000 ng/g striatal
DA), and those with partial lesions. Of the animals with partial lesions, those that
were treated with DNSP-11 had significantly higher levels of striatal dopamine
(Figure 4.11). Indeed, the partially lesioned animals that received DNSP-11
treatment possessed striatal dopamine levels not significantly different from their
unlesioned hemispheres. It is hypothesized that natural and uncontrollable
variations in the 6-OHDA lesion severity resulted in a subgroup of severely
lesioned animals that could not be rescued by DNSP-11 treatment at the dose
provided. Furthermore, the significant, negative effects observed in the
microdialysis studies were driven primarily by the three severely lesioned animals
of the DNSP-11 group. This variability may be overcome in restoration studies in
which animals can be prescreened for lesion severity. In addition, due to the
inherent variability of intranasal delivery, reduction of lesion variability becomes
important. As such, other toxic lesion or genetic models of Parkinson’s disease
may prove to be better models to quantify the effects of intranasal treatment with
DNSP-11.
Dose-response curve
The dose response in normal, unlesioned animals shows an increase in
striatal dopamine turnover at the 300 µg per day dose, but no significant
difference from vehicle-only treated controls at the 1000 µg per day dose,
suggesting a possible bimodal response curve. When considering the effect of
DNSP-11 on neurochemical content aside from dopamine it may be
hypothesized that this bimodal response was due to regulatory or compensatory
mechanisms. At the 1000 µg dose, serotonin content in the nigra was
significantly lower (Figure 4.6) than the vehicle treated animals while serotonin
turnover was significantly higher (Figure 4.7). This may indicate a regulatory or
compensatory mechanism, or it may indicate differential efficacy at a range of
concentrations on other monoamine systems compared to the dopamine system.
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The exact roles of serotonin on the dopaminergic motor system are
complex, but it is observed that these and other monoamine systems are subject
to profound loss in patients suffering from Parkinson’s disease (Scatton et al.,
1983; Miyawaki et al., 1997). In fact, in many patients, the symptoms of mood
disorder and autonomic dysfunction precede the motor signs of Parkinson’s
disease (Kummer and Teixeira, 2009; Lohle et al., 2009). Outstanding questions
remain in the literature surrounding the effects of serotonin interaction in the
dopaminergic system, but it has been shown that 5-HT receptor subtypes
differentially affect the dopaminergic system, some antagonizing dopamine and
others agonizing dopamine release in the striatum (Lucas et al., 2000a; Lucas et
al., 2000b; Lucas and Spampinato, 2000; Di Matteo et al., 2008).
While norepinephrine levels were not significantly altered with DNSP-11
treatment, levels of the metabolites of norepinephrine were not measured.
Furthermore, small changes in neurochemical levels may have appreciable
regulatory impacts. Similar to serotonin, the effects of changes in NE levels
remain to be fully described, but it is known that lesions of the locus ceruleus
increase the pathology and behavior deficits in Parkinson’s disease animal
models (Mavridis et al., 1991; Srinivasan and Schmidt, 2003) suggesting that NE
is sufficient, at some stages of the disease, to attenuate the behavioral output
and neuronal loss associated with the disease. The locus ceruleus directly
innervates the SN and striatum, stimulating burst firing of the dopaminergic
system (Grenhoff and Svensson, 1993). However, like the serotonin receptors,
norepinephrine is bound by a multitude of receptors, all with different functions
and localizations, complicating the explanation of circuit interactions (Hein et al.,
1999). Norepinephrinergic projections in the striatum have been shown to
modulate dopamine turnover by the α2CAR NE receptor (Sallinen et al., 1997),
and may do so indirectly by modulating glia and astrocyte activity by the whole
range of membrane bound NE receptor families (Mori et al., 2002). Furthermore,
the α2CAR norepinephrine receptors in the striatum are known to be sensitive to
dopamine at low synaptic concentrations (Hein et al., 1999; Zhang W. et al.,
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1999) while not being activated by apomorphine (Fox et al., 2001), indicating
complex cross-sensitivities to these various neurotransmitters.
As such, the dose response to DNSP-11 may be best described under the
hypothesis of differential effects to the monoamine systems both pre- and postsynaptically. Such effects may be elucidated by primary cell culture studies or by
highly localized analysis in animal models, but are beyond the scope of the
present study. Due to the powerful effect on the striatal dopamine system and
the relative paucity of changes to other systems and anatomical regions at the
300 µg per treatment dose, it was determined that the protection studies should
focus on this concentration of administered DNSP-11.
The use of isoflurane anesthesia in this study may in itself alter
neurochemical production, however no significant correlation between duration of
isoflurane anesthesia and striatal dopamine turnover was found (m=0.0004,
R2=0.4, P=0.0959, data not shown). Furthermore, the anesthetic used during
intranasal administration may alter respiration and blood-flow, changing the
dynamic of intranasal delivery. Indeed, reports differ on the use of anesthesia in
rodent models of intranasal delivery. Some suggest that isoflurane anesthesia
adversely affects intranasal delivery by drying the nasal mucosa, while other
reports indicate anesthetics may open the blood-brain barrier (Tetrault et al.,
2008). However, these effects appear to be minimal in scope. Ideally, future
studies would move to self-administration, which is feasible in non-human
primate models.
Effects of intranasal DNSP-11 in 6-OHDA lesioned animals
While DNSP-11 produced effects on the monoamine systems in the normal,
unlesioned animal, the protective effects of DNSP-11 on dopamine
neurochemical content were only observed in a subset of animals with partial
lesions (Figure 4.11). Lesion variability among this cohort resulted in a subgroup
of severely lesioned animals (Figure 4.12) upon which DNSP-11 was insufficient,
at the dose given, to produce the same protective effect seen in the partially
lesioned subgroup of animals.
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It is important to note the differences between the location of lesion
induction and the location of the measurements of both neurochemical content
and functional release by microdialysis. In contrast with previous DNSP-11
studies (Bradley et al., 2010) which utilized a severe lesion of the medial
forebrain bundle (MFB) and neurochemical content analysis targeted specifically
to the dorsolateral rat striatum, the present study used a lesion of the substantia
nigra and analysis of the whole striatum. A targeted analysis of the dorsolateral
striatum, or the use of other models including the MFB lesion model, may result
in reduced noise and variability. In addition, the repeated intranasal dosing
regimen in which the animals were off-treatment for the two days prior to
neurochemical endpoint may have created unintended consequences. The
intent of this timeline was to emphasize long-term protective effects of DNSP-11
treatment; however, this may also have introduced a negative rebound or a
“wash-out” effect due to being off of treatment, perhaps complicating the
neurochemical data.
The effects of DNSP-11 on functional neurochemistry, as collected by
microdialysis, most closely resemble the data obtained from aged Fischer 344
rats administered DNSP-11 in a single intracranial injection (Fuqua, 2010), in
which potassium-evoked and baseline release of dopamine were found to be
significantly decreased in DNSP-11 treated animals. In the present study, the
DNSP-11 treated animals exhibited a significant decrease in potassium evoked
dopamine (Figure 4.13) and a non-significant trend toward decreased baseline
levels of dopamine and its metabolites, while d-amphetamine evoked release
was unchanged. This decrease was driven primarily by the small (n=3 DNSP-11
treated) subgroup of severely lesioned animals suggesting these changes may
be occurring only in the severely depleted striatum or may be a statistical artifact.
If this effect is confirmed, one hypothesis is that DNSP-11 may have pleiotropic
effects aside from long-term protection against neurotoxic lesions, all while not
affecting dopamine content or d-amphetamine evoked release of dopamine. The
decrease specifically in potassium-evoked, calcium-dependent release may
indicate that DNSP-11 affected dopamine release pre-synaptically through a
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calcium-dependent mechanism. Other possibilities include post-synaptic
sensitization or an increase in auto-inhibition of the pre-synaptic neuron. Indeed,
5-HT has been shown to increase auto-inhibition of the substantia nigra and VTA
by DA (Olijslagers et al., 2004). This may be an important area for future studies
of long and short term effects of DNSP-11.
Acute versus long-term effects of DNSP-11
It was observed in the protection studies that a subgroup of severely
lesioned animals exhibited greatly reduced potassium-evoked, calciumdependent release of dopamine after three weeks of intranasal DNSP-11
treatment, and this led to questions about possible pleiotropic effects of DNSP11. Here, naïve animals were taken for striatal microdialysis, during which they
were perfused with a 50 µM solution of DNSP-11 in aCSF, or aCSF-only without
peptide, through the microdialysis probe. Potassium-evoked dopamine release
was performed before and after the perfusion of DNSP-11 or aCSF-only, and
was found to be decreased after perfusion with DNSP-11 and significantly lower
than in aCSF-only perfused animals. Data from this study supports the
hypothesis that DNSP-11 has acute effects on calcium-dependent, potassiumevoked dopamine release within two hours of introduction to the striatum via
microdialysis probe. Additionally, no significant intra-animal variability in
potassium-evoked DA release was observed in the control animals, indicating the
analysis of the second potassium-evoked release as a percentage of the first
potassium-evoked release is valid. This finding of the equality of multiple
potassium-evoked releases is consistent with one report of microdialysis in
awake animals (Ripley et al., 1997) but contradicts another in anesthetized
animals (Kametani et al., 1995).
In summary, while DNSP-11 significantly affected the ratio of dopamine to
its metabolites in the striatum and substantia nigra of normal animals, the dose of
DNSP-11 provided to lesioned animals may be insufficient to protect against a
severe, acute toxic loss of neurons in a subset of animals. The data supports the
overall hypothesis that intranasal DNSP-11 produces biological effects on the
central nervous system.
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Figure 4.1 – Representative placement of the microdialysis probe in the striatum.
The vertical black line with blue end represents the CMA 11 microdialysis probe
with 4 mm long 6,000 MW cut-off membrane at its final position at the following
coordinates (with respect to bregma): AP: +1.5 mm, ML: -2.3 mm, DV: -8.0 mm
(from dural surface), TB: -3.3 mm. Modified from (Paxinos and Watson, 2005).
(ac, anterior commissure; cc, corpus callosum; LV, lateral ventricle.)
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Table 4.1 – Animal groups for dose response study in normal, unlesioned rats.

Numbers:

Vehicle
0 µg

DNSP-11
100 µg

DNSP-11
300 µg

DNSP-11
1000 µg

9

6

6

6

A total of 27 animals were used in this study. For every 6 animals in each dosing
group, 3 animals were concomitantly administered and evaluated vehicle only (0
µg), and the neurochemical content of the DNSP-11 administered animals were
compared as a percentage of the concomitantly administered vehicle only
animals. Due to the bilateral treatment, each hemisphere was used as an
independent data point. No animals were excluded from this study. Treatment
was performed in a blinded manner.
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Table 4.2 – Striatal neurochemical levels in normal rats given a range of
intranasal doses of DNSP-11.
Treatment

DA
(ng/g)
DOPAC
(ng/g)
HVA
(ng/g)
(HVA+DOPAC)
/DA
5-HT

(ng/g)
5-HIAA

(ng/g)

(5-HIAA/5-HT)

NE

(ng/g)
n=
(hemispheres)

0 µg DNSP-11
per day
(Vehicle only)

12427
± 1693
1919
± 400
832
± 254

0.221
± 0.032
576
± 104
653
± 126
1.14
± 0.17
100
± 31
18

100 µg DNSP11
per day

9043
**
± 3496
t(50)=3.695
1257
**
± 425
t(50)=3.722
570
**
± 192
t(50)=3.515
0.215
± 0.051
t(50)= 0.3571
625
± 110
t(50)=1.317
605
± 74
t(50)=1.364
0.980
*
± 0.099
t(50)=3.028
139
± 83
t(50)=2.064
12

300 µg DNSP11
per day

11923
± 2213
t(50)=0.5494
2422
*
± 635
t(50)=2.820
843
± 154
t(50)=0.1406
0.274 **
± 0.040
t(50)= 3.709
555
± 94
t(50)=0.5423
739
± 61
t(50)=2.474
1.35 ***
± 0.17
t(50)=3.869
92
± 28
t(50)=0.3348
12

1000 µg DNSP- Treatment
Statistics
11
per day

9910
*
± 2428
t(50)=2.748
1574
± 455
t(50)=1.938
658
± 147
t(50)=2.366
0.227
± 0.032
t(50)= 0.4492
582
± 93
t(50)=0.1594
640
± 78
t(50)=0.3618
1.11
± 0.10
t(50)=0.6256
99
± 50
t(50)=0.06490
12

P=0.0006
##

F(3,50)=5.913

P=0.0001
####

F(3,50)=13.21

P=0.0016
##

F(3,50)=5.916

P=0.0014
##

F(3,50)=6.042

P=0.3859
F(3,50)=1.033

P=0.0077
##

F(3,50)=4.436

P<0.0001
####

F(3,50)=13.62

P=0.1135
F(3,50)=2.089

Animals treated intranasally with DNSP-11 exhibited significant changes in the
levels of striatal dopamine and its metabolites. (Values are displayed as “analyte
mean ng/g of analyte ± standard deviation”. Analysis by one-way ANOVA with
Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated group,
*P<0.05; **P<0.01; ***P<0.001.)
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Figure 4.2 – Striatal dopamine and metabolites in normal rats given intranasal
DNSP-11.
A significant decrease in dopamine content was observed in the 100 µg/day and
1000 µg/day treated groups, DOPAC was significantly different at the 100 µg/day
and 300 µg/day groups, and HVA was significantly decreased in the 100 µg/day.
(DA: ##Treatment P=0.0016; DOPAC: ####Treatment P=0.0001; HVA: ##Treatment
P=0.0016 by one-way ANOVA. 0 µg, n=18 hemispheres; 100 µg, n=12
hemispheres; 300 µg, n=12 hemispheres; 1000 µg, n=12 hemispheres. Analysis
by one-way ANOVA with Bonferroni’s post hoc test. With respect to 0 µg vehicleonly treated group, *P<0.05; **P<0.01. Error bars displayed as SEM.)
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Figure 4.3 – Striatal total dopamine turnover in normal rats given intranasal
DNSP-11.
A significant increase in total dopamine turnover was observed in the striatum of
normal rats treated with 300 µg/day DNSP-11 for five of seven days a week for
three weeks. (##Treatment, P=0.0014. 0 µg, n=18 hemispheres; 100 µg, n=12
hemispheres; 300 µg, n=12 hemispheres; 1000 µg, n=12 hemispheres. Analysis
by one-way ANOVA with Bonferroni’s post hoc test. **P<0.01 with respect to 0
µg vehicle-only treated group. Error bars displayed as SEM.)
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Table 4.3 – Nigral neurochemical levels in normal rats given a range of
intranasal doses of DNSP-11.
Treatment

DA
(ng/g)
DOPAC
(ng/g)
HVA
(ng/g)
(HVA+DOPAC)
/DA
5-HT

(ng/g)
5-HIAA

(ng/g)

(5-HIAA/5-HT)

NE

(ng/g)
n=
(hemispheres)

0 µg DNSP-11
per day
(Vehicle only)

620
± 250
151
± 69
55
± 18

0.332
± 0.047
882
± 252
685
± 152
0.796
± 0.105
303
± 75
18

100 µg DNSP11
per day

481
± 203
t(50)=1.749
103
± 50
t(50)=1.977
37
*
± 17
t(50)=3.057
0.289
± 0.066
t(50)=1.340
767
± 161
t(50)=1.637
572
*
± 109
t(50)=2.606
0.757
± 0.135
t(50)=0.6823
293
± 86
t(50)= 0.2434
12

300 µg DNSP11
per day

815
± 204
t(50)=2.439
269 ****
± 72
t(50)=4.872
81
***
± 18
t(50)=4.198
0.443
**
± 0.119
t(50)=3.556
928
± 107
t(50)=0.6653
812
*
± 78
t(50)=2.898
0.882
± 0.099
t(50)=1.508
299
± 82
t(50)= 0.1009
12

1000 µg DNSP- Treatment
Statistics
11
per day

416
*
± 173
t(50)=2.559
124
± 66
t(50)=1.099
51
± 11
t(50)=0.7712
0.436
**
± 0.103
t(50)=3.331
606
***
± 158
t(50)=3.940
582
± 95
t(50)=2.375
1.011 **
± 0.249
t(50)=3.763
334
± 191
t(50)= 0.7191
12

P=0.0002
####

F(3,50)=8.201

P<0.0001
####

F(3,50)=15.63

P<0.0001
####

F(3,50)=15.30

P<0.0001
####

F(3,50)=13.17

P=0.0003
###

F(3,50)=7.380

P<0.0001
####

F(3,50)=11.04

P=0.0006
###

F(3,50)=6.789

P=0.8191
F(3,50)=0.3085

Animals treated intranasally with DNSP-11 exhibited significant changes in the
levels of nigral dopamine and its metabolites. Significance is shown with respect
to the 0 µg vehicle-only treated group. (Values are displayed as “analyte mean
ng/g ± standard deviation”. Analyses by one-way ANOVA with Bonferroni’s post
hoc test. With respect to 0 µg vehicle-only treated group, *P<0.05; **P<0.01;
***P<0.001; ****P<0.0001.)
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Figure 4.4 – Nigral dopamine and metabolites in normal rats given intranasal
DNSP-11.
A significant change in the levels of dopamine and its metabolites were observed
in the substantia nigra after treatment with intranasal DNSP-11. (DA:
###

Treatment P=0.0002; DOPAC: ####Treatment P<0.0001; HVA: ####Treatment

P<0.0001. 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12
hemispheres; 1000 µg, n=12 hemispheres. Analyses by one-way ANOVA with
Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated group,
*P<0.05; ***P<0.001; ****P<0.0001. Error bars displayed as SEM.)
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Figure 4.5 – Nigral total dopamine turnover in normal rats given intranasal
DNSP-11.
The ratio of HVA+DOPAC to DA was significantly different between vehicle only
and DNSP-11 treated groups (####Treatment P<0.0001; 0 µg, n=18 hemispheres.
100 µg, n=12 hemispheres; **300 µg, P<0.01, n=12 hemispheres; **1000 µg,
P<0.01, n=12 hemispheres. Analysis by one-way ANOVA with Bonferroni’s post
hoc test. Significance is shown with respect to 0 µg vehicle-only treated group.
Error bars displayed as SEM.)
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Figure 4.6 – Serotonin levels in the substantia nigra of normal rats given
intranasal DNSP-11.
Serotonin levels were significantly decreased in animals treated intranasally with
DNSP-11 for three weeks when compared with concomitant vehicle-only
negative control animals. (###Treatment P=0.0003; **1000 µg, P<0.01, n=12
hemispheres; 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12
hemispheres. Analysis by one-way ANOVA with Bonferroni’s post hoc test.
Significance is shown with respect to 0 µg vehicle-only treated group. Error bars
displayed as SEM.)
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Figure 4.7 – Serotonin turnover in the substantia nigra of normal rats treated with
DNSP-11.
Serotonin turnover was significantly elevated in animals treated intranasally with
DNSP-11 for three weeks when compared with concomitant vehicle-only
negative control animals. (###Treatment P=0.0006; **1000 µg, P<0.01, n=12
hemispheres; 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12
hemispheres. Analysis by one-way ANOVA with Bonferroni’s post hoc test.
Significance is shown with respect to 0 µg vehicle-only treated group. Error bars
displayed as SEM.)
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Table 4.4 – Neurochemical levels in the olfactory bulb of normal rats given a
range of intranasal doses of DNSP-11.
Treatment

DA
(ng/g)
DOPAC
(ng/g)
HVA
(ng/g)
(HVA+DOPAC)
/DA
5-HT

(ng/g)
5-HIAA

(ng/g)

(5-HIAA/5-HT)

NE

(ng/g)
n=
(hemispheres)

0 µg DNSP-11
per day
(Vehicle only)

30
± 14
15
±5

46
± 12
1.63
± 0.51
176
± 34
133
± 21
0.771
± 0.138
183
± 62
18

100 µg DNSP11
per day

16
**
±7
t(50)=3.426
16
±7
t(50)=0.5192
42
± 13
t(50)=0.7615
1.42
± 0.32
t(50)=1.331
207
± 49
t(50)=1.152
141
± 25
t(50)=0.6271
0.699
± 0.144
t(50)=1.313
204
± 39
t(50)=1.145
12

300 µg DNSP11
per day

38
±5
t(50)=1.865
15
±4
t(50)=0.02533
39
± 12
t(50)=1.316
1.42
± 0.36
t(50)=1.308
219
± 105
t(50)=1.605
157
± 40
t(50)=1.830
0.779
± 0.175
t(50)=0.1541
209
± 34
t(50)=1.376
12

1000 µg DNSP- Treatment
Statistics
11
per day

43
**
± 13
t(50)=3.223
14
±7
t(50)=0.3166
38
± 16
t(50)=1.534
1.20
*
± 0.39
t(50)=2.743
210
± 88
t(50)=1.287
148
± 50
t(50)=1.131
0.724
± 0.130
t(50)=0.8603
121
**
± 51
t(50)=3.371
12

P<0.0001
####

F(3,50)=13.88

P=0.8963
F(3,50)=0.1994

P=0.4091
F(3,50)=0.9813

P=0.0671
F(3,50)=2.538

P=0.3703
F(3,50)=1.070

P=0.3194
F(3,50)=1.200

P=0.4583
F(3,50)=0.8791

P=0.0002
###

F(3,50)=8.005

Animals treated intranasally with DNSP-11 exhibited significant changes in the
levels of some neurochemicals in the olfactory bulb. Significance is shown with
respect to the 0 µg vehicle-only treated group. (Values are displayed as “analyte
mean ng/g ± standard deviation”. Analyses by one-way ANOVA with
Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated group,
*P<0.05; **P<0.01.)
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Figure 4.8 – Olfactory bulb dopamine and metabolites in normal rats given
intranasal DNSP-11.
Significant differences in the levels of dopamine were observed in the olfactory
bulb of normal rats given intranasal DNSP-11 daily for three weeks. (Dopamine:
####

Treatment P<0.0001. 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres;

300 µg, n=12 hemispheres; 1000 µg, n=12 hemispheres. Analyses by one-way
ANOVA with Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated
group, *P<0.05; **P<0.01. Error bars displayed as SEM.)
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Figure 4.9 – Olfactory bulb total dopamine turnover in normal rats given
intranasal DNSP-11.
Total dopamine turnover in the olfactory bulb was not significantly different
between groups. (Overall treatment P=0.0671; *1000 µg P=0.0253, n=12
hemispheres 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12
hemispheres. Analyses by one-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM.)
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Table 4.5 – Animal groups for neurochemical content study in 6-OHDA lesioned
animals.

Numbers

Vehicle-only
Treated

Scrambled
Treated

DNSP-11
Treated

12

9

14

Scrambled and vehicle (saline only) were combined into one group for analysis
due to similarities in response. The DNSP-11 and Scrambled peptide treated
groups received 300 µg in 50 µL per treatment of each compound respectively.
Due to similarities in response, vehicle-only and scrambled peptide treated
groups were combined into one “Negative Control” group. Of the animals above,
one DNSP-11 treated and one scrambled treated animal were excluded due to
complications during endpoint collection. Three animals not included in the
above numbers died due to anesthetic complications during the lesion induction
surgery: two were in the DNSP-11 group and one was in the scrambled treated
group. Treatment was performed in a blinded manner.
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Table 4.6 – Striatal neurochemical content of 6-OHDA lesioned animals.
Treatment
Vehicle Only

Scrambled
Peptide

DNSP-11 Peptide

One-way
ANOVA
Treatment
Statistics

3738
5022
4795
P=0.7953
± 3577
± 4391
± 5701
677
1062
831
P=0.5073
DOPAC
(ng/g)
± 552
± 790
± 852
433
453
452
P=0.9936
HVA
(ng/g)
± 390
± 446
± 555
(HVA+DOPAC)/DA
0.527
0.421
0.394
P=0.5669
± 0.456
± 0.262
± 0.158
5-HT
613
640
660
P=0.7392
(ng/g)
± 182
± 120
± 137
5-HIAA
1198
1174
1267
P=0.6286
(ng/g)
± 209
± 286
± 246
2.10
1.83
1.91
P=0.4243
(5-HIAA/5-HT)
± 0.66
± 0.26
± 0.38
NE
75
92
79
P=0.7923
(ng/g)
± 65
± 49
± 57
10621
9772
11252
P=0.2263
DA
(ng/g)
± 1847
± 1829
± 2062
1777
1591
1771
P=0.5344
DOPAC
(ng/g)
± 474
± 333
± 409
880
779
822
P=0.5489
HVA
(ng/g)
± 201
± 166
± 231
(HVA+DOPAC)/DA
0.258
0.247
0.233
P=0.4656
± 0.047
± 0.049
± 0.049
5-HT
650
671
677
P=0.8611
(ng/g)
± 152
± 126
± 106
5-HIAA
1154
1109
1125
P=0.8855
(ng/g)
± 225
± 245
± 183
1.84
1.66
1.67
P=0.3687
(5-HIAA/5-HT)
± 0.45
± 0.24
± 0.28
NE
143
150
145
P=0.8971
(ng/g)
± 34
± 42
± 36
n=
12
8
13
The striatal neurochemical profile of rats subjected to a 6-OHDA lesion is

Intact hemisphere

Lesioned hemisphere

DA
(ng/g)

provided above. While this data represents the mean values (± standard
deviation) of the animals in each group, the animals were present in two distinct
populations within these groups: those with severe lesions and those with partial
lesions. These populations were separated for further analysis below.
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Figure 4.10 – Striatal dopamine content in lesioned animals after 21 days with
intranasal treatment.
Striatal dopamine content in the lesioned hemisphere was not significantly higher
in animals given DNSP-11 compared with vehicle-only and scrambled-peptide
treated animals (P=0.3727, t-test). Note the severely lesioned population in both
the DNSP-11 and Negative Control treated groups below 1000 ng/g DA. As
predicted, the lesioned hemispheres of Vehicle only and Scrambled peptide
treated animals were not significantly different (P=0.4815) and were combined as
one “Negative Control” group. Dopamine content was also not significantly
different in the intact hemispheres (P=0.8437, two-tailed t-test). (DNSP-11, n=13;
Negative Controls: Vehicle-only, n=11, Scrambled n=9.) (One vehicle-only, intact
hemisphere data point is outside the plot at 35877 ng/g DA and was found to be
a significant outlier by Grubb’s test. Displayed as mean ± SEM.)
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Table 4.7 – Striatal neurochemical content of partially lesioned animals.
Treatment
Vehicle Only

Scrambled
Peptide

DNSP-11 Peptide

One-way
ANOVA
Treatment
Statistics

6198
6673
10037
P=0.1354
± 2539
± 3728
± 4095
1083
1350
1651
P=0.1470
DOPAC
(ng/g)
± 305
± 629
± 488
714
604
953
P=0.1579
HVA
(ng/g)
± 236
± 411
± 419
(HVA+DOPAC)/DA
0.308
0.284
0.276
P=0.6677
± 0.073
± 0.049
± 0.073
5-HT
697
641
658
P=0.7771
(ng/g)
± 174
± 132
± 132
5-HIAA
1266
1162
1287
P=0.6908
(ng/g)
± 251
± 328
± 260
1.91
1.80
1.99
P=0.7176
(5-HIAA/5-HT)
± 0.57
± 0.23
± 0.40
NE
116
113
122
P=0.9237
(ng/g)
± 53
± 29
± 37
10090
9959
1210
P=0.1311
DA
(ng/g)
± 1913
± 2042
± 1920
1629
1644
1845
P=0.5766
DOPAC
(ng/g)
± 504
± 340
± 321
919
813
993
P=0.1537
HVA
(ng/g)
± 163
± 175
± 136
(HVA+DOPAC)/DA
0.268
0.253
0.238
P=0.6165
± 0.060
± 0.054
± 0.038
5-HT
687
689
660
P=0.9304
(ng/g)
± 185
± 139
± 108
5-HIAA
1193
1134
1155
P=0.9144
(ng/g)
± 281
± 275
± 237
1.82
1.66
1.77
P=0.7156
(5-HIAA/5-HT)
± 0.50
± 0.27
± 0.31
NE
146
161
143
P=0.6671
(ng/g)
± 41
± 40
± 40
n=
7
7
6
As predicted, Vehicle only and Scrambled peptide treated animals were not

Intact hemisphere

Lesioned hemisphere

DA
(ng/g)

significantly different with regards to dopamine (P=0.7905, two-tailed t-test) and
were combined as one “Negative Controls” group for further analysis below.
Analysis by one-way ANOVA with Bonferroni’s post hoc. Values are mean ± SD.
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Figure 4.11 – Striatal dopamine content in partially lesioned animals after 21
days with intranasal treatment.
Among the animals with a partial lesion, those animals treated with intranasal
DNSP-11 exhibited significantly greater dopamine content in the lesioned
hemisphere when compared with animals treated with Vehicle only or Scrambled
peptide (Overall effect of treatment ###P<0.0006, F(3,33)=7.481. Lesioned
hemispheres *P=0.0343, t(33)=2.679). The lesioned hemispheres of the DNSP-11
treated animals was not significantly different than their unlesioned hemispheres
(P=0.6017, t(33)=0.1448). Analysis by one-way ANOVA with Bonferroni’s post
hoc test. As predicted, the lesioned hemispheres of the Vehicle only and
Scrambled peptide treated animals were not significantly different (P=0.7905 by
two-tailed t-test) and were combined as one “Negative Control” group. The intact
hemispheres were significantly different between groups (∗P=0.0301 by t-test,
t(16)=2.022). Displayed as mean ± SEM.
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Table 4.8 – Striatal neurochemical content of severely lesioned animals.
Treatment
Vehicle Only

Scrambled
Peptide

DNSP-11 Peptide

One-way
ANOVA
Treatment
Statistics

293
67
302
P=0.2939
± 279
± 41
± 96
109
54
128
P=0.4681
DOPAC
(ng/g)
± 84
± 26
± 70
39
0
26
P=0.5316
HVA
(ng/g)
± 60
±0
± 28
(HVA+DOPAC)/DA
0.832
0.835
0.495
P=0.2876
± 0.602
± 0.107
± 0.142
5-HT
495
635
661
P=0.1565
(ng/g)
± 124
± 104
± 151
5-HIAA
1102
1217
1174
P=0.3704
(ng/g)
± 79
± 67
± 124
2.36
1.95
1.84
P=0.2958
(5-HIAA/5-HT)
± 0.74
± 0.42
± 0.38
NE
18
19
42
P=0.4608
(ng/g)
± 21
±1
± 43
11258
9118
10524
P=0.4085
DA
(ng/g)
± 1739
± 802
± 2024
1984
1406
1708
P=0.2994
DOPAC
(ng/g)
± 382
± 327
± 488
791
661
675
P=0.5798
HVA
(ng/g)
± 236
± 22
± 192
(HVA+DOPAC)/DA
0.246
0.226
0.229
P=0.7990
± 0.028
± 0.018
± 0.059
5-HT
598
607
692
P=0.2434
(ng/g)
± 81
± 2
± 111
5-HIAA
1098
1021
1083
P=0.7835
(ng/g)
± 120
± 89
± 145
1.87
1.68
1.59
P=0.3262
(5-HIAA/5-HT)
± 0.41
± 0.15
± 0.24
NE
139
112
147
P=0.3990
(ng/g)
± 27
± 24
± 34
n=
5
2
7
As predicted, Vehicle only and Scrambled peptide treated animals were not

Intact hemisphere

Lesioned hemisphere

DA
(ng/g)

significantly different (P=0.3300, two-tailed t-test) and were combined as one
“Negative Control” group for further analysis. Analysis by one-way ANOVA with
Bonferroni’s post hoc. Values are mean ± SD.
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Figure 4.12 – Striatal dopamine content in severely lesioned animals after 21
days with intranasal treatment.
The lesioned hemispheres of animals that exhibited a severe lesion of striatal
dopamine (<1000 ng/g DA, see Figure 4.10) were not significantly different
between groups (P=0.2427, t-test). As predicted, Vehicle only and Scrambled
peptide treated animals were not significantly different (P=0.3300, two-tailed ttest) and were combined as one “Negative Control” group. Analysis by one-way
ANOVA with Bonferroni’s post hoc test. Displayed as mean ± SEM.
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Table 4.9 – Animal groups for functional neurochemical study in 6-OHDA
lesioned animals.

Numbers:

Vehicle-only
Treated

Scrambled
Treated

DNSP-11
Treated

12

10

14

Scrambled and vehicle treated animals were combined into one group for
analysis due to similarities in response. The DNSP-11 and scrambled treated
group received 300 µg in 50 µL per treatment of each compound respectively.
Due to similarities in response (Chapter Three), vehicle-only and scrambled
peptide treated groups were combined into one “Negative Control” group. Of the
DNSP-11 treated animals, one was excluded due to complications during
microdialysis resulting in premature death and one was excluded due to a bad
microdialysis probe or poor collection. Two vehicle treated animals were
excluded due to a bad microdialysis probes or poor collection. Two scrambled
treated animals were excluded due to bad microdialysis probes or poor
collection. Three animals not included in the above numbers died due to
anesthetic complications during the lesion induction surgery: two were in the
DNSP-11 group and one was in the scrambled treated group. Treatment was
performed in a blinded manner.
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Table 4.10 – Neurochemical concentrations of microdialysis collected samples.
Perfusate
solution
and
Sample #
aCSF
Samples
4-6
(Baseline)

Analyte

Vehicle Only
group

Scrambled
Peptide group

DNSP-11
Peptide group

DA

7.79 ± 4.00

5.61 ± 5.49

4.88 ± 3.32

DOPAC

2360 ± 1276

2052 ± 1447

1328 ± 873

HVA

1504 ± 826

1394 ± 882

1673 ± 2139

100 mM K+
Sample 7

DA

413
± 189

331
± 283

191
± 184

****
$$$

250 µM
d-Amp
Sample 11

DA

335
± 163

408
± 230

288
± 200

$$

[nM]

[nM]

[nM]

Neurochemical concentrations collected during microdialysis were significantly
affected by treatment with DNSP-11. Significantly lower potassium (K+) evoked
release of dopamine was observed in animals treated intranasally with DNSP-11
daily for three weeks following 6-OHDA lesion induction of the substantia nigra
compared with negative control treated animals. The overall effect of treatment
on dopamine was significant (#P=0.0184, F(2,436)=5.073), the effect of treatment
on 100 mM K+ evoked DA was significant (****P<0.0001, t(436)=6.838 with
respect to vehicle; $$$P=0.0001, t(436)=4.149 with respect to scrambled). Effect of
treatment on 250 µM d-Amp evoked DA was significant ($$P=0.0026, t(436)=3.334
with respect to scrambled). Overall effect of treatment on DOPAC was
significant (####P<0.0001), but no significant difference in baseline, K+ evoked, or
d-amp evoked DOPAC levels were observed. Overall effect of treatment on HVA
was not significant (P=0.4251). As predicted, no significant difference in
dopamine was observed between scrambled and vehicle treated groups (overall
effect of treatment: P=0.7244). Analysis by two-way ANOVA with Bonferroni’s
post hoc test. Values shown are “mean nM of analyte ± SD.”
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Figure 4.13 – Functional release of dopamine collected by microdialysis in the
striatum of lesioned animals.
Significantly lower potassium (K+) evoked release of dopamine was observed in
animals treated intranasally with DNSP-11 daily for three weeks following 6OHDA lesion induction of the substantia nigra compared with negative control
treated animals. No changes in baseline dopamine release were observed.
(#Treatment P=0.0184, F(2,436)=5.073. ****K+ P<0.0001, t(436)=6.838 with
respect to Vehicle, $$$K+ P=0.0001, t(436)=4.149 with respect to Scrambled.
$$d-amp P=0.0026, t(436)=3.334 with respect to Scrambled.) DNSP-11 group,
n=12. Negative controls: vehicle-only treated, n=10; scrambled-sequence treated
n=8. Analysis by two-way ANOVA with Bonferroni’s post hoc test. These
observed effects were driven by severely lesioned animals of striatal dopamine
(<1000 ng/g DA striatal tissue content, see Figure 4.10). In animals with only a
partial lesion, no significant differences between groups were observed with
regards to striatal microdialysis (see Figure 4.15). Data points are mean nM ±
SEM.
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Figure 4.14 – Baseline dopamine release and metabolites in the lesioned
striatum collected by microdialysis.
Baseline levels of dopamine and its metabolites, as determined by microdialysis,
were not significantly different between groups. For each data point, the levels of
each compound were averaged over the fourth through sixth samples.
Dopamine P=0.1926, t(27)=1.336; DOPAC P=0.0552, t(27)=2.004; HVA P=0.2841,
t(26)=1.094. (DNSP-11, n=12. Negative controls: vehicle-only treated, n=10,
scrambled-sequence treated n=8.) The HVA concentration from one animal (at
8088 nM) was found to be a significant outlier by Grubb’s test and was removed.
Analyses by two-tailed t-test. Displayed as mean ± SEM.
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Figure 4.15 – Functional release of dopamine collected by microdialysis in the
striatum of animals that exhibited a partial lesion.
Of the animals that exhibited only a partial lesion of the striatum, as defined in by
a striatal dopamine content of under 1000 ng/g (see Figure 4.10), there was no
statistically significant difference of functional dopamine release between groups
(P=0.9929 with respect to overall treatment effect). DNSP-11 group, n=4.
Negative controls: vehicle-only treated, n=6; scrambled-sequence treated n=7.
Analysis by repeated measures two-way ANOVA with Bonferroni’s post hoc test.
Data points are mean nM ± SEM.
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B

A

Figure 4.16 – Acute effects of DNSP-11 during microdialysis infusion on
dopamine overflow.
Naïve 3 month old Fischer 344 male rats were challenged with a 100 mM K+
aCSF solution and allowed to time to return to baseline. After infusion with
DNSP-11 during samples 10-14, K+ evoked release of dopamine was decreased
by 40.8% from previous K+ evoked release (Figure 4.16A: F(1,4)=2.112 ****K+,
P<0.0001, t(72)=5.780. n=4 aCSF, n=2 DNSP-11. Analysis by two-way repeated
measures ANOVA with Bonferroni’s post hoc test; Figure 4.16B: **P=0.0014,
t(6)=5.620. 37.1% decrease, n=4 aCSF, n=4 DNSP-11 perfused.Analysis by twotailed t-test). No differences between groups were observed in baseline
dopamine. Of four DNSP-11 perfused animals, two were excluded from (A) due
to undetectable baseline concentrations of dopamine. Data points are mean nM
± SEM.
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Figure 4.17 – Acute effects of DNSP-11 during microdialysis infusion on DOPAC
overflow.
No significant differences were observed in DOPAC overflow with acute
microdialysis infusion. (P=0.8256. Analysis by two-way repeated measures
ANOVA with Bonferroni’s post hoc test; n=4 Controls, n=2 DNSP-11. Of four
DNSP-11 perfused animals, two were excluded due to undetectable baseline
concentrations of dopamine. Data points are mean nM ± SEM.)
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Figure 4.18 – Acute effects of DNSP-11 during microdialysis infusion of HVA
overflow.
No significant differences were observed in HVA overflow with acute
microdialysis infusion. (P=0.4906. Analysis by two-way repeated measures
ANOVA with Bonferroni’s post hoc test; n=4 Controls, n=2 DNSP-11. Of four
DNSP-11 perfused animals, two were excluded due to undetectable baseline
concentrations of dopamine. Data points are mean nM ± SEM.)
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Chapter Five: A study of the behavioral and physiological effects of
intranasally administered DNSP-11 in a 6-hydroxydopamine lesion model of
the substantia nigra
Hypothesis: Efficacious doses of DNSP-11 can be delivered intranasally to enter
the CNS in quantities sufficient to prevent the development of apomorphineinduced rotation behavior from a moderate 6-hydroxydopamine lesion of the
substantia nigra.

Introduction
Behavioral metrics are the ultimate measure in the study of interventions
for neurological disorders, especially in a neurodegenerative disease primarily
concerning motor function such as Parkinson’s disease. The complexity of the
neurological pathways can mean that molecular measures such as the presence
of tyrosine hydroxylase or dopamine may not indicate a symptomatic relief in the
organism. Feedback circuitry, compensatory sensitization, secondary pathways,
and molecular regulators may all stymie the translation of molecular measures to
the ultimate amelioration of motor-output. As such, neuroscience has often relied
on behavioral measures. The well-characterized unilateral 6-OHDA lesion model
of parkinsonism in rodents provides an excellent foundation for the quantification
of a variety of behavioral functions (Woodlee and Schallert, 2004; Ciucci et al.,
2008; Fleming et al., 2012). One behavioral metric of particular importance is
drug-induced rotation behavior in the unilateral 6-OHDA lesion model used in the
present studies.
The hypothesis that DNSP-11 will prevent the development of
apomorphine-induced rotation behavior was tested in all animals in this study
that were subjected to a unilateral 6-OHDA lesion (n=42). Animals were
assessed weekly for apomorphine-induced rotation behavior according to the
study timeline (Figure 2.3). Animals were weighed daily; and body temperature
and activity level was recorded continuously using an implanted “MiniMitter”
device (Chapter Two).
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Drug-induced rotation behavior in unilateral lesion models of
parkinsonism
Ungerstedt and Arbuthnott first characterized rotation behavior as a
method for quantifying nigrostriatal pathway function in rodents in 1970, and they
hypothesized that rotation behavior would result from an imbalance between the
pathways of the two hemispheres (Ungerstedt and Arbuthnott, 1970). This
asymmetry was validated in 1988 when Sonsalla, et al demonstrated changes in
dopamine receptor function in rotating animals with an induced lesion (Sonsalla
et al., 1988).
Two drugs are used to induce rotation behavior in rodent models of
Parkinson’s disease: apomorphine and d-amphetamine, and they have different
modes of action, producing rotations in different directions relative to the lesion.
Apomorphine has been shown to induce rotation behavior when lesion severity in
the substantia nigra is greater than 90% cell loss, providing a relatively highfidelity, “binary” measure of animals with severe loss in the nigrostriatal pathway
(Hudson et al., 1993) stabilizing by the 4th week. The mechanism of action of
apomorphine is due to its role as a dopamine receptor agonist. In a highly
denervated striatum a compensatory phenomenon referred to as “dopamine
receptor super-sensitization” results in a high rate of activation of the striatum
ipsilateral to the lesioned substantia nigra by dopamine analogues such as
apomorphine (Kostrzewa, 1995). This results in rotation behavior toward the
contralateral hemisphere. In other words, the animal rotates “away from” the
lesion, or the circle formed by the animal’s rotations places the unlesioned
hemisphere closest to the center. d-Amphetamine causes the net efflux of
intracellular dopamine into the extracellular space (see Chapter Four). As such,
amphetamine asymmetrically activates the unlesioned, innervated hemisphere,
producing rotations in the ipsilateral direction, “toward” the lesion, thereby placing
the lesioned hemisphere closer to the center of the rotation’s circle.
Amphetamine’s mechanism of action also produces a relatively gradual increase
in rotations as the nigrostriatal pathways become less symmetrical as the lesion
becomes progressively worse (Hudson et al., 1993). In these studies,
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apomorphine based rotations were used, primarily to minimize variability in the
behavioral measure. It has been shown that a portion of normal, unlesioned rats
can elicit rotation behavior after d-amphetamine administration (Hudson et al.,
1993). In order to reduce the possibility of false negatives of DNSP-11 treatment
effect, apomorphine was used.
Total activity levels and body temperature as a sign of general health
Efficacy of a compound is not the only important metric when evaluating a
drug for ultimate translation to human subjects. The safety of a drug on the
organism is also of importance. As such, the use of the MiniMitter device
(described in Chapter Two) allowed the continual recording of body temperature
and activity levels, providing indicators of the overall health of the animals in
these trials. The monitoring of body temperature provided a surrogate measure
of inflammatory response to the nasal administration of the test subject, and
overall activity levels similarly provided information regarding any overall
neurophysiological effect the test subject may have on the animal both in the
short- and long-term. In conjunction with measurements of body-weight, these
studies provide insight into the overall health of the animals and their reactions to
the treatment regimen relative to the control treated groups.
Materials and Methods
Semi-quantitative, subjective behavior observations in unlesioned
animals
Animals were observed for the five minute period immediately following
righting as a sign of recovery from the isoflurane anesthetic session. The extent
of their activity was recorded on a scale ranging from 0, no movement after
righting from the supine position, to 5, constant movement after righting. For
instance, a score of “3” would indicate the animal was moving throughout the
cage for approximately 3 of the 5 observed minutes. These observations were
only recorded in unlesioned animals in the dose-response study, and were done
so by a researcher blind to the treatment groups.
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Rotation behavior procedure
To confirm that these effects correlate with the prevention of transition to
the rotation behavior phenotype present in animals challenged with a unilateral 6OHDA lesion, all animals in the study (n=42) were tested every seventh day for
apomorphine-induced rotation behavior, quantified by an automated rotometer
system. Animals were administered apomorphine (0.05 mg/kg, s.c.) and tests
carried out in rotometer bowls with automated unbiased rotation measurement
utilizing a thoracic harness connected to a counting head that interfaces with
computer software (SDI Rotation, San Diego, CA USA) (Hudson et al., 1993;
Hoffer et al., 1994). The numbers of contralateral and ipsilateral rotations (in
relation to 6-OHDA lesion hemisphere) were recorded for 2 hours in 5 minute
intervals. Rotation behavior was collected the day prior to 6-OHDA lesion
induction and weekly thereafter until euthanasia (Figure 2.3). Total ipsilateral
rotations for the first 60 minutes of testing was subtracted from total contralateral
rotations for the first 60 minutes of testing and that number used in analysis. No
animals were excluded from this study. The rotometer bowls were cleaned with
disinfectant prior to use.
MiniMitter recording of activity and body temperature
MiniMitter E-Mitter probe was surgically implanted subcutaneously in the
back concurrently with 6-OHDA lesion induction surgery, as described in Chapter
2. The animal’s activity and body temperature was recorded at one minute
intervals until the end of the experimental timeline. These values were averaged
over the 12 hour long day (light) and night (dark) cycles and compared across
groups. Additionally, the total activity for the 5 minutes following recovery from
the anesthetic session used for daily intranasal dosing was summed and
compared across groups.
Body weight measurements
The animals’ body weights were measured daily through the entirety of the
study, beginning the day prior to lesion induction and concluding on the day of
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endpoint analysis. If the animal underwent anesthesia on a specified day, body
weight was measured while the animal was anesthetized.
Results
Animal health and comfort
Animals tolerated the treatment and daily anesthesic sessions well. They
did not exhibit signs of distress or discomfort. All animals exhibited a smooth,
well groomed coat, and none displayed signs of agitation, guarding, or audible
vocalization. There were no signs of nasal irritation such as edema or erythema.
Drug-induced rotation behavior
Animals challenged with a 6-OHDA lesion were tested weekly for
apomorphine (0.05 mg/kg, s.c.) induced rotation behavior, beginning with
baseline rotation the day prior to lesioning (day -1). Rotations, both contralateral
and ipsilateral to the lesioned hemisphere, were quantified by an automated
rotometer system (SDI Rotation, San Diego, CA USA). As predicted, Vehicle
Only and Scrambled Peptide treated animals was not significant (Table 5.1,
P=0.4201) and were combined in to one negative control group for further
analysis. A small set of animals began to exhibit rotation behavior during the
second week (day 13), but during the third week (day 20) this level rose to
significance. Animals treated intranasally with DNSP-11 showed mean
contralateral rotations of 0.25 (± 2.0, n=16), compared with animals treated with
scrambled peptide or vehicle-only that exhibited a combined mean of 89.9 (±
35.5, n=26), resulting in significance (Figure 5.1). Furthermore, none of the
animals treated intranasally with DNSP-11 exhibited rotation behavior at any
timepoint during the study, either from the histological (Figure 5.2) or
neurochemical (Figure 5.3) cohorts. The control treated animals were present in
two populations, those that exhibited rotation behavior (≥50 rotations/hour, n=7,
range of 88 to 669 rotations), and those that did not rotate (<50 rotations/hour ,
n=19, range of -23 to 38 rotations).
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Subjective behavior
Of the unlesioned animals in the dose response study, animals treated
daily with 1000 µg of DNSP-11 exhibited elevated mean subjective activity
(Figure 5.4) or daily levels of subjective activity (Figure 5.5) immediately following
intranasal treatment when contrasted with vehicle-only treated animals.
Expository notes also suggest the 300 µg per day DNSP-11 treated animals were
more active. The animals given 1000 µg of DNSP-11 per day exhibited a mean
daily post-treatment activity level of 2.9 ± 0.31 with a range of 2.5 to 3.4,
compared with 1.8 ± 0.46 with a range of 1.4 to 2.6 for the saline-only treated
animals (P<0.01, Figure 5.4), on a subjective scale of 0 to 5, with 5 being the
most active and 0 being not active. The animals given 1000 µg of DNSP-11 per
day were significantly more active during the first and second week of treatment,
but by the third week their activity levels had decreased in line with vehicle only
treated animals (Figure 5.5).
MiniMitter activity levels and body temperature
There was no observed significant difference between groups of the 6OHDA lesioned animals in the measure of mean post-treatment activity (Figure
5.6), nor did it show a significant difference in daily post-treatment activity (Figure
5.7). In addition, there was no difference between groups in mean or daily daytime or night-time activity levels (Figure 5.8 through Figure 5.11) or body
temperature (Figure 5.12 through Figure 5.15).
Body weight
Body weight was not significantly different between the DNSP-11 or
negative control treated groups (Figure 5.16).
Discussion
These results support the hypothesis that intranasal DNSP-11 treatment
would prevent the development of apomorphine-induced rotation behavior in 6hydroxydopamine lesioned rats. Furthermore, the animals treated with DNSP-11
did not show signs of distress, discomfort or nasal irritation. Neither their activity
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levels nor body weight were negatively impacted by DNSP-11 treated, providing
some broad data on the safety of intranasal DNSP-11 treatment.
Subjective behavior and activity
None of the animals in the study exhibited signs of distress or
discomforting, including edema or erythema of the nasal region, suggesting the
treatment itself did not produce irritation. The animals did not display guarding or
unusual vocalization, suggesting the treatment regimen was well tolerated.
Among the unlesioned animals in the dose-response study, those treated
with DNSP-11 exhibited higher levels of subjective activity immediately following
intranasal treatment, subjectively recorded by a researcher blind to the treatment
groups. This could suggest an acute and direct neuropsychological effect of
DNSP-11 on the motor system, or olfactory stimulation leading to normal
searching behavior. To attempt to control for this and the observed
neurochemical changes, later studies included a scrambled version of the DNSP11 peptide sequence (Table 2.1) as a negative control.
Apomorphine-induced rotation behavior
While apomorphine induced rotation behavior stabilizes by the 4th week
after lesion, this study only evaluated rotation behavior to the 3 week timepoint.
At that time point, a significant difference arose between those treated
intranasally with DNSP-11 or with negative controls (Figure 5.1). None of the
DNSP-11 treated animals exhibited rotation behavior, indicating DNSP-11 may
be able to prevent the progression of super-sensitization caused by striatal
denervation within the 3 weeks observed in this study. The negative control
treated animals were present in two populations: those that did exhibit rotation
behavior (88 to 669 rotations, n=7), and those that did not rotate (negative 23 to
38 rotations, n=19), defined as <50 rotations per hour (Hudson et al., 1993), due
to lesion variability. All of the animals that exhibited rotation behavior were
among the severely lesioned subgroup of animals as defined by striatal
dopamine content of <1000 ng/g (see Figure 4.10). This behavior data supports
the histological protection observed while suggesting that longer-term studies in
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the 4 to 6 week time period may provide stronger efficacy data regarding the
potential of intranasal DNSP-11 for protection against dopaminergic loss and the
behavioral consequences. In addition, the use of d-amphetamine induced
rotation behavior, after pre-screening against animals that rotate prior to
lesioning, may identify significant results at earlier time points.
MiniMitter activity levels and body temperature
MiniMitter data did not reveal any differences between treatment groups
with regard to post-treatment activity (Figure 5.6 and Figure 5.7) average daytime
or nighttime activity levels or body temperature (Figure 5.8 through Figure 5.15).
The objective MiniMitter activity data does not mirror the subjective,
blinded activity data. This disparity may be due to a number of reasons. The
MiniMitter device, implanted in the back of the animal, may have emphasized
activities that the subjective observer disregarded, such as shaking, shivering, or
grooming behavior, resulting in relatively higher “noise” in the MiniMitter data.
The animals implanted with the MiniMitter device were also challenged with a 6OHDA lesion of the substantia nigra while the subjectively observed animals
were unlesioned, possibly altering this subjectively observed effect.
Animals treated with DNSP-11 did not exhibit elevated body temperature
values compared with saline or scrambled-peptide treated controls. This may
indicate that the peptide does not produce an inflammatory response that could
be detected by the MiniMitter device, providing some broad and preliminary data
on the safety of the DNSP-11 peptide when delivered intranasally.
A further element of the MiniMitter studies was to determine if their use
would equate to open-field testing and the Actical (Philips Respironics, Bend, OR
USA) monitoring devices used in human and non-human primate studies of
Parkinson’s disease and its models. Significant differences between groups in
this study were not observed, however unlesioned animals were not tested with
the MiniMitter system providing no basis for comparison against normal rodents.
Average activity over the 12 hour light or dark periods did not indicate significant
differences in activity, but these values are during an extended length of time and
are not similar to one hour open-field behavior testing. The total activity
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immediately after intranasal administration was not significantly different between
groups. Testing the device in normal unlesioned animals for comparison and
using the device for before/after treatment measurements may allow for the
discernment of effects elicited by treatments and the 6-OHDA lesion model.
Body weight
Subject body weight can be an indicator of the overall health and speed of
recovery in animal studies. The fact that the animals in this study exhibited
statistically similar body weights throughout the experiment (Figure 5.16) may be
an important finding. A side-effect of GDNF treatment is weight loss (Hovland et
al., 2007a). Although the timeframes and means of delivery are different
between the cited study and the present data, the present study suggests DNSP11 does not produce significant weight loss as a side effect. This provides some
important safety information regarding the repeated use of DNSP-11.
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Table 5.1 – Number of apomorphine-induced turns per hour in control and
DNSP-11 treated animals
Group
Day -1
Vehicle
2.714
Only Group ± 7.819
Scrambled
1.167
Peptide
± 5.606
DNSP-11
-0.438
Peptide
± 6.750

Day 6
3.429
± 11.581
3.500
± 10.318
6.750
± 12.902

Day 13
8.500
± 21.533
33.000
± 63.356
-1.063
± 10.299

Day 20
69.214
± 179.436
114.083
± 187.615
0.250
*
$$$
± 8.153

n=
14
12
16

None of the animals treated with intranasal DNSP-11 exhibited rotation behavior
at any time point. On day 13, one animal in the Vehicle Only group and two
animals in the Scrambled Peptide group exhibited rotation behavior, defined as
>50 turns per hour (Hudson et al., 1993). By the 20th day after 6-OHDA lesion
induction, three Vehicle Only and four Scrambled Peptide treated animals
exhibited rotation behavior. This resulted in a significant difference between
control and DNSP-11 treatment groups (overall effect of treatment P=0.0782,
F(2,39)=2.722. *P=0.0248, t(156)=2.530 with respect to Vehicle, and $$$P=0.0002,
t(156)=4.003 with respect to Scrambled). As predicted, the overall effect of
treatment between the Vehicle Only and Scrambled Peptide treated animals was
not significant (P=0.4201, F(1,24)=0.6730) at any time point (Day -1 through Day
13: P>0.9999, Day 20: P=0.9246). No animals were excluded from this analysis.
Data displayed as “mean rotations per hour ± standard deviation”. Analysis
performed by two-way repeated measures ANOVA with Bonferroni’s post hoc
test.
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Figure 5.1 – Rotation behavior in negative control and DNSP-11 treated lesioned
animals.
Animals treated with DNSP-11 intranasally exhibited no abnormal rotation
behavior on the 20th day after 6-OHDA lesioning of the substantia nigra,
contrasted with negative control treated animals. As predicted, vehicle and
scrambled peptide treated animals did not exhibit a significant difference in effect
(P=0.4201). (Overall effect of treatment P=0.0782. *P=0.0248 with respect to
Vehicle, and $$$P=0.0002 with respect to Scrambled. Vehicle treated, n=14;
Scrambled peptide treated, n=12; DNSP-11 treated, n=16.) No animals were
excluded from this analysis. Data displayed as “mean rotations per hour ± SEM”.
Analysis by two-way repeated measures ANOVA with Bonferroni’s post hoc.

116

Figure 5.2 – Individual rotation behavior of the histological cohort.
Of animals in the histology cohort, none of the animals treated with DNSP-11
exhibited apomorphine-induced rotation behavior on day 20.
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Figure 5.3 -- Individual rotation behavior of the neurochemistry cohort.
Of animals in the neurochemistry cohort, none of the animals treated with DNSP11 exhibited apomorphine-induced rotation behavior on day 20.
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Figure 5.4 – Average subjective activity levels recorded by observer blind to
treatment immediately following intranasal administration.
Average subjective activity levels immediately following intranasal administration
were significantly different in the group of animals administered 1000 µg per day
of DNSP-11 for three weeks (##P=0.0038 overall; **1000 µg P<0.01). Activity
levels in the 300 µg daily dose cohort were not recorded, but expository notes
suggest elevated activity compared to the concomitantly treated 0 µg animals.
Subjective behavior was assessed by a research blind to treatment. (n=6 animals
per group. Analysis by one-way ANOVA with Bonferroni’s post hoc. Shown as
mean ± SEM.)
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Figure 5.5 – Daily subjective activity levels recorded by observer blind to
treatment immediately following intranasal administration.
Animals given 1000 µg of DNSP-11 intranasally began the treatment regimen
with significantly elevated subjective activity levels, especially on day 2; and
these activity levels decreased as the treatment progressed to the final week.
Vehicle-only treated animals exhibited significantly lower activity levels, and that
subjective activity level remained low throughout the treatment. The 100 µg
treated animals were not significantly different from saline vehicle only treated
animals. Subjective behavior was assessed by a research blind to treatment.
(##P=0.0043 overall; ****Day 2 activity levels, P<0.0001 between 1000 µg and 0
µg vehicle-only treated groups. **Day 8 and 9, P<0.01 between 1000 µg and 0
µg groups. Analysis by repeated measures two-way ANOVA with Bonferroni’s
post hoc. Shown as mean ± SEM.)
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Figure 5.6 – Average post-treatment activity levels recorded by MiniMitter.
The animals’ activity levels for the five minutes immediately following recovery
from isoflurane anesthetic used during the intranasal treatment session shows no
significant differences between negative control or DNSP-11 treated animals
(P=0.7168 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10. Analysis by
one-way ANOVA with Bonferroni’s post hoc test. Shown as mean ± SEM).
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Figure 5.7 – Daily post-treatment activity levels recorded by MiniMitter.
The animals’ activity levels for the five minutes immediately following recovery
from isoflurane anesthetic used during the intranasal treatment session shows no
significant differences between negative control or DNSP-11 treated animals
(P=0.6466 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10. Analysis by
repeated measures two-way ANOVA with Bonferroni’s post hoc test. Shown as
mean ± SEM).
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Figure 5.8 – Average daytime activity levels recorded by MiniMitter.
The 12-hour “light” period activity levels in the animals were not significantly
different between groups (P=0.5398 overall; Vehicle, n=8; Scrambled, n=6;
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM).
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Figure 5.9 – Daily daytime activity levels in animals as recorded by MiniMitter.
Daily daytime “light” activity levels were not significantly different between groups
(P=0.5414 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10. Analysis by
repeated measures two-way ANOVA with Bonferroni’s post hoc test. Shown as
mean ± SEM). Note that Days 5, 12 and 19 the animals were off-treatment and
only body weight measurements were taken.
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Figure 5.10 – Average nighttime activity levels recorded by MiniMitter.
The 12-hour “dark” period activity levels in the animals were not significantly
different between groups (P=0.0973 overall; Vehicle, n=8; Scrambled, n=6;
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM).
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Figure 5.11 – Daily nighttime activity levels recorded by MiniMitter.
Daily nighttime “dark” activity levels were not significantly different between
groups (P=0.0927 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10.
Analysis by repeated measures two-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM).
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Figure 5.12 – Average daytime body temperature recorded by MiniMitter.
The 12-hour “light” period body temperature in the animals was not significantly
different between groups (P=0.1449 overall; Vehicle, n=8; Scrambled, n=6;
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM).

127

Figure 5.13 – Daily daytime body temperature recorded by MiniMitter.
Daily daytime light-period body temperature was not significantly different
between groups (P=0.1456 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11
n=10. Analysis by repeated measures two-way ANOVA with Bonferroni’s post
hoc test. Shown as mean ± SEM).
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Figure 5.14 – Average nighttime body temperature recorded by MiniMitter.
The 12-hour night-period body temperature in the animals was not significantly
different between groups (P=0.2454 overall; Vehicle, n=8; Scrambled, n=6;
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM).
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Figure 5.15 – Daily nighttime body temperature recorded by MiniMitter.
Daily nighttime dark-period body temperature was not significantly different
between groups (P=0.2454 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11
n=10. Analysis by repeated measures repeated measures two-way ANOVA with
Bonferroni’s post hoc test. Shown as mean ± SEM).
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Figure 5.16 – Daily animal body weight post-lesion.
Animals were weighed daily before and after lesion induction no significant
difference between groups was observed (P=0.2225 overall, n=42. Negative
Controls, n=14 vehicle and 12 scrambled treated; DNSP-11 (300 µg), n=16.
Analysis by repeated measures two-way ANOVA with Bonferroni’s post hoc test.
Shown as mean ± SEM).
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Chapter Six: An immunohistochemical study of the endogenous DNSP-11
sequence in the rat brain
Hypothesis: The DNSP-11 sequence is endogenously present in the rat brain as
a peptide that has differential patterns of spatial and temporal localization from
that of mature glia cell line-derived neurotrophic factor (GDNF).

Introduction
The dopamine neuron stimulating peptide-11 (DNSP-11) peptide was
identified as a theoretical cleavage product from the prosequence of GDNF, and
we and others have shown that the sequence is biologically active in the present
study and in the literature, both in vitro and in vivo (Immonen et al., 2008; Bradley
et al., 2010; Kelps et al., 2011), but questions remain regarding its endogenous
cleavage and localization in the brain. Lending further support to a biological role
for DNSP-11, the peptide sequence shares homology across species: homo
sapiens and macaca mulatta share 100% homology, and homo sapiens shares
73% homology with both mus musculus and rattus norvegicus (P1L, P2L, R9H).
Furthermore, DNSP-11 immunoreactivity has been observed to colocalize with
TH+ cells of the substantia nigra in the post-natal day 10 rat brain (Bradley et al.,
2010). While DNSP-11 and GDNF are likely co-expressed and processed, their
target cell populations and trafficking may be quite different.
Roles of pro-protein and signal peptides in the CNS
Putative peptides have been identified in the pro-region of other
neurotrophic factors expressed in the CNS. These peptides are, like DNSP-11,
flanked by dibasic amino acids that are purported to be cleavage sites. Two of
the most studied pro-region peptides are located within the proNGF protein,
referred to as LIP1 and LIP2, and have defined biological activities through
specific signaling cascades (Clos and Dicou, 1997; Dicou et al., 1997; Dicou,
2006), and their endogenous identification has been linked to conditions of aging
(Dicou, 2008).
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Pro-forms of other proteins have differential effects and distinct binding
from their mature forms. A well studied example of this is brain-derived
neurotrophic factor (BDNF), which can bind to either p75NTR or the Trk-family of
receptors, if it is secreted as proBDNF or mature BDNF (Buttigieg et al., 2007).
Many members of the TGFβ family of proteins can be secreted as pro-proteins,
especially the bone morphogenetic proteins (BMPs), and this affects the
targeting of the protein (Gregory et al., 2005). The GDNF protein is a member of
the TGFβ family of proteins and its pro-region contains the DNSP-11 sequence
flanked by consensus sites for cleavage by prohormone convertase (K26R27
and H/R40R41R42). Based on these consensus sites and the evidence of
biological effects of DNSP-11, it is reasonable to suggest that the DNSP-11
sequence is endogenously processed and has a native function. Similar to other
proteins, many possibilities exist for the proGDNF molecule: a) the DNSP-11
sequence itself may be cleaved to form a bioactive peptide in its own right, b) the
proGDNF protein may be secreted whole with the DNSP-11 sequence
representing the smallest necessary binding sequence, c) the whole pro-region
may be cleaved as a signal peptide containing the active DNSP-11 sequence, or
d) any combination of cleavage patterns may produce a biologically active
derivative of proGDNF. Of note, the consensus site for cleavage contains minor
differences between rats (H40) and humans (R40), possibly resulting in a
difference in processing between species (Duckert et al., 2004). Based on the
wide array of effects elicited by the DNSP-11 sequence both in animal models
and a range of cell culture lines (Bradley et al., 2010; Turchan-Cholewo et al.,
2010; Kelps et al., 2011; Bradley et al., 2012), it seems possible that the
conserved DNSP-11 sequence acts as a natural ligand for a receptor, perhaps
involved in metabolic homeostasis and developmental cell sparing.
Homologous sequences in the CNS
Neuropeptide Y (NPY) is a 36 amino acid peptide that shares five
consecutive amino acids beginning with amino acid 12 (NPY sequence:
YPSKPDNPGE DAPAEDMARY YSALRHYINL ITRQRY; compared to the
DNSP-11 sequence: PPEAPAEDRSL. For full proGDNF precursor, see Figure
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1.6). This five amino acid sequence homologue is found in the rat and human
CNS, as determined by protein BLAST in silico analysis (Altschul et al., 1997).
NPY is typically observed in the hypothalamus, amygdala and cortex, with little to
no immunoreactivity detected in the midbrain (Dawbarn et al., 1984; de Quidt and
Emson, 1986b) nor in tyrosine hydroxylase positive neurons (Everitt et al., 1984).
In addition to NPY, there also exists an approximately 42.9 kDa protein
referred to as the TRK-Fused Gene product (Tfg) which contains a homologous
sequence to DNSP-11 (Tfg amino acids 194-206 sequence: PPSAPTEDRSG,
DNSP-11 sequence: PPEAPAEDRSL) and which is also expressed in the rat
brain (Maebayashi et al., 2012). Tfg immunoreactivity in the CNS is prevalent in
regions including the mesencephalic nucleus of the trigeminal nerve and dorsal
raphe nucleus, as well as the cytoplasm of Purkinje cells of the cerebellum and
vestibular and cochlear nuclei of the pons.
The use of expression patterns to target DNSP-11 for increased
efficacy and decreased off-target effects
While the endogenous developmental and maintenance roles of DNSP-11
are interesting in their own right, the localization of DNSP-11 within the CNS may
provide insight into its effectiveness as an exogenously applied therapy. Any
observed anatomical localization of an endogenous, or exogenously applied,
DNSP-11 signal may indicate a reactive cell population, possibly utilizing unique
receptors and signaling cascades. This information can provide insights into the
possible functions of DNSP-11 and may help explain potential effects of
exogenously administered DNSP-11. With this information, modifications to the
peptide sequence, delivery approach or formulation may help increase on-target
effects while minimizing side effects.
Materials and Methods
Animals
A combination of both young adult and post-natal day 10 Fischer 344 rats
naïve to treatment were euthanized and processed for immunohistochemical
visualization of brain tissue. A total of 9 young adult (3 to 6 month old) male rats
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were euthanized and their brains sectioned either sagittally (n=6) or coronally
(n=3) for anatomical localization of signal. Post-natal day 10 animals (n=4) of
undetermined sex and one young adult female rat sectioned sagittally (n=1) were
also used.
Equipment and Reagents
The immunoprecipitation kit by Life Sciences (Cat. No. 143.21D,
Invitrogen, Oslo, Norway) was used. A custom DNSP-11 polyclonal antibody
(see below) was used for immunohistochemistry, immunoprecipitation, and
ELISA. Tyrosine hydroxylase antibody was purchased from Millipore Chemicon
(MAB318, Millipore Chemicon, Temecula, CA). GDNF antibody was purchased
from R&D Systems (AF-212-NA, R&D Systems, Minneapolis, MN). Secondary
antibodies include peroxidase-conjugated anti-rabbit IgG (PI-1000, Vector
Laboratories, Burlingame, CA), Alexafluor anti-goat 568 and Alexafluor anti-rabbit
488 fluorescent (Life Sci. Invitrogen Molecular Probes). VectaShield H-1400
Hard-Set Mounting medium for coverslipping dual-fluorescent specimens was
used (Vector Laboratories, Burlingame, CA). Fluorescent images acquired on a
Nikon microscope. Refrigerators and freezers were continuously monitored for
temperature variations. Other reagents were purchased from Fisher Scientific
unless otherwise specified.
Custom antibody to DNSP-11
The custom polyclonal antibody to DNSP-11 (PPEAEPDRSL-NH2) used in
these experiments was obtained under contract from α-Diagnostics laboratory,
was raised in rabbit and affinity purified against the synthesized, amidated
DNSP-11 peptide in a CN-Br activated agarose matrix and eluted in 0.1M
glycine-HCl and neutralized to pH 8.0 with 1M Tris and 0.1% BSA added for
stabilization. Titer by ELISA was quantified at 1:10K-100K. Pre-absorption of
the antibody with 10:1 (mass:mass) human or rat DNSP-11 peptide completely
prevented reactivity with tissue. A custom antibody to the rat DNSP-11
sequence (LLEAEPDHSL-NH2) was obtained under the same contract
conditions, resulting in a similar titer, produced indistinguishable tissue

135

localization, and pre-absorption with peptide similarly prevented tissue reactivity.
However, antibodies raised against the human sequence produced more intense
visual signal in rat brain tissue and was used for visualization.
Tissue preparation for immunohistochemistry
Adult rats were perfused with approximately 200 mL ice cold saline
followed by ice cold 4% paraformaldehyde, while post natal rats were not
perfused. The animals’ brains were removed whole and placed in ice cold 4%
paraformaldehyde fixative overnight for immunohistochemical analysis. Rat
brains were sectioned to 30 µm thickness and stored in cryoprotectant solution
(30% sucrose, 30% ethylene glycol in 100 mM KPBS) at -20°C until
histochemical processing. I would like to acknowledge April Dawn RichardsonHatcher, Ph.D. for the prepararation of tissue from four post-natal day 10 rats.
Immunohistochemical processing
Every 12th section was blocked with 4% normal goat serum for 1 hour at
room temperature. The sections were then immunolabeled with antibody to a
custom polyclonal human DNSP-11 (1:1000, α-Diagnostic, San Antonio, Texas
USA) raised in rabbit and incubated overnight at 4°C. The sections were
incubated with peroxidase-conjugated secondary antibody (1:1000, Vector Labs,
Burlingame, CA USA) and visualized with nickel enhanced 3,3’-diaminobenzidine
(NiDAB) chromogen.
Dual-fluorescence immunohistochemical processing
Sections were incubated with the polyclonal primary antibody against
DNSP-11 (α-Diagnostic, 1:1000) overnight at 4 °C, then incubated in Alexa Fluor
488 goat anti-rabbit secondary antibody (1:1000; Molecular Probes Inc., Eugene,
OR) for 1 hour at room temperature. The same sections were subsequently
incubated in an anti-GDNF antibody (1:500, Chemicon Millipore, Temecula, CA
USA) overnight at 4 °C, followed by 1 hour at room temperature in Alexa Fluor
568 goat anti-mouse IgG secondary antibody (1:1000; Molecular Probes Inc.).
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Tissue homogenization
Rat brain tissue from 3 month old male Fischer 344 rats was dissected,
placed in cold lysis buffer (10mM TrisHCl, pH 7.4, 150mM NaCl, 0.5% Triton X100 and 0.1% Proteinase Inhibitor Cocktail (Sigma P8340)), and homogenized
by sonication. The homogenate was allowed to incubate on ice for one hour,
followed by the removal of cell debris by centrifugation at 14,000 g at 4°C for 5
minutes.
Immunoprecipitation
Immunoprecipitation kit was purchased from Life Sciences (143.21D,
Invitrogen, Oslo, Norway) and was performed as follows. A total of 10 mg of
Dynabeads were coupled with 70 µg of polyclonal, custom DNSP-11 antibody by
overnight incubation at 37°C under constant movement. Beads were washed,
and then tissue homogenate was incubated with the antibody-conjugated beads
for 30 minutes at 4°C under constant movement. Immunoreactive compounds
were then eluted and retained at -70°C. A total of 3 animals were used per
immunoprecipitation resulting in an average 0.1 to 0.2 g of tissue per
immunoprecipitation. The resultant fractions containing the immunoprecipitated
contents were concentrated by lyophilization, and verified by an SDS-PAGE gel
to confirm the purity of the immunoprecipitation eluent by Coomassie blue and
silver-stain visualization. I would like to acknowledge Kristen A. Kelps in the
laboratory of Luke H. Bradley, Ph.D. for performing immunoprecipitations.
Peptide identification
Immunoprecipitated fractions from brain tissue homogenate underwent
protein identification, compared to the synthetic amidated 11-amino acid rat
sequence of DNSP-11, as performed by LC-MS/MS in the University of Kentucky
Proteomics Core Facility (Lexington, KY).
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Results
Differential immunostaining patterns for GDNF and DNSP-11
To characterize the location of the endogenous DNSP-11 peptide within
the rat brain (Table 6.1, Figure 6.1), immunohistochemical staining of sagittal and
coronal sections of the rat brain were performed using a polyclonal antibody
raised to the DNSP-11 sequence. Intense immunoreactive signal of neuronal
cell bodies was apparent in the locus coeruleus (LC) (Figure 6.2 and Figure 6.3),
with strong signal in the ventral tegmental area (VTA), substantia nigra pars
compact (SNc) (Figure 6.4) and glomeruli of the olfactory bulb (OB). Moderate
signal was observed in granule-like cells of the dentate gyrus (DG) and CA1-CA3
of the hippocampus (Figure 6.5), the nucleus of Purkinje-like cells of the
cerebellum, and neurons of the facial motor nucleus and mesencephalic nucleus
of the trigeminal nerve. Weaker signal appeared in granule-like cells throughout
the cortices of the brain, including but not limited to the olfactory cortex,
accessory olfactory bulb, cerebral cortex (Figure 6.1). Both the antibodies to the
rat and human DNSP-11 sequences showed comparable immunoreactivity, but
the antibody raised against the human sequence resulted in more intense
visualization and detection by ELISA to a lower concentration of the peptide.
Pre-absorbing both antibodies with either the rat or human DNSP-11 sequence
produced no non-specific signal.
It has been previously shown that DNSP-11 signal colocalizes to tyrosine
hydroxylase positive neurons at post-natal day 10 in the Sprague Dawley rat
(Figure 6.6) (Richardson, 2009; Bradley et al., 2010) and differential expression
patterns of GDNF and DNSP-11 in embryonic and post-natal animals described
(Richardson, 2009). Here, dual-fluorescence immunoreactive signals for DNSP11 and GDNF in post-natal day 10 Fischer 344 rats revealed midbrain (Figure
6.7) and dorsal raphe (Figure 6.8) neurons containing DNSP-11 signal without
GDNF. Furthermore, dual-fluorescence studies indicated some colocalization of
DNSP-11 and GDNF signals within the neuronal cell bodies of the SN, which
may represent the uncleaved prosequence; however, DNSP-11 signal was also
found to be differentially localized from GDNF signal in the, SN and VTA (Figure
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6.9) and the LC (Figure 6.10). Of note, DNSP-11 signal distinct from GDNF
signal was observed in the nucleus, but not cytoplasm, of Purkinje-like cells of
the cerebellum (Figure 6.11). DNSP-11 signal was present in the DG of the
hippocampus without discernible GDNF signal, and DNSP-11 and GDNF signals
were highly colocalized in the adult facial motor nucleus, the adult striatum,
cerebellum, and medial lemniscus (not shown).
Immunoprecipitation
Peptide identification from the immunoprecipitated fractions were
inconclusive. While compounds were pulled down by the antibody, none had
the same LC retention time as the synthetic amidated rDNSP-11 peptide, and the
mass spectroscopy identified breakdown pattern of synthetic rDNSP-11 was not
identified in the immunoprecipitate. A total of three animals were used in this
study, and one was excluded due to no detectable proteins pulled down by the
immunoprecipitation column.
Discussion
Limitations of the technique
The antibody used in these studies was a custom, polyclonal antibody
raised in rabbit against the synthetic 11-amino acid amidated DNSP-11
sequence. While its sensitivity in ELISA is high, and signal is blocked with
excess of the synthetic DNSP-11 peptide, the specificity of the antibody is not
known and the peptide cannot be used to quantitatively assay DNSP-11
concentrations in the brain. Previous studies have shown that the antibody is
effective at identifying the distribution of DNSP-11 in situ after intracranial
injection (Bradley et al., 2010); however, the possibility of the polyclonal antibody
binding to other compounds within the CNS is considerable. Indeed, the
polyclonal antibody used in these studies strongly binds NPY as determined by
ELISA. Taken at face value, this data only indicates that the antibody raised to
synthetic DNSP-11 encounters binding partners in the observed regions of the
brain, which may include at least the known preproGDNF and NPY proteins but
may also include the DNSP-11 sequence. An exhaustive identification of the
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binding partners of this antibody has not been performed, but based on
immunoprecipitation results it is unlikely that the 11-amino acid DNSP-11
sequence exists as a free, isolated, amidated peptide. It should also be noted
that the consensus cleavage site for the DNSP-11 sequence is conservatively
mutated between rats (H40) and humans (R40), and that this introduces the
possibility of minor differences in processing across species, based on in silico
analysis (Duckert et al., 2004). Future studies would benefit from a sensitive,
specific monoclonal antibody to the DNSP-11 sequence.
Sequence homologs in the rat CNS
The immunoreactivity presented in this study may be complicated by the
presence of both neuropeptide Y (NPY) and TRK-Fused Gene product (Tfg)
which contain partially homologous sequences to DNSP-11 (see Table 6.1).
However, it has been reported in the literature that NPY does not localize to
catecholaminergic neurons such as the LC, SN or VTA based on radiographic
binding assays and immunohistochemical analysis (de Quidt and Emson,
1986a). Furthermore, Tfg immunoreactivity is restricted to the mesencephalic
nucleus of the trigeminal nerve, the dorsal raphe nucleus, Purkinje cells of the
cerebellum, and the vestibular and cochlear nuclei. As such, NPY and Tfg do
not, individually or in combination, recapitulate the immunoreactive patterns
observed in this study utilizing the custom polyclonal DNSP-11 antibody (see
Table 6.1). In addition, the extensive differential localization of GDNF and
DNSP-11 signals, both temporally and spatially, suggest the immunoreactivity is
not explained by the presence of the unprocessed preproGDNF protein. Future
studies may focus on the dual-fluorescence signals between DNSP-11, NPY and
Tfg, or other potentially homologous proteins.
Differential immunoreactive signals for DNSP-11 and GDNF in postnatal and young adult rats
The DNSP-11 peptide sequence is theoretically processed from the proregion of GDNF. In the absence of specific transport mechanisms GDNF and
DNSP-11 should highly colocalize both spatially and temporally in the rat CNS. It
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has been shown that the DNSP-11 peptide does not bind to GFRα1 or RET
(Bradley et al., 2010), the canonical receptors of GDNF, and due to the
differences in effects observed in the literature between GDNF and DNSP-11
(Bradley et al., 2010; Turchan-Cholewo et al., 2010; Kelps et al., 2011), it is
hypothesized that GDNF and DNSP-11 are distinct biologically active
compounds.

The data obtained through dual-fluorescence

immunohistochemical analysis showing differential localization of GDNF and
DNSP-11 signals supports the hypothesis that DNSP-11 is present and is
subjected to different transport or expression mechanisms than that of GDNF,
and that there are cellular populations differentially sensitive to DNSP-11.
DNSP-11 and GDNF were found to colocalize at post-natal day 10, the
time of maximal GDNF expression in the rat, but the signals did not exclusively
colocalize. A subset of neurons of the developing mesencephalon were
intensely immunoreactive for DNSP-11 while not exhibiting any detectable
immunoreactivity to GDNF (Figure 6.7). While beyond the scope of this study,
some possibilities present themselves: first, DNSP-11 may be processed from
the pro-region of GDNF and undergoes transport by a mechanism specific to
DNSP-11; and second, that splice variants of the GDNF gene may allow
differential expression of DNSP-11 and GDNF. There are currently seven known
splice variants of the GDNF gene in the human, and two of them (variant 005 and
006) produce a variant from the pro-region that omits a 27 amino acid section
containing the DNSP-11 sequence (omitted section of human splice variants:
GKRPPEAPA EDRSLGRRRA PEALSSDS) (Flicek et al., 2013). While
speculative, it should not be ruled out that an as yet unidentified splice variant of
the GDNF gene may allow differential expression of DNSP-11 and GDNF.
Expression of GDNF is known to decrease markedly in the adult rat, but it
was observed that the DNSP-11 signal remains intense in the mesencephalon of
adult rats (Figure 6.9). This observation supports the hypothesis of differential
expression levels or a prolonged half-life of endogenous DNSP-11 in the rat
CNS. It may be speculated that endogenous DNSP-11 has a biological function
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in the monoaminergic neuron populations identified here as containing DNSP-11
signal, such as the locus ceruleus, substantia nigra, and raphe nuclei.
The DNSP-11 sequence as a processed biological peptide
The highest intensity signal for DNSP-11 was observed in the locus
ceruleus, the norepinephrinergic center of the CNS (Figure 6.10). It has been
shown in the literature that the GDNF gene is necessary for the development and
maintenance of the neurons of the locus ceruleus. In a conditional GDNF-null
mouse model, it was shown that the approximate 60% reduction of GDNF mRNA
and protein levels in these mice during adulthood results in the complete loss of
the catecholaminergic neurons of the locus ceruleus with only moderate losses in
the substantia nigra and VTA (Pascual et al., 2008), indicating that the GDNF
gene is necessary for normal maintenance and survival of adult
catecholaminergic neurons, especially the locus ceruleus. This is an interesting
finding in light of the observation by others that the locus ceruleus contains no
detectable mRNA for GDNF and only trace levels of mRNA for its receptors
GFRα and RET in the rat (Trupp et al., 1997), contrasted with the substantia
nigra which is characterized by extensive levels of GDNF receptor mRNA. The
SN and VTA, with extensive GDNF receptor expression, only underwent
moderate loss in these conditional knock-out animals, while the locus ceruleus,
with very low levels of GDNF receptor expression, underwent a near total loss.
This indicates that the locus ceruleus may be highly sensitive to GDNF gene
product expression levels or the effects of GDNF gene products on receptors
other than the canonical GDNF receptors.
The observed localization of the DNSP-11 signal in the rat CNS may
provide evidence of the sensitivity of cell populations to DNSP-11 and may allow
for increased therapeutic effect through targeting specific brain regions. Indeed,
loss of the locus ceruleus in human Parkinson’s disease patients precedes and is
greater than the loss of the substantia nigra neurons (German et al., 1992; Patt
and Gerhard, 1993; Braak et al., 2003; Zarow et al., 2003). This loss contributes
to many of the secondary symptoms and may exacerbate the primary motor
symptoms. Shown within this work is data suggesting DNSP-11 affects
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monoamine systems (Chapter Four), and while inconclusive the
immunohistochemical studies of this chapter support the hypothesis that these
nuclei interact with DNSP-11.
Immunoprecipitation studies indicate that the binding partners of the
antibody raised to DNSP-11 do not match the LC-MS identity for the synthetic,
amidated 11-amino acid DNSP-11 sequence. The results do not rule out the
endogenous presence of DNSP-11, but suggest that it may be in a form other
than that of the synthetic peptide. The endogenous DNSP-11 sequence may be
covalently modified or it may be contained within a larger signal peptide.
Additionally, endogenous DNSP-11 may degrade quickly under the conditions of
the immunoprecipitation, or be present at concentrations too low to quantify.
While the antibody used in these studies binds NPY and DNSP-11,
immunoreactive signal was identified in brain regions not typically associated
with NPY expression. Also, in other regions where NPY expression is found the
antibody did not result in signal (Table 6.1). The detection and isolation of
endogenous DNSP-11 would benefit from the production and use of a highly
specific monoclonal antibody.
Although the studies in this chapter produced many questions, the insights
gleaned may guide future studies on possible cell populations responsive to
DNSP-11 and the possible existence of the DNSP-11 sequence as an active
element of endogenous biological processes.
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Table 6.1 – An overview of expression patterns for DNSP-11 and sequence
homologues, GDNF, NPY, and Tfg in the adult.

DNSP-11

GDNF

NPY

Tfg

PPEAPAEDRSL-NH2

-PPEAPAEDRSL(proGDNF)

-GEDAPAEDMAR-

-PPSAPTEDRSG-

-

±

++

-

±

+

-

-

-

-

++

-

-

-

++

-

+

+

+

-

Substantia
nigra

++

+

-

-

Ventral
tegmental area

++

-

-

-

+

-

-

++

+++

-

±

-

+

+

-

+

+

-

-

-

-

+

-

+

Homologous
sequence
Cortex
Striatum
Amygdala
Hypothalamus
Hippocampus

Raphe nuclei
Locus ceruleus
Mesencephalic
nucleus of
Trigeminal
Cerebellar
Purkinje cell
nucleus
Cerebellar
Purkinje cell
cytoplasm

This table summarizes the localization of various proteins related and/or
homologous to DNSP-11 in the adult rat. Note that information for NPY, Tfg, and
GDNF is based on a survey of the literature.
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Figure 6.1 – Whole sagittal section of the rat brain immunoreacted for DNSP-11.
An overview of immunoreactive hotspots of DNSP-11 signal in a sagittal view of
the rat CNS. Especially intense intracellular signal was observed in the locus
ceruleus, VTA and SN, glomeruli layer of the olfactory bulb (OB), and dentate
gyrus of the hippocampus (DG). Diffuse signal was also present in the striatum
(CPu). Representative section (n=6 sagittal, n=3 coronal).

145

ic

PC

LC

Figure 6.2 – DNSP-11 signal in the locus ceruleus and cerebellum in sagittal
view.
A sagittal view of the locus ceruleus and cerebellum shows intense DNSP-11
signal in the neuronal cell bodies and projections of the locus ceruleus and light
signal in the Purkinje cell layer of the cerebellum. (LC, locus ceruleus; PC,
Purkinje cell layer of cerebellum; ic, inferior colliculus; 4V, fourth ventricle.)
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Figure 6.3 – A detailed view of DNSP-11 signal in the locus ceruleus.
Observed in this sagittal view of the locus ceruleus of naïve adult male Fischer
344 rats is intense immunoreactivity for DNSP-11, including cytoplasmic
localization and vesicle-like concentrations in neuronal projections.
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Figure 6.4 – DNSP-11 signal in the VTA and SN of adult rats.
DNSP-11 signal was intense in neurons of both the VTA and substantia nigra
pars compacta in the adult rat.
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Figure 6.5 – DNSP-11 signal in the dentate gyrus and cornu ammonis of the
hippocampus.
Moderate DNSP-11 immunoreactivity was observed in granule-like cells of the
dentate gyrus (DG) and cornu ammonis (CA) formations of the hippocampus.
(LV, lateral ventricle; 3V, third ventricle.)
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Figure 6.6 – DNSP-11 signal highly colocalizes to TH-positive neurons in the
midbrain of post-natal day 10 Sprague Dawley rats.
In immunohistochemical experiments performed by April Dawn RichardsonHatcher, Ph.D., contained within her dissertation work (Richardson, 2009), it was
observed that DNSP-11 signal highly colocalizes with TH+ neurons at post-natal
day 10.
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Figure 6.7 – DNSP-11 signal, but not GDNF signal, is present in a developing
post-natal day 10 midbrain cell.
Shown here is a representative neuron in the midbrain of a post-natal day 10
Fischer 344 rat with only immunoreactive signal for DNSP-11. DNSP-11 is
thought to be processed from the pro-region of GDNF, suggesting a high degree
of colocalization. However, DNSP-11 signal does not exclusively colocalize with
GDNF signal, suggesting DNSP-11 may have unique and efficient active
transport mechanisms and specific reactive cell populations.
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Figure 6.8 – DNSP-11 signal in the raphe of post-natal day 10 animals.
In the serotonergic raphe nucleus of post-natal day 10 animals, DNSP-11 signal
is present in the cytoplasm of neurons, while GDNF signal is only weakly present
and differentially localized. DNSP-11 signal in the raphe was also observed in
the adult rat CNS.
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POST-NATAL DAY 10
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Figure 6.9 – DNSP-11 signal remains intense in adulthood, while GDNF signal
dissipates.
The time of maximal GDNF expression in the rodent is post-natal day 10, which
would theoretically be the time of maximal DNSP-11 expression was well. While
GDNF and DSNP-11 signals do colocalize extensively, they do not exclusively
colocalize. In the adult, 3 month old Fischer 344 male rat, GDNF expression is
markedly reduced, while the DNSP-11 signal remains intense. This suggests
that GDNF and DNSP-11 may be differentially expressed or be subject to
different post-signal processing or half-lives in vivo. (A-C) Post-natal day 10
animals. (A) Merged DNSP-11 and GDNF signals. DNSP-11: green, GDNF:
red. (B) GDNF signal. (C) DNSP-11 signal. (D-F) Young adult animals. (D)
Merged DNSP-11 and GDNF signals. DNSP-11: green, GDNF: red. (E) GDNF
signal. (F) DNSP-11 signal.
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Figure 6.10 – DNSP-11 signal is intense in the adult locus ceruleus where GDNF
is not expressed.
In the adult male 3 month old Fischer 344 rat, DNSP-11 does not exclusively
colocalize with GDNF. DNSP-11 signal is highly concentrated in the locus
ceruleus (LC), a region with no mRNA for GDNF and only low levels of mRNA for
the GDNF receptor GFRα and its co-receptor RET (Trupp et al., 1997). This
suggests differential transport methods for DNSP-11 and GDNF. In addition,
DNSP-11 is present in the cells of the mesencephalic nucleus of the trigeminal
nerve (MeV), involved in proprioception of the muscles of mastication.
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Figure 6.11 – DNSP-11 signal presence in the Purkinje cell layer of the adult
cerebellum is differentially localized from GDNF signal.
Here we see DNSP-11 signal localized to the nucleus of Purkinje-like cells of the
cerebellum in the adult rat CNS. While GDNF signal is also present within these
cells, it is restricted to small vesicle-like cytoplasmic concentrations.

Copyright © James William Hendry Sonne
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Chapter Seven: Synopsis, Conclusions, and Future Directions
In this body of work, intranasally administered DNSP-11 has been shown
to protect tyrosine hydroxylase positive cell bodies of the substantia nigra and
striatal fiber densities in 6-OHDA lesioned young adult male Fischer 344 rats
(Chapter Three); to modulate the dopaminergic neurochemistry of normal Fischer
344 rats and 6-OHDA lesioned rats (Chapter Four); and to prevent apomorphineinduced rotation behavior in 6-OHDA lesioned rats (Chapter Five). While future
studies are needed, the data strongly supports the hypothesis that intranasally
administered DNSP-11 has therapeutic potential for Parkinson’s disease.
Furthermore, dual-fluorescence immunohistochemical visualization of post-natal
day 10 and young adult Fischer 344 rat brain tissue provides evidence that
DNSP-11 is endogenously present in the rat brain (Chapter Six).
The 6-OHDA lesion parameters used in the present study follow the
parameters used in studies on the effects of GDNF authored by Kearns et al. in
1995 and 1997 also in the laboratory of Don M. Gash, Ph.D. In those studies,
the lesion produced approximately 91% loss of TH+ neurons of the substantia
nigra two weeks after lesioning, compared with 92.1% loss three weeks after
lesioning in the present study. In those previous studies, when GDNF was
administered as a single injection intranigrally 24 hours prior to 6-OHDA lesion
induction, nigral TH+ cell loss was significantly reduced to 53% two weeks after
lesioning. In the present study in which DNSP-11 was repeatedly administered
for three weeks with the first dose 30 minutes prior to 6-OHDA lesion induction,
TH+ cell loss was reduced to 75.2%. In the previous study published in 1997
that looked at the 3 week post-lesion time point, it was identified that pretreatment with injected GDNF was most effective 6 hours prior to lesion
induction, and both DA and DOPAC were significantly higher in the lesioned
hemisphere of GDNF treated animals compared with citrate buffer control treated
animals. In the present study, DA was significantly higher only in a subgroup of
partially lesioned animals.

In the animals simultaneously treated with GDNF

and 6-OHDA, a 75% TH+ cell loss was observed, similar to the present study.
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The similarity of the lesion and time points of analysis between this and
the previous studies of GDNF allow more direct comparison of the effects of
intranigral GDNF and intranasal DNSP-11. While the effects observed in this
intranasal DNSP-11 study did not reach the same magnitude as the intranigral
GDNF studies, the positive impact of intranasal DNSP-11 is clear. It may be
possible to reach effect parity with simple changes to the dose of DNSP-11, the
time point of initial treatment, or frequency of administration. Of note, no
significant protective effects of GDNF were observed with pretreatment of less
than 6 hours before 6-OHDA lesion induction in the previous study (Kearns et al.,
1997), while the present study administered intranasal DNSP-11 30 minutes prior
to lesioning and repeatedly afterward. This could suggest that DNSP-11 enters
the CNS quickly and rapidly protects cell populations, or that DNSP-11 treatment
produces strong restorative effects after lesioning, as observed in previously
published work on rats with a stable 6-OHDA lesion of the medial forebrain
bundle four weeks prior to DNSP-11 injection (Bradley et al., 2010).
The similarities of effects from intranasal DNSP-11 and intranigral GDNF,
along with the strong prevention of rotation behavior with intranasal DNSP-11,
provide exciting, positive data on the potential for an easy-to-administer, noninvasive preventive and restorative therapy for parkinsonism. Future studies
should seek to rapidly advance this potential therapy toward clinical trials by
focusing on faster assays and shorter time points of analysis to identify the
sources of variability in the treatment.
Answers and Questions
This work began with the goal of determining whether the intranasal
administration of DNSP-11 could result in the transport of efficacious quantities of
the peptide into the brain to produce a protective effect. This goal was
accomplished, but many new questions were raised in the course of this study.
Data reported in Chapter Three indicates that DNSP-11, when
administered intranasally, is transported throughout the CNS in biologically
relevant quantities. Repeated intranasal administrations of DNSP-11 over a
three week time period resulted in significantly higher numbers of tyrosine
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hydroxylase positive substantia nigra neurons in a unilateral 6-hydroxydopamine
lesion rat model. The projections of these neurons to the striatum were likewise
higher in DNSP-11 treated rats. This supports the hypothesis that DNSP-11 has
cellular protective effects in the rat. Furthermore, DNSP-11 treatment modulated
monoamine neurotransmitter content and prevented apomorphine-induced
rotation behavior, a hallmark of the unilateral 6-OHDA lesion model of
Parkinson’s disease.
These data replicate previously published data on DNSP-11 injected
intracranially, directly to the substantia nigra (Bradley et al., 2010; Fuqua, 2010;
Littrell, 2011). In these studies it was shown that a single intra-nigral injection of
DNSP-11 in stably lesioned animals reduced rotation behavior and modulated
the dopaminergic system of the rat. DNSP-11 also protects cultured cells from a
variety of cellular and mitochondrial toxins (Bradley et al., 2010; TurchanCholewo et al., 2010; Kelps et al., 2011).
Effects of DNSP-11
While this study resulted in many answers, many more questions were
raised. The most important of these questions surrounds the modulation of
dopamine release observed in both normal and lesioned animals. While it was
found that dopamine turnover was increased in normal animals after three weeks
of intranasal treatment this was due to increases in the metabolites of dopamine
and not due to an increase in dopamine. A subgroup of partially lesioned
animals in this study exhibited an increase in dopamine content of the striatum
with DNSP-11 treatment. However, a small group of naïve animals infused with
DNSP-11 during striatal microdialysis revealed a significant decrease in
potassium-evoked, calcium-dependent release of dopamine in the striatum,
suggesting acute effects. For an overview of the effects observed in this study,
refer to Table 7.1.
What is the mechanism behind this modulation of the dopamine system?
Based on the animals’ physiological parameters, observed health and behavior,
histological, neurochemical and apomorphine-induced rotation metrics, it
collectively and firmly supports that DNSP-11 produces protective or restorative
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effects on the motor system. The loss of striatal dopamine content is the major
factor in the motor impairments of Parkinson’s disease, and increases in striatal
dopamine are believed to be the mechanism behind many of the symptomatic
treatments currently available at the clinical level for Parkinson’s disease, such
as L-DOPA and MAO-inhibitors.
While increases in striatal dopamine were observed in a subgroup of
partially lesioned DNSP-11 treated animals in the present study, focusing solely
on the dopamine system may be insufficient to explain the observed effects.
Some treatments for Parkinson’s disease, such as deep-brain stimulation,
produce their symptomatic relief through the targeting of downstream nuclei in
the basal ganglia circuitry such as the subthalamic nucleus or substantia nigra
pars reticulata. Other striatal inputs may play a role in Parkinson’s disease, such
as serotonin inputs from the raphe nuclei, norepinephrinergic inputs from the
locus ceruleus or glutamatergic input from the thalamus and cortex.
Furthermore, data presented in this study and in the literature (Immonen et al.,
2008) indicate that DNSP-11 may have profound effects on other nuclei in the
body such as the raphe nuclei (Chapter Four, Chapter Six), the locus ceruleus
(Chapter Six), and the hippocampus (Chapter Six). Many of these effects were
beyond the scope of this study, but are deserving of future efforts.
Converging data points to the role of DNSP-11 on mitochondria.
Protective effects of DNSP-11 against mitochondrial toxins in cell culture has
been published in the literature (Bradley et al., 2010; Kelps et al., 2011) and
strong changes in mitochondrial respiration and electrical potential are observed
with DNSP-11 treatment (Turchan-Cholewo et al., 2010; Bradley et al., 2012).
This may explain some of the cellular protective effects as well as neurochemical
effects of DNSP-11. Synaptic mitochondria show a strong capacity to buffer
calcium. While merely speculation, it is possible that DNSP-11 transiently
increases mitochondrial respiratory reserve capacity through the increased
buffering of calcium, leading to a decrease in cytosolic calcium and the calciumdependent, potassium-evoked release of dopamine observed in this and other
studies (Fuqua, 2010).
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If DNSP-11 is a potent anti-apoptotic compound and can induce increases
in mitochondrial respiration, it may also be useful as a treatment for a variety of
other diseases of degeneration or metabolic imbalance, including metabolic
syndrome (Mitchell et al., 2013), Alzheimer’s disease (Silva D. F. et al., 2012),
and even cancer. It has been reported in the literature that cancerous cells
upregulate aerobic glycolysis, shutting down their mitochondria and the
mitochondrial apoptotic pathways. Stimulation of mitochondria and increases in
their respiration reactivate these apoptotic pathways inducing cell death in
cancerous cells (Scatena, 2012). Future work on the effects of DNSP-11 and its
mechanisms may warrant the evaluation of its effects in other models and
disorders.
The identification and characterization of the GDNF pro-region
While immunoprecipitation studies resulted in the elution of bound
compounds, these compounds did not match the LC-MS/MS profile of the
synthetic, amidated rat sequence of DNSP-11 (Chapter Six). The polyclonal
antibody used in these studies was confirmed to bind both the rat and human
DNSP-11 sequences to a high titer by ELISA, but the specificity of the antibody
was not established. Indeed, it was noted that there exists homologous amino
acid sequences in the central nervous system in the form of Neuropeptide Y
(NPY) and TRK-Fused Gene product (Tfg). While data in the literature indicates
the immunoreactive patterns observed in the CNS are inconsistent with both
NPY and Tfg expression, the possibility remains that the observed signal in the
CNS is from compounds other than the DNSP-11 sequence. The
immunoprecipitation data suggests that, if the DNSP-11 sequence is
endogenously expressed, it is covalently modified and/or processed to produce a
peptide dissimilar to the synthetic amidated peptide, that it may degrade quickly
under the conditions of the immunoprecipitation, or that it is present in quantities
too low to detect.
The observed immunoreactive cell populations in the CNS (Chapter Six)
and the observed neurochemical changes (Chapter Four), may provide insight
into the effects of DNSP-11 in order to optimize its therapeutic use. While it is
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hypothesized that the endogenous DNSP-11 sequence from the pro-region of
GDNF produces biological effects, the acquisition of a sensitive monoclonal
antibody to DNSP-11 would have benefits including the isolation and
characterization of the endogenous DNSP-11 sequence. Furthermore, genetic
knock-out studies focusing on the pro-region of GDNF could provide information
on the developmental and maintenance roles of endogenous DNSP-11.
Mechanisms of action of DNSP-11 and the search for faster assays
The mechanisms of action of DNSP-11 are yet to be elucidated, but some
clues do exist. DNSP-11 produces the strongest protective actions against
mitochondrial toxins in cell culture, especially toxins against complex I, by
inhibiting caspase 3 activation (Kelps et al., 2011; Bradley et al., 2012). DNSP11 has also been shown to bind to GAPDH, an anti-apoptotic nuclear factor
(Bradley et al., 2012), and to phosphorylate ERK1/2, part of an anti-apoptotic
pathway (Turchan-Cholewo et al., 2010; Bradley et al., 2012) which suggests a
possible membrane-bound trophic factor receptor. These many different
proposed signaling pathways may be part of a multifaceted cascade, but the
determination of the cellular target and downstream signaling pathways would
provide a tool for optimizing the DNSP-11 peptide. It is also possible that DNSP11, after rapid internalization, acts directly on downstream signaling cascades,
bypassing a membrane-bound receptor. Having the ability to determine the
activity of a cellular signaling pathway would allow the rapid evaluation of
changes to the peptide, vehicle and delivery techniques.
The studies contained within this work required daily administration over
three weeks, and although they show the efficacy of intranasal DNSP-11, the
time and resources required to perform them are not ideal for quickly advancing
DNSP-11 as a therapy. These studies were impaired by lengthy time periods, an
administration routine prone to variability, and endpoints with low fidelity for the
identification of the sources of variability. Any small change to the dosing
regimen, peptide, or formulation would require an excessive length of time to test
by this study design. Faster assays of the effects of intranasal DNSP-11 are
required. One such possibility is in the radiolabeled 125I-DNSP-11 studies by
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Mallory J. Stenslik. These studies can provide detailed information about the
results of different time points and formulations on transport to the central
nervous system, allowing for the identification of sources of variability from the
dosing of the compound. However, an ideal assay would provide data on the
biological effectiveness of the administration at such short time periods. Such an
assay may be found in the cellular signaling cascades involved in the biological
effects of DNSP-11, perhaps including ERK1/2 phosphorylation or mitochondrial
effects previously shown in cell culture studies (Turchan-Cholewo et al., 2010;
Bradley et al., 2012).
Furthermore, DNSP-11 may activate transcription factors producing longterm as well as short-term effects. The effects observed in the present study can
be interpreted as long-term effects, but may be the result of short-term changes,
for instance on mitochondrial potential, resulting in cellular protection as opposed
to long-term changes in cellular transcription. It may be possible to positively
identify the short-term effects as the dominant mechanism by blocking protein
synthesis thus removing transcriptional activation as the possible protective
effect. Strong and acute mitochondria effects in cell culture observed in
published studies (Turchan-Cholewo et al., 2010; Bradley et al., 2012) may
indicate the potential of an assay of ex vivo mitochondrial respiration and/or
mitochondrial potential after intranasal administration. This assay would require
euthanasia and is prone to variability in mitochondrial extraction. While these
assays are interesting possibilities they are still not ideal for in vivo analysis.
Rapid changes to potassium-evoked release of dopamine was identified
by microdialysis in a small group of naïve animals (Chapter Four) within two
hours of the perfusion of a 50 µM DNSP-11 aCSF solution through a
microdialysis probe placed in the striatum, but using microdialysis to assay
changes to intranasal administration of the peptide may be unwieldy. Such acute
changes may indicate the possibility of other assays, such as changes to bloodoxygen level dependent (BOLD) contrast by MRI after DNSP-11 administration.
It may also be possible to implant electrodes to measure striatal dopamine, or
other basal ganglia nuclei and neurotransmitters, with high precision both before
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and after intranasal administration. The benefits of BOLD-MRI and electrode
implantation are the rapid acquisition of the data and repeatability within the
same animal. Furthermore, BOLD-MRI in particular is an assay with the potential
to be easily translated to trials in non-human primates and even humans.
Regardless of the specific mechanism used, faster assays of the biological
effects of DNSP-11 are necessary for the rapid advancement of DNSP-11 toward
therapeutic use. While long-term studies provide the benefits of behavioral
assays and safety studies in an animal model, they are cumbersome for the
purposes of optimizing DNSP-11 as a therapeutic. Whether the assay evaluates
mitochondrial respiration, cellular signaling cascades, or neuronal activity, the
development of a rapid assay that positively identifies the effects of DNSP-11
soon after administration would provide the biggest advance in development of
DNSP-11 by allowing high-throughput analysis of optimizations. As the
treatment progresses, long term efficacy and toxicology studies can be
performed across species and sexes.
Conclusion
Within this body of work, data has been shown that supports the
hypothesis that intranasal administration of DNSP-11 does produce protective
effects in a 6-hydroxydopamine lesion model of Parkinson’s disease. Tyrosine
hydroxylase positive neurons were higher in DNSP-11 treated animals (Chapter
Three), striatal dopamine content was higher by DNSP-11 treatment in a
subgroup of partially lesioned animals (Chapter Four), and apomorphine-induced
rotation behavior was prevented in the DNSP-11 treated animals (Chapter Five).
This is strong evidence that intranasal DNSP-11 protected the basal ganglia
dopamine system from the 6-OHDA lesion. It was also shown that DNSP-11
modulates the dopaminergic system in both normal and lesioned animals
(Chapter Four). The acute effects of infused DNSP-11 on potassium-evoked
dopamine release raise questions about the mechanism of action of DNSP-11
(Chapter Four). Animals treated with DNSP-11 did not lose excessive weight,
exhibited no detrimental changes in body temperature or activity levels, and did
not show signs of distress or discomfort from the treatment (Chapter Five)
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providing evidence of the safety of the treatment. The endogenous DNSP-11
sequence was not positively identified, and the specificity of the polyclonal
antibody to DNSP-11 was not validated, but endogenous immunoreactive
patterns with the antibody do not match patterns of homologous sequences
found in the brain, including that of NPY, Tfg, or the preproGDNF unprocessed
parent protein (Chapter Six).
The data obtained in this study supports much of the data previously
published on DNSP-11. DNSP-11 administered either intranasally or
intracranially shares some effects with GDNF while having the potential to
provide greater benefits than current therapies such as L-DOPA (Table 7.2).
Intracranially injected DNSP-11 has been shown to rapidly enter the cytoplasm of
tyrosine hydroxylase positive neurons, to increase dopamine and metabolite
concentrations in the normal and stably lesioned rat striatum, and to reduce
rotation behavior. Furthermore, DNSP-11 increases TH+ neuron count, neurite
length and branching in primary cultured embryonic neurons. DNSP-11 also
protects against known mitochondrial toxins in cell culture, reducing caspase-3
activation. (Bradley et al., 2010; Fuqua, 2010; Turchan-Cholewo et al., 2010;
Kelps et al., 2011; Littrell, 2011; Bradley et al., 2012)
With the increasing average age of the population and increasing
individual longevity, the impact of Parkinson’s disease is growing (Dorsey et al.,
2007; Collier et al., 2011). The disease progresses insidiously and it profoundly
impacts not just the individual but families as well as society. A protective
therapeutic can potentially delay the manifestation of serious symptoms until
much later in life, diminishing the personal, societal, and economic impact of this
neurodegenerative disease. For the reasons provided in this dissertation, DNSP11 is a good candidate for further development as a prevention and treatment for
Parkinson’s disease.
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Table 7.1 – Overview of the effects observed in this study

Dopamine Content
Dopamine Metabolite Content
TH+ substantia nigra cell bodies
TH+ striatal fiber density
Baseline Dopamine Release
Baseline Dopamine Metabolites
K+-Evoked Dopamine Release
Apomorphine-induced rotations

Intranasal DNSP-11
Normal Rats
Lesioned Rats
Partial
Severe
inconclusive
no change
↑↑
inconclusive no change
↑↑
not tested
↑↑
not tested
↑↑
no change
no change
↓
not change
no change
↓
no change
↓↓
↓↓
not tested
↓↓

Overview of the effects observed with various endpoints in the studies
composing this dissertation. Up arrows indicate positive changes with respect to
controls, down arrows indicate negative changes.

165

Table 7.2 – Overview of the effects of DNSP-11 and GDNF

DNSP-11
Administration
Organism
Lesion toxin
Lesion location
Treatment timepoint
Post-lesion timepoint
TH+ nigral cell count
TH+ Striatal fiber density
Dopamine content
Dopamine metabolites
Striatal dopamine release
Behavioral protection

GDNF

Present study

(Bradley et al, 2010)

(Kearns et al.,
1995, 1997)

Intranasal
Rodent
6-OHDA
Acute SN
Repeated
3 weeks
+
+
inconclusive
+
inconclusive
++

Intracranial
Rodent
6-OHDA
Stable MFB
Post-lesion
5 weeks
inconclusive
inconclusive
+
++
++
++

Intracranial
Rodent
6-OHDA
Acute SN
Pre-lesion
2 and 3 weeks
++
++
++
++
not tested
not tested

This table represents data from the present work on intranasal DNSP-11,
published reports on intracranial DNSP-11 (Bradley et al., 2010) and from work in
the same laboratory evaluating the effects of GDNF using the same lesioning
parameters (Kearns et al., 1995, 1997). Most significant from the Kearns
articles, significant effects of GDNF were observed with pretreatment 6+ hours
prior to lesion induction; simultaneous application of GDNF and the 6-OHDA
toxin did not produce significant effects. While the most effective dose or timing
of intranasal DNSP-11 administration may not yet be identified, intranasal
treatment with DNSP-11 produced strong protective or restorative effects similar
to GDNF treatment. This study has provided important evidence for the efficacy
of a non-invasive administration route for the DNSP-11 peptide to protect or
restore dopaminergic neurons from a 6-hydroxydopamine rodent model of
Parkinson’s disease.
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